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*Corresponding author Nicky.Welton@bristol.ac.uk
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that increases the risk of thromboembolic
events. Anticoagulation therapy to prevent AF-related stroke has been shown to be cost-effective. A national
screening programme for AF may prevent AF-related events, but would involve a substantial investment of
NHS resources.
Objectives: To conduct a systematic review of the diagnostic test accuracy (DTA) of screening tests for AF,
update a systematic review of comparative studies evaluating screening strategies for AF, develop an
economic model to compare the cost-effectiveness of different screening strategies and review observational
studies of AF screening to provide inputs to the model.
Design: Systematic review, meta-analysis and cost-effectiveness analysis.
Setting: Primary care.
Participants: Adults.
Intervention: Screening strategies, defined by screening test, age at initial and final screens, screening
interval and format of screening {systematic opportunistic screening [individuals offered screening if they
consult with their general practitioner (GP)] or systematic population screening (when all eligible individuals
are invited to screening)}.
Main outcome measures: Sensitivity, specificity and diagnostic odds ratios; the odds ratio of detecting
new AF cases compared with no screening; and the mean incremental net benefit compared with
no screening.
Review methods: Two reviewers screened the search results, extracted data and assessed the risk of bias.
A DTA meta-analysis was perfomed, and a decision tree and Markov model was used to evaluate the
cost-effectiveness of the screening strategies.
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Results: Diagnostic test accuracy depended on the screening test and how it was interpreted. In general,
the screening tests identified in our review had high sensitivity (> 0.9). Systematic population and
systematic opportunistic screening strategies were found to be similarly effective, with an estimated
170 individuals needed to be screened to detect one additional AF case compared with no screening.
Systematic opportunistic screening was more likely to be cost-effective than systematic population
screening, as long as the uptake of opportunistic screening observed in randomised controlled trials
translates to practice. Modified blood pressure monitors, photoplethysmography or nurse pulse palpation
were more likely to be cost-effective than other screening tests. A screening strategy with an initial
screening age of 65 years and repeated screens every 5 years until age 80 years was likely to be
cost-effective, provided that compliance with treatment does not decline with increasing age.
Conclusions: A national screening programme for AF is likely to represent a cost-effective use of resources.
Systematic opportunistic screening is more likely to be cost-effective than systematic population screening.
Nurse pulse palpation or modified blood pressure monitors would be appropriate screening tests, with
confirmation by diagnostic 12-lead electrocardiography interpreted by a trained GP, with referral to a
specialist in the case of an unclear diagnosis. Implementation strategies to operationalise uptake of
systematic opportunistic screening in primary care should accompany any screening recommendations.
Limitations: Many inputs for the economic model relied on a single trial [the Screening for Atrial
Fibrillation in the Elderly (SAFE) study] and DTA results were based on a few studies at high risk of bias/of
low applicability.
Future work: Comparative studies measuring long-term outcomes of screening strategies and DTA
studies for new, emerging technologies and to replicate the results for photoplethysmography and GP
interpretation of 12-lead electrocardiography in a screening population.
Study registration: This study is registered as PROSPERO CRD42014013739.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
A trial fibrillation (AF) is the most common heart rhythm disorder. AF is a major cause of stroke andsubsequent disability and mortality. Many AF patients benefit from blood-thinning drugs (anticoagulation
therapies), which have been shown to reduce the risk of an AF-related stroke. AF is often diagnosed only after
an AF-related stroke. Earlier detection could prevent AF-related strokes, disability and mortality. This study
aimed to assess whether or not a national screening programme for AF would represent good value for
money. To do this, we reviewed studies looking at how well screening tests identify individuals with AF and
also studies that compare different methods of screening. We found that a national screening programme in
which older individuals (aged 65–70 years) are invited to be screened during a routine appointment with their
doctor is likely to be cost-effective. There was also evidence that repeated screening every 5 years until age
80 years would prove to be of value. The screening test most likely to be cost-effective involves either a nurse
taking a pulse rhythm check or a specific blood pressure monitor that is also able to detect AF. Whichever
screening test is used, patients with a positive result would need to have their diagnosis confirmed by a trained
doctor using an electrocardiogram machine before discussing treatment options.
New studies on (1) how to implement screening in general practice, (2) the performance of new tests
(patches, smartphone/watch devices, iPads, hand-held devices) and (3) the effectiveness of screening with
regard to the long-term risks of AF-related stroke and mortality would be useful.
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Scientific summary
Background
Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, and
AF is more prevalent in men than in women. AF increases the risk of thromboembolic events, in particular
stroke, with a fivefold increase in stroke risk in individuals with AF. Treatment of AF focuses on rhythm and
rate control, and on prevention of stroke using oral anticoagulation therapy in individuals in whom return to
sinus rhythm is unlikely. It is estimated that one-third of those with persistent AF will not have symptoms,
and therefore that a first presentation of this might be a stroke. It is these individuals who would benefit
most from a national screening programme for AF and subsequent anticoagulation therapy for stroke
prevention. A national screening programme for AF would, however, involve a substantial investment of
NHS resources, and the cost-effectiveness of such a programme would need to be established.
Objectives
The aim of this study was to assess the cost-effectiveness of different national screening strategies for AF
in older adults. To achieve this aim we:
1. conducted a systematic review of diagnostic test accuracy (DTA) studies to determine the diagnostic
accuracy of screening tests for detecting AF in adults who have not sought medical attention in a
primary or community care setting on account of symptoms associated with AF, and to determine
the diagnostic accuracy of screening tests in systematic opportunistic, targeted and population
screening settings
2. updated a previous systematic review of screening strategies for AF to answer the following questions:
(i) does systematic screening increase the detection of AF compared with routine practice?; (ii) what
are the characteristics of those identified with AF by screening strategy?; (iii) which combination of
screening strategy, screening population and test is the most effective at detecting AF compared with
routine practice?; (iv) what are the potential safety issues and adverse events associated with individual
screening programmes?; (v) how acceptable is the intervention to the target population?; and (vi) what
are the costs associated with systematic screening for AF?
3. developed an economic model to compare the cost-effectiveness of different national screening
strategies (including no screening) based on a review of previous economic evaluations of screening for
AF and a review of recent literature on the prevalence, disease progression and risk profiles of AF and
screening strategies relevant to a UK population-based screening setting.
Methods
Diagnostic test accuracy review
We searched for diagnostic cohort or case–control studies in MEDLINE, PreMEDLINE, EMBASE, The Cochrane
Library, the Centre for Reviews and Dissemination and the Science Citation Index. Databases were searched
without language or date restrictions until January 2015. The population of interest was individuals registered
in primary care and/or presenting to primary care or community centres who had not sought medical attention
on account of symptoms associated with AF. The index test could be any non-invasive test for AF that could be
utilised in a primary care setting or in the community. The reference standard was a 12-lead electrocardiogram
(ECG) interpreted by a cardiologist. Two reviewers screened the search results, extracted and checked the data
and assessed the study quality using the QUality Assessment of Diagnostic Accuracy Studies – 2 (QUADAS-2)
tool. Evidence synthesis was conducted by fitting a hierarchical summary receiver operating characteristic
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(HSROC) model to estimate the relationship between sensitivity and specificity of the index tests, accounting
for heterogeneity between studies. Heterogeneity was explored using preplanned subgroup analyses.
Review of randomised controlled trials comparing screening strategies
We updated and adapted a recent Cochrane review of screening strategies for AF. The population of
interest was adults aged ≥ 40 years in whom population-based screening could be conducted. The
interventions of interest were population-based, systematic (opportunistic, targeted or population)
screening programmes for AF. We relaxed the requirement for confirmation of AF with a 12-lead ECG
interpreted by a general practitioner (GP), specialist or suitably trained ECG technician because of a lack of
studies. During the course of our review, we identified that the Health Information and Quality Authority
(HIQA) in Ireland had published a health technology assessment (HTA) in which it had updated the
Cochrane review from June 2012 to June 2015. We were also informed that the Cochrane review itself
was being updated (currently undergoing peer review) and, with the assistance of the review authors, we
updated this version of the review while expanding the scope as described above. Because the Cochrane
update was restricted to randomised controlled trials (RCTs), we also restricted our review to RCTs. In
addition, we updated the update by running searches from July 2015 to December 2015. Two reviewers
screened the search results, extracted and checked the data and assessed the risk of bias. The study results
were pooled using meta-analysis when sufficient evidence was available.
Economic evaluation
We reviewed the literature to identify previous economic evaluations of screening strategies for AF, using
the NHS Economic Evaluation (NHS EED) and HTA databases from inception until close (end of December
2015), the Cochrane screening study review searches with economic filters and the Cost-Effectiveness
Analysis (CEA) Registry. On the basis of this review, together with discussions with the project team, we
developed an economic model consisting of a decision tree for the screening process and outcome and a
discrete-time Markov model from a linked National Institute for Health Research HTA project, to provide
the expected lifetime costs and benefits of anticoagulation therapy, if appropriate, given the outcomes of
the screening model. We searched MEDLINE and EMBASE between 1 January 2000 and 22 January 2016
to identify studies providing information on the natural history of AF and screening for AF relevant to our
economic model. The sensitivity and specificity of different screening tests came from the results of the
DTA review meta-analysis. A probabilistic analysis is presented to reflect uncertainty in the model inputs.
We report the mean total incremental costs, mean total incremental quality-adjusted life-years (QALYs) and
mean incremental net benefit (INB) at a willingness to pay of £20,000 per QALY. To compare different
screening strategies by age at first screen and number of repeated screens, we multiplied the per-person
INB by the population size that will benefit (for a given age cohort). Costs and outcomes in future years
over a lifetime time horizon were discounted at an annual rate of 3.5%.
Results
Diagnostic test accuracy review
We identified 15 studies of screening tests for the detection of AF, including a 12-lead ECG, single-lead ECGs,
between 1- and 12-lead ECGs, pulse palpation, modified blood pressure monitors, photoplethysmography and
two-stage testing. Screening tests varied in whether they were interpreted by a cardiologist, a GP, a nurse or
an automatic algorithm, although evidence was not available for every test and interpreter combination and,
when present, few observations were reported, leading to a lack of statistical power to detect meaningful
differences. There was a high degree of variability between studies and a high level of uncertainty in the
estimates of DTA. In general, most tests had a high sensitivity, in excess of 0.9. Specificity was, in general,
lower than sensitivity for all of the tests. Tests with the highest diagnostic odds ratio (DOR) were the 12-lead
ECG (regardless of interpreter), between 1- and 12-lead ECG (automatic or cardiologist interpretation),
two-stage tests and single-lead ECG interpreted by a GP, with all of these tests having similar DORs.
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In general, for a given interpreter, the results for the single-lead ECG were less accurate and more variable
than ECGs with more than one lead. Nurse interpretation of single-lead ECGs performed similarly to
single-lead ECGs with other interpretation methods, but nurse interpretation of 12-lead ECGs did not
perform as well as other interpretation methods. Automatic interpretation did not have a consistent impact
on test accuracy, with automatic interpretation of single-lead ECGs having a high sensitivity but variable
specificity. In contrast, automatic interpretation of ECGs with more leads had good specificity but variable
sensitivity. The different two-stage screening strategies all had very high specificity, but sensitivity was high
only when a 12-lead ECG was used as the second-stage test.
Although photoplethysmography had very high test sensitivity, this estimate was based on a single
study not based in primary care, in which the index test was rated as being at high risk of bias and the
applicability of the patient selection was unclear. We are therefore cautious in interpreting the results from
this screening test.
The results were robust to the sensitivity analyses, but we could perform only some of these because of a
lack of data.
Review of randomised controlled trials comparing screening strategies
We identified five RCTs comparing screening strategies for AF; however, only two of these provided data
that could be included in our review and only one was included for our primary outcome (the number of
new AF diagnoses). The Screening for Atrial Fibrillation in the Elderly (SAFE) study therefore remains the main
source of evidence on the comparative efficacy of different screening strategies for AF. Systematic population
and systematic opportunistic screening strategies were found to be similarly effective, with an estimated
170 individuals needed to be screened to detect one additional AF case compared with no screening. There
was no evidence that systematic screening targeted to high-risk individuals was effective compared with
no screening.
Uptake of systematic population screening was typically around 50%, although uptake was as high as
70% in one study and there was variability in uptake between practices. Reasons for not attending for
screening were varied, although older age and decreased mobility were commonly cited reasons. The
proportion of individuals having their pulses checked under systematic opportunistic screening varied
across studies (from 30% to 66%) and between practices within studies (from 8% to 93%). The
proportion of individuals consulting with their GP was not reported, so it is unclear how much these
uptake rates are driven by consultation rates, GPs offering pulse palpation and uptake of pulse palpation
by individuals. Of those with an irregular pulse who did not have a previous diagnosis of AF, approximately
18% did not attend for an ECG test, although again this was variable across practices.
For systematic opportunistic screening, a greater proportion of the 75 newly identified cases were diagnosed
outside the screening programme (44/75, 59%) than within it (31/75, 41%). This suggests that the full
benefits seen in the systematic opportunistic arm may not be realised outside the context of a RCT.
There were no comparative studies of repeated screening strategies, and the majority of the evidence
related to those aged 65–75 years.
Economic evaluation
Our results indicate that both systematic opportunistic and systematic population screening followed by
directly acting oral anticoagulant therapy, where indicated, are likely to be cost-effective compared with no
screening (current practice). Systematic opportunistic screening was more likely to be cost-effective than
systematic population screening, as long as the proportion of flagged individuals who have their pulses
checked observed in the SAFE study is realised in practice.
We found that photoplethysmography, modified blood pressure monitors and pulse palpation by a nurse
were more likely to be cost-effective than other screening tests, because these are cheaper than other
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screening tests while having adequate test sensitivity. This finding relies on the use of a 12-lead ECG
diagnostic test interpreted by a GP (referred to a cardiologist when the diagnosis is unclear) in individuals
with a positive screening test result.
For a single screen of a given age cohort, we found that strategies that use a higher age of screening were
more likely to be cost-effective. However, when allowing for the possibility of repeated screening strategies
with 5-year intervals, single screens were no longer found to be cost-effective; instead, an initial screen
at age 65 followed by repeat screens every 5 years until age 80 years was found to be most likely to be
cost-effective, provided that compliance with treatment does not decline with increasing age.
Although our model made many assumptions, we found that in general these were robust when tested in
sensitivity analyses. If the uptake of pulse palpation in flagged patients is lower than that seen in the SAFE
study, then a screening strategy in which individuals are invited by letter may be more appropriate. If the
diagnosis rate of AF in the absence of screening is high, then the age at which to initiate screening is likely
to be higher (70 years rather than 65 years).
Conclusions
A national screening programme for AF is likely to represent a cost-effective use of resources. Systematic
opportunistic screening is more likely to be cost-effective than systematic population screening. Nurse
pulse palpation or modified blood pressure monitors (if available) would be appropriate screening tests,
followed by a diagnostic 12-lead ECG interpreted by a trained GP in those who screen positive, with
referral to a cardiologist/specialist in cases in which the diagnosis is unclear. Implementation strategies to
operationalise uptake of opportunistic screening in primary care should accompany any screening
recommendations.
Research needs identified by this report are (1) the development and evaluation of strategies for the
implementation of screening; (2) the evaluation of diagnostic performance against a reference standard
of recent innovations (patches, smartphone/watch devices, iPads, hand-held devices) as well as devices
used for other reasons that can also detect AF (pacemakers, implantable cardioverter defibrillator and
implantable loop recorder devices), which may be of relevance to screening, particularly the detection of
paroxysmal AF; (3) a comparative study to evaluate the long-term benefits of screening for chronic and
paroxysmal AF and the yield from repeated screening tests; and (4) studies to replicate the DTA results for
photoplethysmography and GP interpretation of 12-lead ECGs (with referral to a cardiologist/specialist in
cases in which diagnosis is unclear) in a screening population.
Study registration
This study is registered as PROSPERO CRD42014013739.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Atrial fibrillation and its health consequences
Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age
and it is more prevalent in men than in women.1,2 The prevalence of diagnosed AF in England has been
estimated to be 1.6%,3 although total prevalence including undiagnosed AF has been estimated at 2.4%.1
Estimates of annual incidence range from 0.025% in the under-sixties to 0.3% in the over-eighty-fives.4
Symptoms of AF include palpitations, breathlessness, syncope or presyncope, angina and exhaustion. AF is
typically categorised into three types, and patients may remain in one category or can progress through
these types of AF as their condition worsens. The categories are:
1. paroxysmal AF, which is intermittent with episodes that usually last < 48 hours and that stop without
antiarrhythmic therapy
2. persistent AF, which lasts for > 1 week if untreated with antiarrhythmic therapy
3. permanent AF, which is no longer corrected with antiarrhythmic therapy.
Atrial fibrillation increases the risk of thromboembolic events, in particular stroke, because of pooling of blood
in the left atrium and embolisation to the brain. The risk of stroke is increased fivefold in individuals with AF.5
Approximately one-sixth of all strokes are attributed to AF.6 Patients with thromboembolic stroke from AF
have a higher mortality and morbidity than patients with other stroke subtypes.7 Moreover, there appears to
be a ‘dose–response’ relationship, with stroke risk increasing as AF progresses from paroxysmal to persistent
to permanent AF.8,9 The presence of AF is also associated with an approximately twofold higher risk of future
acute myocardial infarction (MI).10
Treatment of AF focuses on rhythm and rate control, and the prevention of stroke using oral
anticoagulation (OAC) therapy in individuals in whom return to sinus rhythm is unlikely. A strategy of
treatment is recommended by the National Institute for Health and Care Excellence (NICE)11 and similar
bodies worldwide, for example, the Canadian Agency for Drugs and Technologies in Health (CADTH)12 and
the European Society of Cardiology.13 However, this is only in individuals in whom a diagnosis of AF has
already been made because they present with symptoms. It is estimated that, of those with persistent AF,
one-third will not have symptoms14 and therefore a first presentation of persistent AF might be a stroke.
It is these individuals who would benefit most from anticoagulation therapy for stroke prevention, and
underdetection of AF in this population represents a major gap in clinical care.15 OAC therapies include
warfarin and a class of novel directly acting oral anticoagulant therapies termed DOACs or NOACs
(including dabigatran (Pradaxa®, Prazaxa®, Pradax®, Boehringer Ingelheim GmbH, Germany), rivaroxaban
(Xarelto®, Bayer Health Care, Germany), apixaban (Eliquis®; Bristol-Myers Squibb, NY, USA) and edoxaban
(Lixiana®, Daiichi Sankyo, Japan). Because NOACs will not remain ‘novel’ forever, in this report we will refer
to this class of therapies as DOACs. Given the potential benefits of anticoagulation therapy and the
underdiagnosis of AF, calls have been made for a national screening programme to identify patients with
AF who may benefit from the prevention of AF-related stroke.16
A national screening programme would involve a substantial investment of NHS resources, and the
cost-effectiveness of such a programme needs to be demonstrated. The benefits of screening depend
on the additional number of AF cases detected and the resulting reduction in AF-related sequelae,
in particular stroke, achieved by earlier therapeutic intervention in the additional detected cases.
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Current practice in the diagnosis and treatment of atrial fibrillation
There is currently no systematic screening strategy for AF in the UK. Current NICE guidelines11 state that a
pulse palpation should be performed to assess for AF in patients presenting with dyspnoea, palpitations,
syncope or chest discomfort, or who have had a transient ischaemic attack (TIA). Once AF is identified
(symptomatic, asymptomatic, paroxysmal, persistent or permanent), management strategies involve rate and/
or rhythm control. For rate control, medications including beta-blockers, digoxin or calcium channel blockers
are recommended. Individuals who have new-onset AF or who are young with persistent AF may be offered
electrical cardioversion, with a 4-week period of anticoagulation prior to cardioversion. Rhythm control may
be achieved with medications used for rate control in some individuals. Where rhythm control is unlikely to
be achieved, or there is a high risk of arrhythmia following cardioversion (electrical or by medication), it is
necessary to assess stroke risk using the Score for Stroke Risk in Atrial Fibrillation (CHA2DS2-VASc)
[constructed as a sum of the following risk factors: congestive heart failure, hypertension, aged ≥ 75 years
(x2), diabetes, stroke (x2), vascular disease, age 65–74 years, and sex (female)].17,18 Anticoagulation should be
offered to patients with a CHA2DS2-VASc score of ≥ 2, taking bleeding risk into account [using the Score for
Bleeding Risk in Atrial Fibrillation (HAS-BLED)]. Left atrial occlusion may be offered to patients who are
deemed to be at high risk of anticoagulation because of comorbidities including falls and bleeding risk or
intolerance to drugs. Ablative therapies may also be offered for the same indication.
Systematic screening strategies
A population-based screening programme for AF could take a variety of different formats, depending on
(1) the population to be screened, (2) the screening test procedure and (3) the setting in which it is
conducted. We follow Hobbs et al.19 in using the following definitions of screening strategies:
l systematic population screening: general screening of a defined population, for example individuals
aged ≥ 65 years
l systematic targeted screening: screening people at higher risk of AF, for example those with risk factors
such as cardiac failure, hypertension, rheumatic heart disease or history of MI, angina, diabetes
mellitus, hyperthyroidism, stroke or TIA
l systematic opportunistic screening: when a health-care professional takes the opportunity to screen an
individual for AF during a consultation.
Current NICE guidelines11 represent opportunistic case finding, rather than a screening strategy.
The current strategy recommended by NICE is pulse palpation, although any screening strategy would need to
consider how this or other methods perform compared with a gold standard. For permanent or persistent AF,
a 12-lead electrocardiogram (ECG) interpreted by at least one trained cardiologist/heart rhythm specialist is
considered a gold standard. However, in a screening programme, quicker/cheaper methods are likely to be
adopted, with confirmation of a positive result using the gold standard as necessary. Paroxysmal AF is
challenging to diagnose because of its intermittent nature, and there is no accepted gold standard method
for its diagnosis.20 Continuous Holter monitoring has been shown to detect more cases than intermittent
monitoring, and more cases are detected as the length of monitoring increases from 24 hours to 7 days to
30 days.20
For a national screening programme, we assumed that primary care, community care (e.g. pharmacies)21 or
domiciliary testing would be the most appropriate setting.22 However, we restricted our evaluation to a
primary care setting as being the most likely setting for an AF screening programme in England and Wales.
Detection of AF occurs in secondary care following investigations after an event (e.g. ischaemic stroke);
however, because current NHS practice following such an event is to investigate potential causes, such as
AF, then in effect an opportunistic case-finding programme is already in place in this setting, and therefore
this setting was not included in the analysis.
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The need for an evaluation of the cost-effectiveness of a national
screening programme for atrial fibrillation
The World Health Organization (WHO) sets out the Wilson and Jungner23 criteria that should be met
before the introduction of a population-based screening programme. Each of these criteria has recently
been assessed for a population-based screening programme for AF.24–26 The criteria relevant to AF are
discussed in the following sections.
The condition should be an important health problem
Atrial fibrillation is a major cause of ischaemic stroke, with a fivefold increase in risk of ischaemic stroke5
and associated increased mortality,5,6,27–29 increased morbidity15 and reduced quality of life.30 AF incidence
and prevalence increases with age, and a recent report with 50 years’ follow-up indicates that the
incidence and prevalence of AF are increasing over time, largely because of an ageing population and
increased detection.31 It has been estimated that AF is responsible for about 25,000 AF-related strokes per
year in the UK.6 AF therefore represents an important health problem that is likely to increase over time
with an ageing population.
The natural history of the disease, including from latent to declared disease,
should be adequately understood and there should be a detectable disease
marker for the latent period/early symptomatic stage of the disease
The natural history of AF is a progression from paroxysmal to persistent to permanent AF.32 Risk factors
for AF-related stroke risk in patients are well described by the CHA2DS2-VASc score.11 All types of AF
may be either symptomatic or asymptomatic.33,34 It is expected that, compared with routine practice,
a population-based screening programme is likely to detect a higher proportion of asymptomatic cases
that would not otherwise present until a stroke or cardiovascular event occurs. We would also expect that,
unless an extended screening test is used, the majority of screen-detected cases would be persistent or
permanent AF, because only a small proportion of paroxysmal cases would be in AF at the time of testing.
Flaker et al.35 found that stroke risk was higher in symptomatic patients than asymptomatic patients, but
that this difference was explained by baseline characteristics.
Cost-effective primary prevention interventions should have been implemented as far
as practical
Across the UK there are programmes in place to help prevent modifiable risk factors of AF (MI, angina,
diabetes mellitus, hyperthyroidism, stroke or TIA11,19).
There should be a simple, safe, precise and validated screening test, and the
distribution of the test values in the target population should be known and
a suitable cut-off level defined and agreed
A 12-lead ECG interpreted by at least one cardiologist is considered a gold standard for the diagnosis of
permanent or persistent AF. However, in a screening programme quicker/cheaper screening tests are likely
to be adopted, with confirmation of a positive result using the gold standard diagnostic test as deemed
necessary. In one arm of the Screening for Atrial Fibrillation in the Elderly (SAFE) study, Hobbs et al.19 used
pulse taking as a screening test with a follow-up ECG if an irregular pulse was found, whereas in another
arm a 12-lead ECG interpreted by a cardiologist was used directly as a screening test. However, there
are a variety of possible screening tests available (e.g. modified blood pressure monitors, one-lead ECG,
three-lead ECG, Holter monitor), as well as devices used for other reasons that can also detect AF
[pacemakers, implantable cardioverter defibrillator (ICD) and implantable loop recorder devices]. There are
also newer, smaller, non-obtrusive technologies currently being trialled (patches, smartphone/watch devices,
hand-held devices) that may be of relevance to a screening programme. In this report, we consider only
non-invasive tests for which information on sensitivity and specificity compared with a gold standard
(12-lead ECG interpreted by at least one cardiologist) is available.
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A screening programme would generate patients identified with an irregular pulse on the screening test
used (e.g. pulse taking), some of whom may then need a confirmatory 12-lead ECG. There is some
evidence that the sensitivity and specificity of diagnostic tests depend on the interpreter [nurse, general
practitioner (GP), cardiologist or computer algorithm].19,36 Therefore, a confirmatory ECG would add an
additional burden to the NHS, either through training GPs to interpret them or through referral to
cardiology units.
Long-term continuous Holter monitoring is considered appropriate to detect paroxysmal AF, although there
is no accepted gold standard for the diagnosis of paroxysmal AF. This may change with the introduction
of newer, non-invasive devices for home monitoring. Note, however, that a 12-lead ECG interpreted by a
cardiologist would detect only the small proportion of patients with paroxysmal AF who happened to be in
AF at the time of testing. A population-based screening programme with only short-term monitoring is
unlikely to detect many paroxysmal AF cases.
The test should be acceptable to the population
The SAFE study reported an approximately 50% uptake rate for screening and, of those identified as
having an irregular pulse, 73% had an ECG. In a post-screening questionnaire, only 3.7% reported that
screening was not convenient.19 No adverse results were reported.
There should be an agreed policy on the further diagnostic investigation of individuals
with a positive test result and on the choices available to those individuals
We assumed that AF detected using a screening test would be confirmed using a 12-lead ECG, as set out in
the NICE clinical guidelines.11 The gold standard is a 12-lead ECG interpreted by a cardiologist; however,
increasingly GPs are being trained to interpret ECGs, with referral to a cardiologist only in unclear cases. For
the purposes of our economic model we assumed that, following a screening test, there would be a diagnostic
12-lead ECG interpreted by a GP with referral to a specialist to help with interpretation if necessary. Following
a confirmed diagnosis, treatment and care options are set out in the NICE clinical guidelines.11
There should be an accepted treatment/therapy for patients identified through
early detection, with evidence of early treatment/therapy leading to better
outcomes than later treatment/therapy
As the morbidity and mortality associated with AF-related stroke are substantial, therapy to reduce AF-related
stroke risk earlier rather than later is likely to lead to better outcomes; however, earlier treatment also implies
more adverse events (bleeding events). The cost-effectiveness of anticoagulant therapy (warfarin or DOACs)
to prevent stroke in eligible AF patients has been established,37 indicating that it is an efficient use of NHS
resources. However, the trials informing these assessments were not conducted in screen-detected cases.
Mant et al.38 found that screen-detected AF patients had a lower risk of stroke than diagnosed AF patients,
but they found no evidence that the relative efficacy of warfarin compared with aspirin depends on whether
AF is screen detected or not. However, the low event rates mean that this result is very uncertain, and the
data were consistent with both a beneficial and a harmful effect of warfarin.
Other treatment options include rate control and rhythm control therapies. As screen-detected AF is likely to
be asymptomatic, we would assume that a small proportion would be offered rate control until their heart
rhythm disorder progresses to be symptomatic. Cardioversion may be offered to younger patients to avoid
long-term anticoagulation; however, in an elderly population-based screening programme this would be a
small proportion of screen-detected cases.
There should be agreed evidence-based policies covering which individuals
should be offered therapy and the appropriate therapy to be offered
The NICE clinical guideline11 clearly sets out who is eligible for anticoagulation and rate and rhythm control
according to stroke and bleeding risk scores (see Current practice in the diagnosis and treatment of atrial
fibrillation). Screen-detected patients would be eligible for anticoagulation only if the CHA2DS2-VASc score
is ≥ 2, taking bleeding risk into account using the HAS-BLED score.
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Clinical management of the condition and patient outcomes should be optimised in all
health-care providers prior to participation in a screening programme
It has been estimated that around 35% of patients with diagnosed AF who are eligible and who do not
have a contraindication are not receiving anticoagulation.39 In addition, the introduction of DOACs has not
led to uptake as expected. The potential therapy benefits from screening may, therefore, not be realised.
There should be evidence from high-quality randomised controlled trials
that the screening programme is effective at reducing morbidity or mortality
There are currently no randomised controlled trials (RCTs) evaluating a population-based screening
programme that have collected morbidity or mortality outcomes. The STROKESTOP trial26,40 that is currently
under way aims to fill this evidence gap, but is not due to report until 2019. RCT evidence on long-term
outcomes is limited to the follow-up period available and so may not be able to fully answer this question.
There is RCT evidence available on the prevalence of screen-detected cases under different screening
strategies;19 however, it is currently an assumption that early detection and treatment leads to morbidity
and mortality benefits.
There should be evidence that the complete screening programme
(test/diagnostic procedures/therapy/treatment/intervention) is clinically,
socially and ethically acceptable to health professionals and the public
There have been several publications in the clinical literature calling for a national screening programme
for AF,16,41,42 including a consensus statement from the Royal College of Physicians of Edinburgh in 2012.43
This suggests that such a programme would be acceptable to clinicians. A recent survey44 of health-care
professionals found that general practices have access to resources for AF screening and there is
enthusiasm among non-GP health-care professionals to train and play a role in AF screening. However,
there were concerns about a lack of staff, time and capacity.
Individuals invited to screening may choose to attend or not and so it is reasonable to assume that screening
is acceptable in those that take up the screening opportunity. There may be a variety of reasons why some
individuals do not attend for screening. It is important that this is an informed choice and that sufficient
information is provided on the screening test and what positive and negative results mean, including the
need for subsequent diagnostic tests and the treatment and therapy options that are available.
Patients diagnosed with AF are fearful of the consequences of a debilitating AF-related stroke. It is therefore
important that they understand their risk of AF-related stroke and are able to make an informed choice
about anticoagulation therapy after consulting with their health-care professionals. The options should be
fully explained to them based on their eligibility and suitability and the risks and benefits of treatment,
and should be reviewed periodically. NICE has produced Patient Decision Aids for this purpose.45
Warfarin needs to be dose adjusted with regular monitoring to ensure that the patient stays within the
recommended therapeutic international normalised ratio (INR) range, making warfarin unacceptable to
some patients.46,47 Warfarin also has interactions with other medications including over-the-counter
preparations, foods high in vitamin K and alcohol, which can impact on quality of life, meaning that some
patients are reluctant to take warfarin. Recent NICE guidance DG1448 has recommended coagulometers,
devices that allow patients to self-monitor the INR, which is an alternative to regular INR monitoring,
although some patients have experienced difficulties gaining access and support for these devices
[Diane Eaton, AntiCoagulation Europe (ACE), 2016, personal communication]. DOACs do not require
regular INR monitoring and have fewer drug and food interactions, making them more acceptable to
many patients, although there are some concerns around lack of antidotes if there is a bleed (although
dabigatran now has an antidote and others are in development).
Patients need to understand that, although anticoagulation therapy reduces the risk of AF-related stroke,
it does not delay or reduce symptoms of AF. The importance of adhering to the medication in the absence
of relief from symptoms therefore needs to be stressed repeatedly.
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The proportion of eligible patients being prescribed DOACs is increasing, but is still relatively low.39 If a
population-based screening programme were to be put in place, the benefits of the programme would be
realised only if screen-detected AF patients were put on appropriate anticoagulation therapy (e.g. not
aspirin monotherapy, which is no longer recommended by NICE11). Therefore, there needs to be support at
a local clinical commissioning group level to provide access to anticoagulation therapies recommended by
NICE to eligible patients detected through screening.
The benefit from the screening programme should outweigh the physical and
psychological harm (caused by test, diagnostic procedures and treatment)
The screening tests for AF investigated in this report are non-invasive and unlikely to cause physical harm.
The SAFE study recorded the acceptability of screening to individuals and measured anxiety and quality
of life before and after screening.19 The authors found screening to be acceptable to the majority of
individuals, but anxiety was higher and quality of life was lower in those who received a positive diagnosis
of AF following screening. A 12-lead ECG, used to confirm the diagnosis of AF, is also non-invasive,
although it requires the placement of pads on the upper body under clothing. The benefits in terms
of reducing the risk of AF-related stroke are likely to outweigh adverse events (bleeding risk) and risk
factors for bleeding on anticoagulant therapy are also well described by the HAS-BLED score.11 However,
as described earlier, there is not yet robust evidence of the impact of anticoagulation therapy in a
screen-detected AF population.
The opportunity cost of the screening programme (including testing, diagnosis, therapy
and treatment, administration, training and quality assurance) should represent value
for money
Hobbs et al.19 found that a systematic opportunistic screening programme is likely to be cost-effective
in men and women from the age of 65 years, but their model assumed that benefits in screen-detected
and non-screen-detected populations are the same and it was unclear whether or not lack of compliance
to therapy, if indicated, was modelled. The cost-effectiveness of OACs in non-screen-detected AF has
recently been demonstrated.37
A recent report for the National Screening Committee24 concluded that there was a need to formally
assess the cost-effectiveness of a screening programme for AF, and that such a cost-effectiveness analysis
should include both costs of detecting undiagnosed cases of AF and also allow for stroke risk in screen-
detected AF to be lower than that in clinically diagnosed AF.
Key questions arising from the World Health Organization criteria for the
assessment of a screening programme
Many of the WHO criteria are clearly met, although some questions remain. Key inputs to assess the value
of a screening programme are:
l the relative stroke risk for asymptomatic compared with symptomatic AF
l the proportion of these asymptomatic cases that would be eligible to benefit from
anticoagulation therapy
l the split between AF type (paroxysmal, persistent, permanent) in screen-detected cases and those
missed by screening (false negatives)
l the relative sensitivity and specificity of the range of possible screening tests
l the resources required for performing the screening tests and subsequent diagnostic tests
l the risk factor profiles of screen-detected AF cases
l the proportion of people with AF detected by screening who are eligible for anticoagulation who
would actually receive it
l the impact of screening on long-term morbidity and mortality outcomes.
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Research questions
Aim
The aim of this project was to assess the cost-effectiveness of different national screening strategies for AF
in older adults. To achieve this aim, we conducted a series of reviews and developed an economic model.
Objectives
l To conduct a systematic review of diagnostic test accuracy (DTA) studies to determine:
¢ the diagnostic accuracy of screening tests for detecting AF in adults (≥ 18 years) who have not
sought medical attention in a primary or community care setting on account of symptoms
associated with AF
¢ the diagnostic accuracy in systematic opportunistic, targeted and population screening settings.
l To update a previous systematic review49 of screening strategies for AF to answer the
following questions.
¢ Does systematic screening increase the detection of AF compared with routine practice?
¢ What are the characteristics of those identified with AF by screening strategy?
¢ Which combination of screening strategy, screening population and test is the most effective at
detecting AF compared with routine practice?
¢ What are the potential safety issues and adverse events associated with individual
screening programmes?
¢ How acceptable is the intervention to the target population?
¢ What are the costs associated with systematic screening for AF?
l To develop an economic model to compare the cost-effectiveness of different national screening
strategies (including no screening) in a primary care setting in England and Wales, with the
following objectives:
¢ to review previous economic evaluations of screening for AF
¢ to review recent literature on the prevalence, disease progression and risk profiles of AF and
screening strategies relevant to a UK population-based screening setting
¢ to evaluate the cost-effectiveness of different population-based screening strategies in England
and Wales.
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Chapter 2 Methods for the systematic reviews of
diagnostic test accuracy studies and randomised
controlled trials of screening for atrial fibrillation
Introduction
In this chapter we describe the methods for (1) the systematic review of DTA studies for the diagnosis of
AF and (2) the systematic review of RCTs of screening for AF. The methods for the economic evaluation,
incorporating a review of economic evaluations of mass screening strategies for AF and a review of natural
history parameters relevant to a UK mass screening population, are provided in Chapter 5.
Diagnostic test accuracy systematic review
Objectives
The primary objective of this review was to determine the DTA of screening tests for detecting AF in adults
(aged ≥ 18 years) who have not sought medical attention in a primary or community care setting on
account of symptoms associated with AF.
The secondary objective of this review was to determine the DTA of index tests in various (i.e. systematic
opportunistic, targeted and population) screening settings.
Review question
l Study design. Diagnostic cohort or case–control study.
l Population. People who had not sought medical attention on account of symptoms associated with AF.
l Presentation. Individuals registered in primary care and/or presenting to primary care or a community
centre. Individuals may be invited to screening regardless of medical history (this may be done on the
basis of age – systematic screening); on presenting to the GP for issues unrelated to AF symptoms
(e.g. flu vaccination – systematic opportunistic screening); or based on their medical history/the
presence of risk factors that are associated with AF (targeted screening).
l Prior tests. No prior testing for AF was required for the inclusion of individuals.
l Index test. Any non-invasive test that could be utilised in a primary care setting or in the community.
l Purpose. A screening test to identify people with AF who have not sought medical attention on
account of symptoms associated with AF.
l Target disorder. AF.
l Reference standard. 12-lead ECG interpreted by a cardiologist.
Search strategy and selection criteria
MEDLINE, PreMEDLINE, EMBASE, The Cochrane Library, the Centre for Reviews and Dissemination (CRD)
and the Science Citation Index were searched without language or date restrictions until January 2015.
The search strategy included terms for atrial fibrillation and DTA or atrial fibrillation and diagnosis and
the names of specific tests [pulse palpation, finger probe, ECG (single-lead, 12-lead, ambulatory, serial,
continuous), Holter, cardiac event recorder, modified blood pressure monitor] (see Appendix 1 for the
search strategy run in MEDLINE). Grey literature sources were also searched [Google, National Guideline
Clearing House, Guidelines International Network (GIN), Current Controlled Trials, WHO International
Clinical Trials Registry Platform, ClinicalTrials.gov, UK Clinical Trials Gateway, OpenGrey, NICE website,
King’s Fund, Department of Health, National Institute for Health Research (NIHR) UK Clinical Research
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Network (UKCRN), PROSPERO, European Society of Cardiology, American College of Cardiology, British
Heart Foundation, Atrial Fibrillation Association, Arrhythmia Alliance] with search terms including AF and
diagnosis. Additionally, the reference lists of identified systematic reviews and eligible studies were
hand-searched to identify potentially relevant studies.
Titles and abstracts were screened independently by two reviewers (AM and GO) to identify potentially
relevant studies. At title and abstract screening stage, studies were excluded if the target condition was
not AF, the study was not a DTA study, the study was performed exclusively in people with diagnosed or
treated AF, or if the index test was invasive, not possible in primary care or did not detect arrhythmia. Full
texts of the remaining studies were then obtained and assessed for study eligibility using the full set of
inclusion and exclusion criteria. This was also performed independently by two reviewers (AM and GO).
Conflicts at each stage were resolved through discussion with a third reviewer (PD).
Inclusion/exclusion criteria
Study design/participants
We included cross-sectional, case–control, cohort studies, and RCTs that recruited at least 40 adults
(≥ 18 years) who had not sought medical attention on account of symptoms associated with AF (with the
exception of cases in case–control studies). Case–control studies had to recruit at least 40 adults (≥ 18 years).
Case–control studies that had a control group made up exclusively of people with another diagnosed
arrhythmia were excluded. Studies in stroke inpatients and outpatients, cardiology inpatients and
outpatients, anticoagulant outpatients and intensive care patients were excluded (as case and non-case mix
were likely to be different and/or these were inappropriate settings for screening) as were studies in patients
with a diagnosis of AF who had had treatment such as ablation or cardioversion and studies in people with
pacemakers/paced rhythms.
Tests
The index test must have been non-invasive and suitable for screening to detect arrhythmia and could be
administered in a primary or community care setting and the presence or absence of AF must have been
confirmed with a 12-lead ECG interpreted by a cardiologist (the reference standard). Although the index
test must have been able to be performed in a community or primary care setting, index tests interpreted
by a cardiologist were eligible because it is feasible that screening could take place in primary care but that
the test results could be sent to a cardiologist for interpretation. Studies in which the reference standard
was not a 12-lead ECG interpreted by a cardiologist were excluded. Studies that investigated invasive or
echocardiographic methods of identifying AF were also excluded.
Setting
Studies were eligible for inclusion if they were performed in secondary or tertiary care settings, in addition
to primary care or community care settings, as long as the case and non-case mix was judged to be likely
to be similar to that seen during screening (e.g. outpatient day surgery) and the tests used could be
administered in a primary or community care setting. The requirement for a study population similar to
that seen during screening was to minimise spectrum bias.50
Outcomes
Only studies that reported the results per person and from which either diagnostic two-by-two contingency
tables could be generated (i.e. studies that reported data from which the number of true positives, true
negatives, false positives and false negatives could be extracted or calculated) or direct estimates of
sensitivity (proportion of true positives) and specificity (proportion of true negatives) together with standard
errors could be obtained were included. Studies in which the unit of analysis was not the person (e.g. the
unit of analysis was the reading or the segment of a reading) and studies in which DTA information for AF
only could not be extracted (e.g. if AF and atrial flutter were combined) were also excluded.
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Data extraction
Data extraction was performed by one reviewer (AM) and checked by a second reviewer (GO).
Any disagreements were resolved through discussion with a third reviewer (PD).
The following data were extracted:
l authors, publication year, journal
l study design
l characteristics of study participants including age, sex and ethnicity
l study inclusion and exclusion criteria
l setting
l prevalence of comorbidities (e.g. hypertension, diabetes, renal failure, heart failure, heart disease,
previous stroke or MI) or risk of stroke CHA2DS2-VASc score
l prevalence of AF and prevalence of AF by type (paroxysmal, persistent, permanent)
l method of participant recruitment
l index test, including how and when the test was performed, the frequency of screening and the length
of monitoring, and who performed the test and interpreted the test results
l definition of a positive index test result/cut-off value
l reference test, including definition for positive disease
l whether the readers of the index test and reference standard were blind to the results of the other test
and other clinical information available to readers
l number of missing or unavailable test results
l numbers of true positives, true negatives, false positives and false negatives.
When studies reported the DTA of multiple thresholds for the same test or the DTA of more than one type
of the same class of device, data for all thresholds/devices were extracted.
In studies in which three groups were included (cases with AF, control subjects with another arrhythmia
and sinus rhythm/healthy control subjects), DTA information was extracted for AF cases compared with
sinus rhythm/healthy control subjects when possible. When this was not possible (i.e. the analyses pooled
the two control groups), data were extracted but the study was not included in the meta-analysis.
Study quality
Study quality was assessed using the QUality Assessment of Diagnostic Accuracy Studies – 2 (QUADAS-2)
tool.51 The QUADAS-2 tool consists of four key domains: patient selection, index test, reference standard
and flow of patients through the study and timing of index tests, and reference standard (flow and
timing). Each domain is assessed in terms of risk of bias, and the first three are assessed in terms of
concerns regarding applicability. The tool was tailored to the review by modifying signalling questions,
which help to inform judgements, and developing review-specific guidance. The signalling questions and
guidance for this review are detailed in Appendix 2.
Statistical methods typically used to gauge risk of reporting bias may be misleading if applied to
meta-analyses of test accuracy.52 Therefore, reporting bias was not assessed statistically using methods
such as funnel plots.
Statistical analysis
Data inputs for the statistical analysis
If results were reported for more than one threshold for a study, then we included data for each reported
threshold in the statistical analysis. Some studies reported results broken down by interpreter. For example, in
some studies the same set of readings was independently interpreted by different health-care professionals.
These ‘replications’ provided information on the variability in sensitivity and specificity that is likely to be
achieved in practice across different interpreters. Other studies set out to compare the sensitivity and
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specificity depending on interpreter type (e.g. nurse, GP, cardiologist). We explored whether or not results
for diagnostic accuracy depended on the interpreter by further classifying the tests according to whether
they were interpreted by a nurse, a GP or a cardiologist, or automatically/using an algorithm.
Descriptive analyses
Summary sensitivity and specificity values for each index test (and threshold) compared with the reference
standard were calculated together with confidence intervals (CIs) and were displayed using forest plots.
Evidence synthesis
Formal evidence synthesis was conducted by fitting a hierarchical summary receiver operating characteristic
(HSROC) model53 to estimate the relationship between sensitivity and specificity of the index tests. The
HSROC model estimates a summary receiver operating characteristic (SROC) curve allowing for correlations
between sensitivity and specificity and heterogeneity between studies. The SROC curve depends on the
threshold (cut-off point) for the test, the accuracy of the test and the shape of the curve (Figure 1).
We attempted to fit both symmetrical and asymmetrical HSROC models; however, there were too few data
to identify the shape parameter (regardless of whether this was constant, exchangeable or independent
across studies) and so results for symmetrical HSROC models only are reported. We adapted the HSROC
model to allow an extra level of variability between interpreters in studies with replicates; however, we
again found that there were too few data to estimate this extra level of variability. We therefore reported
results from a model that does not estimate between-interpreter variability. We allowed for multiple
thresholds by treating these as independent observations but with the same study-specific accuracy.
We fitted two models, one with and one without classifying the tests according to the interpreter.
The models were fitted using a Bayesian approach computed in OpenBUGS version 3.2.3 rev 101254
(MRC Biostatistics Unit, Cambridge, UK). Model fit was assessed using the posterior mean deviance,55 and
models were compared using the deviance information criterion (DIC).55 Full details of the model fitted,
including computer code, are provided in Appendix 3.
The results of the HSROC models were presented as SROC curves with confidence regions and prediction
regions for sensitivity and specificity.
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FIGURE 1 Illustration of the SROC curve.
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Investigations of heterogeneity and subgroup and sensitivity analyses
We inspected between-study variance for evidence of heterogeneity and compared the fit of a HSROC
curve with that of a fixed-effects SROC curve. When sufficient evidence was available, we explored possible
explanations for heterogeneity through prespecified subgroup analyses: study design, study year, setting,
method of recruitment into the study (and whether it would mimic a targeted, systematic opportunistic or
systematic screening programme), age of participants, prevalence of AF (and AF subtypes), prevalence of
comorbidities and stroke risk score, frequency of screening (if multiple moment-in-time screening tests were
identified), length of monitoring (if ambulatory tests were identified) and cut-off value. We also conducted
sensitivity analysis for risk-of-bias indicators according to the QUADAS-2 domains.
Systematic review of randomised controlled trials comparing
screening strategies
Objectives
The objective of this systematic review was to update the Cochrane review of screening strategies for AF.49
During the course of our review we identified that the Health Information and Quality Authority (HIQA) in
Ireland had published a health technology assessment (HTA) of a national screening programme for AF
in primary care.25 The HIQA HTA project25 included a review of the effectiveness of screening, which
updated the Cochrane review49 with the results of a literature search covering June 2012 to June 2015. In
addition, we were also informed that the Cochrane review itself was being updated (currently undergoing
peer review, Patrick Moran, Health and Quality Association, Dublin, Ireland, 2015, personal communication)
and, with the assistance of the review authors, we updated this version of the review while expanding the
scope to include head-to-head trials and trials that had not confirmed the presence or absence of AF with a
12-lead ECG interpreted by a GP, a specialist or a suitably trained ECG technician.
Review questions
Our review questions were as follows.
l Does systematic screening increase the detection of AF compared with current routine practice?
l What are the characteristics of those identified with AF by screening strategy?
l Which combination of screening strategy, screening population and test is the most effective at
detecting AF compared with routine practice?
l What are the potential safety issues and adverse events associated with individual screening programmes?
l How acceptable is the intervention to the target population?
l What are the costs associated with systematic screening for AF?
The protocol for the systematic review was registered with the NIHR international prospective register of scientific
reviews (PROSPERO) prior to executing the literature search strategy (registration no. CRD42014013739).56
In line with the Cochrane review, which we aimed to update, our PICO (population, intervention,
comparator, outcome) framework was as follows.
Study design
We had originally planned to include all of the study designs that were considered by the original
Cochrane review (RCTs, cluster RCTs, controlled before-and-after studies and interrupted time series).
However, the Cochrane update was restricted to RCTs only (Patrick Moran, personal communication). We
therefore changed our inclusion criteria to focus solely on RCTs.
Population
The population of interest was adults aged ≥ 40 years of either sex. This age cut-off point was chosen
based on epidemiological data which suggest that AF is extremely uncommon below the age of 40 years.57
We restricted the population to those in whom screening could occur (and therefore, for example, excluded
testing/monitoring for AF in stroke patients).
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Interventions and comparator
The interventions of interest were population-based, systematic (opportunistic, targeted or population)
screening programmes for AF (see Chapter 1, Systematic screening strategies). In contrast to the Cochrane
review, in which studies that compared one or more screening strategies with no screening (routine
practice) were included, we additionally included studies that compared two or more screening strategies
(without a ‘no screening’ arm).
Our primary interest was in screening strategies conducted within a primary care setting, but we did not
exclude studies on the basis of setting as long as the population screened was generalisable to the
general population.
Primary outcome
The primary outcome was the difference in the detection of new AF cases associated with screening
compared with usual practice. To be eligible for the Cochrane review, cases of AF had to be confirmed
using a 12-lead or continuous ambulatory ECG interpreted by a GP, a specialist or a suitably trained ECG
technician. However, because of a lack of studies, we expanded the scope and did not exclude studies on
the basis of the method used to confirm AF.
Secondary outcomes
As in the original Cochrane review,49 other outcomes of interest, including for our economic evaluation, were:
l change in diagnosed AF (after screening compared with before screening)
l the acceptability of systematic screening programmes
l adverse events associated with systematic screening
l costs associated with systematic screening programmes for AF.
In addition, we were also interested in the patient characteristics of those detected with AF, for example
age, sex, clinical history, CHA2DS2-VASc score and AF type.
Search strategy and selection criteria
The Cochrane review team confirmed that all head-to-head RCTs of systematic screening would have been
identified by their search strategy and would have been examined at full text, although those without a
no screening control arm or without AF diagnosis confirmed by a 12-lead or continuous ambulatory
ECG interpreted by a GP, specialist or suitably trained ECG technician would then have been excluded.
The Cochrane review team kindly provided us with a list of excluded studies that they thought may be
relevant to this review. We examined this list to identify studies meeting our inclusion criteria. In addition,
we updated the update by searching MEDLINE and PreMEDLINE, EMBASE, The Cochrane Library’s
CENTRAL and CINAHL from July 2015 to December 2015.
An information specialist searched health-care databases and other literature sources to identify published
and unpublished literature on human subjects, in any language. Our searches were developed for MEDLINE
and then adapted for other literature sources when necessary (see Appendix 4 for details). Reference and
citation tracking were undertaken to identify further relevant studies. When necessary, we contacted lead
authors for more information on published and unpublished studies that might be relevant. We also sought
information on studies in progress.
After removal of duplicates, articles were screened in parallel by two reviewers (GO, AM) applying our
eligibility criteria and using a two-stage sifting approach to review article title and abstract and then full
text. As the Cochrane review and the ongoing update review excluded comparative studies that did not
have a no screening arm (control), two reviewers (GO, AM) reassessed the list of excluded studies provided
by the Cochrane review authors for inclusion. In all cases, disagreements were discussed between the two
reviewers and, if not resolved, resolution was sought through the involvement of a third reviewer (PD).
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Data extraction
We developed data extraction forms and piloted them on two studies. Data were extracted from included
studies according to the PICO framework using the piloted extraction forms. Data extraction was
conducted by one reviewer and then reviewed by a second reviewer. Disagreements were discussed
between the two reviewers and, if not resolved, resolution was sought through the involvement of a third
reviewer. We extracted data on the following:
l study details (identifier, study design, location, year, length of follow-up, study funder)
l participant details (number of participants, age, sex)
l intervention details (population screening type, screening test, method of AF diagnosis, timing)
l comparator details
l details relevant to the risk-of-bias assessment
l effect modifiers (demography of the study population, study settings).
Assessment of risk of bias
Risk-of-bias assessments were conducted by one reviewer and then reviewed by a second reviewer.
Disagreements were discussed between the two reviewers and, if not resolved, resolution was sought
through involvement of a third reviewer. Risk of bias was assessed using the Cochrane tool for assessing risk
of bias in randomised trials.58 This tool assigns the judgement of low, high or unclear risk of bias for each of
the following sources of bias: random sequence generation, allocation concealment, blinding of participants
and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting. Additional
items for assessing the risk of bias in cluster randomised trials were derived from the Cochrane-suggested
risk-of-bias assessment tool for Effective Practice and Organisation of Care (EPOC) reviews.59
Abstracts that were assessed to meet the study eligibility criteria for inclusion were subjected to data
extraction only and not to assessment for risk of bias because of a lack of information to enable
judgement on some of the criteria.
We planned to use funnel plots to assess reporting bias; however, insufficient numbers of studies were
identified for this to be possible.
Data analysis
We have tabulated study-specific characteristics, outcome measures and risk-of-bias assessments, and we
provide a narrative overview of the results from the included studies.
We report results for binary outcomes (e.g. proportion of new AF diagnoses) only for studies in which
there is a clear denominator. We report results for the proportion of new AF diagnoses among those
without a previous diagnosis of AF and summarise relative effects between study arms using the odds ratio
(OR). The number needed to screen (NNS) to detect an additional newly diagnosed AF case was calculated
as the reciprocal of the risk difference (difference in proportion of new cases detected between study
arms). We computed the prevalence of previously diagnosed AF prior to screening by pooling across arms
within a study. We calculated the prevalence of AF diagnoses before and after screening to compute the
percentage change in prevalence as a result of screening. We examined the acceptability of systematic
screening programmes within the screened population in three ways: from the level of uptake achieved,
feedback elicited from the participants and health professionals involved and a description of any direct
costs associated with screening that were borne by the person to whom the screening programme was
offered. Patient characteristics of those diagnosed with AF (age, sex, clinical history, CHA2DS2-VASc score,
AF type) are described when reported. We report any adverse events associated with screening reported in
the studies. We also report information on the incremental cost to the NHS per additional newly diagnosed
AF case identified for a given screening strategy compared with routine care when this was reported in
RCTs conducted in the UK. We planned the following subgroup analyses when enough data were
available: aged ≥ 65 years compared with 65–75 years compared with > 75 years; men compared with
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women; different ethnic and socioeconomic groups; and community compared with specialist settings.
We also planned a sensitivity analysis excluding trials with a high risk of bias if there were enough data.
Meta-analysis was conducted when feasible (enough data on outcomes defined in the same way) to
obtain pooled ORs with 95% CIs. We did not anticipate there being a sufficient number of studies
to estimate random-effects meta-analysis models and so reported results from fixed-effects
meta-analysis only.
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Chapter 3 Results: diagnostic test accuracy review
Study selection
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart for the
review is shown in Figure 2. After the removal of duplicate records, we identified 4084 potential citations,
of which 3809 studies were excluded at title and abstract level as it was clear that the target condition
was not AF, the study was not a DTA study, the study was performed exclusively in people with diagnosed
or treated AF, or that the index test was invasive, not possible in primary care or did not detect arrhythmia.
After a full-text review of the remaining 270 studies, 253 studies were excluded because they did not meet
the full set of inclusion criteria. The list of studies excluded and the reasons for their exclusion are detailed
in Appendix 5. Although there was consensus between reviewers that these studies should be excluded,
there were often multiple reasons for exclusion and consensus was not always obtained. Reasons for
exclusion were that the study was not a DTA study; that the target condition was not AF (this included
studies in which DTA data for AF could not be extracted, for example when AF and atrial flutter were
combined); that the information was not per person (i.e. the unit of analysis was not the person, for
example the unit of analysis was the reading or the segment of a reading); population reasons (people
Records identified by systematic search
(n = 6844)
(n = 6352 from MEDLINE and PreMEDLINE,
EMBASE, The Cochrane Library, CRD,
Science Citation index;
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exclusion in Appendix 5)
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FIGURE 2 The PRISMA flow chart.
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with a diagnosis of AF who had had curative treatment such as ablation or cardioversion, people with
pacemakers/paced rhythms, stroke inpatients and outpatients, cardiology inpatients and outpatients,
anticoagulant outpatients and patients in intensive care, and studies with < 40 participants); index test
reasons (invasive, not possible in primary care or does not detect arrhythmia); reference standard
(i.e. not a 12-lead ECG interpreted by a cardiologist).
Seventeen publications19,36,60–74 (15 studies) containing 56 comparisons of an index test with the reference
standard were found to meet the full set of eligibility criteria and were included in the review. One
publication contained two eligible studies.60 The protocol and results of one study were reported in three
publications.19,36,61 One study also had an erratum published.62,63
In addition, four potentially relevant DTA studies were identified (Table 1); these trials are awaiting
assessment against our eligibility criteria as study reports and results were not identified.
Study characteristics
The characteristics of the included studies are summarised in Table 2.
Study design
There were 10 studies with a single set of inclusion criteria (cohort or one-gate studies),19,60,63–69 three
studies with two sets of inclusion criteria (case–control or two-gate studies)70–72 and two studies of unclear
design.73,74 One of the case–control studies grouped participants into those with known sustained AF,
those with other non-AF arrhythmias and those in sinus rhythm.71
Population and setting
Only four studies were performed in primary care.19,67,70,72 The other studies were performed in outpatient
settings (hypertension outpatients,63 presurgery64), secondary care or higher settings60,65,66,68,69 or a mixture
of outpatient and secondary care or higher settings [outpatient clinics including cardiology outpatients and
the preadmission clinic (ECGs carried out prior to surgery in patients aged > 40 years);74 outpatient and
inpatient settings;60 outpatient hypertension clinic, patients admitted to University Department of Medicine
wards and healthy volunteers71]. In one study the setting was unclear (a computerised electrocardiographic
system).73
A secondary objective of this review was to determine the DTA of index tests in systematic (opportunistic,
targeted and population) screening settings. To do this we had to assess whether the populations studied
represented the populations who would attend if a population-based systematic screening programme was
in place. In practice, this was difficult to achieve as it was unclear how the study populations were selected
and recruited. We were able to categorise only four studies, three of which represented population
TABLE 1 Details of potentially relevant DTA studies that are either ongoing or for which no publication was identified
Clinical trial identifier Title Status
NCT02262351 Programme for the Identification of ‘Actionable’ Atrial Fibrillation in
the Family Practice Setting (PIAAF-FP)
Completed
NCT02270112 Enhanced Diagnostics for Early Detection of Atrial Fibrillation
(DETECT-AF)
Completed
NCT02124629 (now NCT02401451) Six Lead Identification of Atrial Fibrillation (SL-AF) Completed
NCT02162394 A Study to Determine the Feasibility of Wireless Echocardiography Completed
RESULTS: DIAGNOSTIC TEST ACCURACY REVIEW
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systematic screening (one recruited individuals aged ≥ 75 years from primary care,67 one case–control study
recruited cases and controls aged ≥ 65 years from primary care70 and one case–control study recruited a
convenience sample of people from primary care72) and one that represented targeted screening (patients
referred to a hypertension clinic63). However, it should be noted that case–control studies, by design,
include individuals who are clearly cases or controls and who do not tend to fully reflect a population-
based screening population. We were unable to classify the population in one study in primary care
because it was part of a RCT that compared systematic population and systematic opportunistic screening,
with participants from both arms feeding into the DTA study.19
In the included cohort studies, the prevalence of AF varied between 0.93%64 and 32.93%.68
Age was an inclusion criterion in seven studies. Participants had to be ≥ 18 years in two studies,63,66 ≥ 35
years in one study,71 ≥ 60 years in one study,69 ≥ 65 years in two studies19,70 and ≥ 75 years in one study.67
Seven of the studies excluded patients with a pacemaker and/or an implanted defibrillator (in some cases
only if they were in active pacing mode).63,65–67,71,72,74
Only seven studies reported any characteristics of the included cohorts19,63,64,66,67,71,72 and, of these, only
three reported on comorbidities and/or treatments received.67,71,72
Index test
The 15 studies contained 56 eligible comparisons of index test with the reference standard. Not all
comparisons in the included studies were included because of ineligible cohorts68,73,74 or because the results
were not reported in a usable format (e.g. pooling multiple readings of the same scans19 or data being
presented per reading rather than per person71).
The index test used was classified into one of eight categories to facilitate the analyses:
l pulse palpation
l photoplethysmography
l modified blood pressure monitor
l single-lead ECG
l > 1- and < 12-lead ECG
l 12-lead ECG
l ambulatory monitoring
l two-stage screening.
Two studies investigated pulse palpation.19,70 In both studies, the pulse palpation was performed by a nurse,
but in one study the accuracy of pulse palpation by nurses with different backgrounds (a nurse who had a
background in both community and accident and emergency nursing and a practice nurse) was compared.70
Pulse palpation may have been investigated as an index test in one other study, but no results for this index
test were presented.67
Photoplethysmography was investigated in one study.69 This study used a portable device (AFS instrument),
which is a finger-probe instrument, as used in pulse oximetry. The resulting pulse waveform was interpreted
using fast Fourier transform analysis and the results were presented for three different cut-off values. The
data on photoplethysmography for the 0.20 cut-off value was obtained directly from raw data kindly
provided to us by Malcolm Lewis (Wales Postgraduate Deanery, Cardiff, 2015, personal communication)
and was used to estimate the data for the 0.25 and 0.30 cut-off values (using the number of false negatives
and false positives reported in the publication). However, we had confirmation from the authors that what
they have termed specificity in their paper is in fact (1 – the proportion of false positives in the whole
population). It was therefore possible to obtain the actual 2 × 2 data only for the 0.20 cut-off value and so
only this cut-off value was included in the meta-analysis.
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A modified blood pressure monitor was used as the index test in three studies.63,67,71 These devices have
been modified to detect pulse irregularity during blood pressure measurement. In all three studies, AF was
detected automatically/by an algorithm. In one study, the WatchBP device was used.67 One study compared
two different blood pressure monitors: Microlife BP A200 Plus and OMRON M6.63 One study used the
Microlife BPA100 Plus and different cut-off values for the number of positive results needed to screen
positive (readings were taken in triplicate and the cut-off values investigated were positive on the first
reading, positive on either of the first two readings, positive on any of the three readings, positive on two of
the three readings).71 This study recruited 27 people with AF, 23 people with non-AF arrhythmias and 23
people with sinus rhythm.71 We specified that, when possible, when studies were made up of three groups
of participants (people with AF, people with another arrhythmia, people in sinus rhythm) we would extract
results for people with AF and people in sinus rhythm (because the people in sinus rhythm are more similar
to our target screening population). However, in this study the authors pooled the people with a non-AF
arrhythmia and the people in sinus rhythm as non-AF cases. This may have impacted on the observed
specificity of the test. Because of this, although all results are reported in Figure 5, we excluded the data
derived from this study71 in the meta-analysis.
Single-lead ECGs were used in five studies.66,67,70,72,74 Various different devices were used. The Omron
(model HCG-801), which requires placing one electrode on the individual’s bare chest while the index
finger of the right hand holds the device, was included in two studies,66,67 interpreted by a cardiologist. The
Merlin ECG event recorder, which resembles a watch that the individual covers with the palm of his or her
right hand to take a reading, was included in one study,67 interpreted by a cardiologist. Bipolar ECG using
just a single bipolar lead from a 12-lead ECG machine was included in a single study,70 interpreted by
nurses with different backgrounds (training/experiences with ECGs). The AliveCor device, which takes a
single-lead ECG recording when fingers from each hand are placed on electrodes on the back of an
iPhone (Apple Inc., Cupertino, CA, USA) case, was used in one study,74 with interpretation by an optimised
algorithm. The MyDiagnostick device, in the form of a rod with a metal handle on both ends containing
electrodes, was included in a single study72 and was also analysed automatically.
Greater than 1- and < 12-lead ECGs were used in two studies.64,65 In one study 12-lead ECGs were
reconstructed from V2 and V5 leads or V1 and V4 leads and interpreted by an algorithm.65 In one study
three-lead tele-ECGs were interpreted by two different cardiologists.64
Twelve-lead ECGs interpreted by different diagnostic algorithms were compared with 12-lead ECGs
interpreted by a cardiologist in six studies, with more than one algorithm tested in some cases.19,60,65,68,73
One of these studies also investigated the effect of the ECG machine by comparing the diagnostic
accuracy of an algorithm for ECGs recorded using two different machines (GE Marquette system
MAC5000 and Bionet EKG3000).60 Twelve-lead ECGs interpreted by nurses with different backgrounds
(experience/training with ECGs) and a GP were compared with 12-lead ECGs interpreted by a cardiologist
in one study.70 We excluded one arm of a study investigating the accuracy of 12-lead tele-ECGs because of
the index test being a variant of the reference standard (sensitivity and specificity were 100%).64
The results of one of the studies that reported the DTA of 12-lead ECGs interpreted by a diagnostic
algorithm were reported in two publications.19,36 In these publications, people could have a positive,
negative or uncertain result on this test. The number of people obtaining an uncertain result was slightly
different in the two publications. The numbers extracted and reported in this review are from the later
publication.36 In addition, in this publication individuals obtaining an uncertain result were considered to
have obtained a negative test result to calculate the sensitivity and specificity of the test. In practice,
those with an uncertain test result may be referred for further testing (effectively treated as test positives).
If the uncertain results were considered to be positive results it would increase the sensitivity but decrease
the specificity.
None of the included studies used any form of ambulatory monitoring.
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Two studies investigated some form of two-stage screening. One study modelled a two-stage screening
process in which individuals who had a positive result with the modified blood pressure monitor (WatchBP)
went on to have a single-lead ECG with autoanalysis (Omron).67 One study looked at six different
combinations of pulse palpation by different nurses (nurse A, who had a background in both community
and accident and emergency nursing and who had experience of taking and interpreting ECGs; and nurse B,
a practice nurse with no additional ECG training) followed by a bipolar or 12-lead ECG interpreted by either
a nurse or a GP for those who screened positive:70
1. pulse palpation assessed by a nurse (A) followed by a bipolar ECG interpreted by a nurse (A) for those
who screened positive
2. pulse palpation assessed by a nurse (A) followed by a bipolar ECG interpreted by a GP for those who
screened positive
3. pulse palpation assessed by a nurse (A) followed by a 12-lead ECG interpreted by a nurse (A) for those
who screened positive
4. pulse palpation assessed by a nurse (A) followed by a 12-lead ECG interpreted by a GP for those who
screened positive
5. pulse palpation assessed by a nurse (B) followed by a bipolar ECG interpreted by a GP for those who
screened positive
6. pulse palpation assessed by a nurse (B) followed by a 12-lead ECG interpreted by a GP for those who
screened positive.
Reference standard
The reference standard in all studies was a 12-lead ECG interpreted by a cardiologist, apart from one study
that used an ECG classified by a clinician and validated by a researcher (a cardiac electrophysiologist),68
which was judged to be equivalent to interpretation by a cardiologist.
Quality assessment
The methodological quality of the included studies assessed using the QUADAS-2 criteria is presented in
Table 3. Many studies investigated multiple index tests. The index tests for each study are listed and
grouped according to their quality assessment.
Risk of bias: patient selection
Four studies were judged to be at low risk of bias for patient selection. Three of the cohort studies reported
that consecutive or randomly selected individuals were included62,65,66 and, although no details were
provided about the method of inclusion, it seemed possible that it was consecutive in one other study.69
The three studies with two sets of inclusion criteria (case–control or two-gate studies)70–72 and the two
studies of unclear study design73,74 were judged to be at high risk of bias.
The other studies were judged to be at an unclear risk of bias because of concerns over or lack of information
on the method of enrolment and/or concerns over or lack of information on exclusion criteria.19,60,64,67,68
Risk of bias: index test
The majority of the studies were scored as being at low risk of bias on the index test domain. However,
one study was judged to have an unclear risk of bias for some of the index tests investigated because it
seemed possible that the test interpreters for some of the index tests were aware of the results of another
of the index tests.67 Three studies were judged to be at high risk of bias on the index test domain, mainly
because the cut-off point used to screen positives was not prespecified.68,69,71
Risk of bias: reference standard
No studies were judged to be at high risk of bias for this domain. Studies were assessed as being at
unclear risk of bias because they did not explicitly report that the interpreters of the reference standard
RESULTS: DIAGNOSTIC TEST ACCURACY REVIEW
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were unaware of the results of the index test60,65,71 or because the index test was interpreted by a clinician
and validated by a researcher (a cardiac electrophysiologist).68
Risk of bias: flow and timing
All studies were judged to be at low risk of bias for the domain of flow and timing.
Applicability: patient selection
Only those studies performed in primary care were judged to have a low level of concern with regard
to applicability.19,67,70,72
Applicability: index test
Studies in which the index test was interpreted by a cardiologist were judged to be less applicable (high
level of concern regarding applicability) than studies interpreted in primary care/by an algorithm.64,66,67
Applicability: reference standard
All of the studies were judged to have a low level of concern regarding applicability apart from one, because
the index test was interpreted by a clinician and validated by a researcher (a cardiac electrophysiologist).68
Study results
The results of the studies are presented in Figures 3–9.The raw results are presented regardless of whether
or not they were included in the statistical analyses.
Statistical modelling results
The data included in the model are described in Appendix 6. There were too few data to estimate
asymmetrical HSROC curves. We therefore present results from the symmetrical HSROC model. Evidence
of heterogeneity across and within studies was found, justifying our choice of random effects at both of
these levels (see Appendix 6). In terms of model fit, there was little difference between the model with and
the model without distinguishing between interpreter type, suggesting that there is no evidence that DTA
depends on interpreter type (see Appendix 6). This finding is, however, partly due to a lack of evidence,
with some index tests investigated using only one particular interpreter type. Furthermore, because the
performance of the tests with different interpreter types is of practical interest in a screening programme,
we present the results with and without the inclusion of interpreter type in the definitions of the
index tests.
Figures 10 and 11 show the estimated HSROC curves for the different index tests, with interpreter and other
test specifics indicated by the different symbols. Figures 12 and 13 show the SROC curves for each index test
and interpreter combination, for those index tests with evidence for more than one interpreter. Tables 4
and 5 show the point estimates of sensitivity and specificity at the mean of the HSROC model, together with
diagnostic odds ratios (DORs) for different index tests and index test/interpreter combinations respectively.
Single-lead ECG generally has high sensitivity and specificity, but there is a lot of heterogeneity, as seen in the
results interpreted by a cardiologist (where the majority of the evidence lies). The sensitivity of 12-lead ECG is
good for all interpreters, but specificity varies by interpreter. Twelve-lead ECG has very good sensitivity and
specificity when interpreted by a GP, suggesting that this could be considered a gold standard test. ECGs with
between 1 and 12 leads have good specificity, but sensitivity is variable depending on the interpreter (but
good when interpreted by a cardiologist). A modified blood pressure monitor with automatic interpretation
has both good sensitivity and good specificity. Photoplethysmography has very good sensitivity, but slightly
less good specificity. Pulse palpation by a nurse has the poorest diagnostic performance, with the lowest
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TABLE 4 Diagnostic test accuracy summaries for the different index tests
Index test
Number of
observations
Number of
studies
Sensitivity at
mean of
HSROC model
Specificity at
mean of
HSROC model DOR (95% CrI)
Modified blood pressure
monitor
3 2 0.955
(0.864 to 0.992)
0.919
(0.777 to 0.982)
2.51
(2.17 to 2.67)
Single-lead ECG 16 5 0.961
(0.917 to 0.986)
0.94
(0.882 to 0.976)
2.56
(2.42 to 2.65)
Two-stage screening
strategy
7 2 0.943
(0.838 to 0.988)
0.966
(0.9 to 0.992)
2.63
(2.46 to 2.7)
Photoplethysmographya 1 1 1 (1 to 1) 0.867
(0.534 to 0.987)
2.39
(1.71 to 2.68)
12-lead ECG 12 7 0.927
(0.859 to 0.968)
0.974
(0.95 to 0.989)
2.65
(2.59 to 2.69)
> 1- and < 12-lead ECG 4 2 0.839
(0.553 to 0.973)
0.993
(0.978 to 0.999)
2.7
(2.66 to 2.72)
Pulse palpation 3 2 0.916
(0.75 to 0.986)
0.788
(0.51 to 0.945)
2.21
(1.67 to 2.57)
CrI, credible interval.
a Sensitivity of photoplethysmography did not converge.
TABLE 5 Diagnostic test accuracy summaries for the different index test and interpreter combinations
Index test/interpreter
Number of
observations
Number of
studies
Sensitivity at
mean of
HSROC model
Specificity at
mean of
HSROC model DOR (95% CrI)
Modified blood pressure
monitor
3 2 0.953
(0.851 to 0.993)
0.916
(0.759 to 0.983)
2.5
(2.14 to 2.67)
Single-lead ECG –
automatic/algorithm
3 3 0.967
(0.9 to 0.995)
0.9
(0.742 to 0.975)
2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 1 0.929
(0.711 to 0.995)
0.92
(0.7 to 0.992)
2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 1 0.94
(0.671 to 0.999)
0.973
(0.838 to 1)
2.65
(2.31 to 2.72)
Single-lead ECG –
cardiologist
9 2 0.959
(0.878 to 0.992)
0.927
(0.802 to 0.984)
2.53
(2.23 to 2.67)
Two-stage screening
strategy
7 2 0.941
(0.826 to 0.989)
0.964
(0.889 to 0.993)
2.62
(2.43 to 2.7)
Photoplethysmography 1 1 1 (1 to 1) 0.866
(0.516 to 0.989)
2.39
(1.68 to 2.69)
12-lead ECG –
automatic/algorithm
9 6 0.903
(0.803 to 0.961)
0.98
(0.958 to 0.993)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 1 0.967 (0.824, 1) 0.84
(0.484 to 0.982)
2.33
(1.62 to 2.67)
12-lead ECG – GP 1 1 1 (1 to 1) 0.973
(0.843 to 1)
2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG
– automatic/algorithm
2 1 0.83
(0.474 to 0.978)
0.985
(0.937 to 0.999)
2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG
– cardiologist
2 1 0.981
(0.756 to 1)
1 (0.999 to 1) 2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 2 0.919
(0.749 to 0.988)
0.787
(0.497 to 0.949)
2.21
(1.64 to 2.58)
CrI, credible interval.
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mean specificity and sensitivity. All of the two-stage tests have good specificity, but sensitivity depends on the
second-stage test, with good sensitivity with a 12-lead ECG as the second-stage test.
The DOR is an overall measure of test performance, with higher values indicating improved test accuracy.
The DOR is lowest for pulse palpation by a nurse, followed by photoplethysmography with automatic
interpretation. All other index tests have very similar DORs, with the highest DORs for 12-lead ECG
(regardless of interpreter), between 1- and 12-lead ECG (automatic or cardiologist interpretation),
two-stage tests and single-lead ECG interpreted by a GP. It should be noted that the DOR gives equal
weight to false-positive and false-negative results. In the context of a screening programme in which
a follow-up diagnostic test is likely to be conducted to confirm the diagnosis, it could be argued that
false-negative results are of more importance than false-positive results. The DOR should therefore be
interpreted alongside the mean sensitivity of the test.
Subgroup and sensitivity analyses
We conducted various subgroup and sensitivity analyses using the analysis in which the test definition
includes the interpreter. Table 6 summarises the proportion of observations for each test by subgroup,
risk of bias and concern of applicability category, indicating where there are enough data to conduct
subgroup/sensitivity analyses. The full results of the subgroup and sensitivity analyses can be found in
Appendix 7 and the results are summarised in the following sections.
Study year
There were too few data to perform a subgroup analysis for recent studies. Only one study reported
before 2000 (in 199273). The study by Slocum et al.73 was also of unclear design and setting, and it was
unclear which screening approach it reflected. Therefore, this study was excluded from the various
subgroup analyses reported in the following sections.
Study design
Study design was classified into cohort, case–control and unclear. Ten out of 15 studies (34 observations)
were cohort studies, and three out of 15 studies (20 observations) were case–control studies. We conducted
analyses including cohort studies only (our preferred study design), but found that the results were robust to
restricting to cohort studies only. It should be noted that single-lead ECG – nurse, single-lead ECG – GP,
12-lead ECG – nurse and 12-lead ECG – GP were studied only in non-cohort studies. Tests studied exclusively
in cohort studies included photoplethysmography and modified blood pressure monitors.
Screening approach
Three out of 15 studies (29 observations) most closely reflected population-based systematic screening,
one out of 15 studies (two observations) most closely reflected targeted screening and the remainder were
unclear. We conducted analyses restricting to studies most closely reflected by population-based systematic
or targeted screening, which are those most relevant to our decision question. The results were robust to
restricting to these populations; however, some tests, including photoplethysmography, were not studied
in systematic or targeted screening studies and so the results for these tests could be less applicable to our
decision question.
Setting
Four out of 15 studies (31 observations) were carried out in a primary care setting, 10 out of 15 studies
(24 observations) were carried out in a non-primary care setting (outpatients or secondary care and above) and
in one study (one observation) the setting was unclear. We present the results of subgroup analysis for the
primary care setting only as this is most relevant to our decision question. No differences were found from the
base-case results but, again, it should be noted that photoplethysmography was studied only in the non-
primary care setting and so the results for this test may be less applicable to screening in a primary care setting.
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Mean age/sex
The mean age of individuals was reported in only seven out of 15 studies (27 observations). Mean age
ranged from 61.4 to 79.7 years, with the majority of studies in the range 65–75 years. Because of the high
level of missing data on age and the similarity in mean age across studies it was not possible to perform
subgroup analyses based on age. The proportion of male participants was reported in the same subset of
studies that reported mean age, varying from 47% to 66%. It was therefore also not possible to report the
results according to sex.
Prevalence of atrial fibrillation and atrial fibrillation subtypes
It was possible to estimate the prevalence of AF in the included studies and this ranged from 0.9% to
53%, with no distinct groupings. We included prevalence as a continuous covariate in a meta-regression,
adding a regression coefficient for the effect of AF prevalence on false positive rate and true positive rate
respectively. We excluded case–control studies from the regression as they do not provide meaningful
estimates of prevalence. No data were reported on type of AF in any of the included studies and we were
therefore unable to report the results according to AF type.
Regression on atrial fibrillation prevalence
We found no evidence of a relationship between diagnostic accuracy and prevalence. Credible intervals
(CrIs) for the regression coefficients were wide and included no effect, also supported by the mode fit
being similar with and without inclusion of prevalence as a covariate.
Prevalence of comorbidities/stroke risk score, length of monitoring for
ambulatory tests and cut-off values for tests with quantitative reading
Only two studies reported information on comorbidities67,72 and only one reported information on CHA2DS2-
VASc score.72 It was therefore not possible to report the results according to comorbidities/stroke risk score.
No data were reported on length of monitoring for ambulatory tests and so no subgroup analysis was
possible. The only study that reported results for different cut-off values was that by Lewis et al.69 but, as
previously noted, the results were reliable only for a single cut-off value in this study (the one with the best
sensitivity). It was therefore not possible to perform a subgroup analysis on the cut-off values used.
QUADAS-2 risk of bias domains
We present the results restricting the analysis to low-risk studies only for each domain separately:
l risk of bias according to patient selection
l risk of bias according to index test
l risk of bias according to reference test
l applicability according to patient selection
l applicability according to index test
l applicability according to reference test.
All studies were rated as being at low risk of bias on the flow/timing of tests domain and so no sensitivity
analysis was necessary for this domain.
We found that the results were robust to all of these sensitivity analyses; however, it should be noted that
there was a lack of data to fully explore these. In particular, for most tests there was at least one domain
in which no observations were graded as being at low risk of bias/applicability. The exception was
modified blood pressure monitors, for which most of the observations were at low risk of bias/applicability.
Photoplethysmography was the only test to have no observations at low risk of bias for the index test,
suggesting that we should be cautious when interpreting the results for this test.
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Discussion
Summary of results
This review of 15 studies of screening tests for detecting AF found that most tests had a sensitivity
(probability of detecting AF in patients with AF) in excess of 0.9. In support of the view that screening could
be carried out in primary care, 12-lead ECG interpreted by a GP had a sensitivity of 1 (95% CrI 1 to 1)
and also a high specificity of 0.97 (95% CrI 0.84 to 1). Photoplethysmography also had a sensitivity of 1
(95% CrI 1 to 1), but with a lower specificity of 0.87 (95% CrI 0.52 to 0.99). Specificity was in general lower
than sensitivity for all of the tests and was lowest for pulse palpation by a nurse (specificity 0.79), 12-lead
ECG interpreted by a nurse (specificity 0.84) and photoplethysmography (specificity 0.87). Tests with the
highest DOR were the 12-lead ECG (regardless of interpreter), between 1- and 12-lead ECG (automatic or
cardiologist interpretation), two-stage tests and single-lead ECG interpreted by a GP, with all of these tests
having similar DORs. However, the DOR gives equal weight to true positives and true negatives, whereas for
a screening programme test sensitivity takes precedence over specificity (if the test is not too burdensome),
so that AF cases are not missed. False positives should be picked up subsequently by a confirmatory
diagnostic test. We are therefore interested in finding a test that primarily has good sensitivity; specificity is a
secondary consideration to avoid too many individuals being referred for a confirmatory diagnostic test.
In general, for a given interpreter, the results for single-lead ECGs were less accurate and more variable
than those for ECGs with more than one lead. Nurse interpretation of single-lead ECGs performed similarly
to single-lead ECGs with other interpretation methods, but nurse interpretation of 12-lead ECGs did not
perform as well as other interpretation methods. Automatic interpretation did not have a consistent impact
on test accuracy, with automatic interpretation of single-lead ECGs having a high sensitivity but variable
specificity. In contrast, automatic interpretation of ECGs with more leads had good specificity but
variable sensitivity.
The different two-stage screening strategies all had very high specificity, but sensitivity was high only
when a 12-lead ECG was used as the second-stage test. This supports the need for a 12-lead ECG as a
diagnostic test. Interestingly, a second-stage 12-lead ECG test interpreted by a (trained) nurse performed
similarly to that interpreted by a GP.
Strengths and limitations
Our review followed a published protocol, registered on PROSPERO.56 Inclusion was restricted to studies that
best represented a population-based screening programme conducted in primary care. A comprehensive
search strategy was used and the risk of bias and applicability of studies was assessed. The effect of
interpreter as well as the screening test utilised were both investigated. Preplanned subgroup and sensitivity
analyses were conducted when data allowed.
Analyses were limited by the small number of studies that met the inclusion criteria and hence the lack of
statistical power to detect meaningful differences. For example, not all combinations of screening test and
interpreter were included in the studies and, when present, few observations were reported. For this
reason tests were grouped in the statistical modelling. In particular, > 1- and < 12-lead ECGs included
3-lead ECGs as well as reconstructed ECGs resulting from different sets of leads. Similarly, two-stage
screening strategies encompassed varying combinations of tests in the two stages.
There was substantial heterogeneity in the test/interpreter combinations when there were repeated
observations, and it is likely that the same heterogeneity would be seen for the other tests if multiple
observations were available. Furthermore, we would expect more heterogeneity in test accuracy in practice
than is seen in research studies.
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None of the included studies was assessed to be at low risk of bias across all domains and to have a low
level of concern regarding applicability. In particular, only four studies were conducted in primary care.
Although we had preplanned a wide range of subgroup analyses and sensitivity analyses, there were
enough data available to perform only some of these. The way that the data were reported was in some
cases challenging. Some studies were designed so that the same ECGs were read by different individuals,
whereas in other studies different individuals read different sets of ECGs. Some studies presented the
results for patients with AF, individuals in sinus rhythm and patients with non-AF arrhythmias, but some
combined the sinus rhythm and non-AF groups when reporting results, which will underestimate test
accuracy as applied to the general population in which the proportion of other arrhythmias is much lower.
Although photoplethysmography performed well, only a single study69 used this method, and this study
was able to provide data only for a single cut-off point, which was chosen retrospectively for having the
best sensitivity. The index test in this study was rated as being at high risk of bias and the applicability of
patient selection was unclear. We are therefore cautious in interpreting the results from this screening test
and would ideally want the results to be replicated in a new cohort of individuals.
Findings in the context of previous research
European Society of Cardiology guidance recommends pulse palpation as the first step for AF screening.32,75
We found pulse palpation to have the lowest DOR, driven by its low specificity.
Guidance from NICE (medical technologies guidance MTG13)76 recommends the use of modified blood
pressure monitors for the detection of AF in individuals undergoing diagnostic testing or monitoring for
hypertension. We found that modified blood pressure monitors had high sensitivity, although specificity
was not as high as with other tests.
During the course of this review, two systematic reviews were published. One reported the accuracy of
methods for detecting an irregular pulse and suspected AF;77 the other reported the accuracy of methods
for diagnosing AF using 12-lead ECG.78 In addition, a systematic review of the DTA of automated blood
pressure monitors for opportunistic AF detection,79 and a review and meta-analysis of the DTA of the
algorithm for AF detection during automated blood pressure measurement80 have been published. These
reviews are summarised in Table 7.
RESULTS: DIAGNOSTIC TEST ACCURACY REVIEW
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Chapter 4 Results: systematic review of
randomised controlled trials comparing
screening strategies
Study selection
The systematic review is summarised in a PRISMA diagram (Figure 14). Seventeen records were identified
from the original Cochrane review49 and a further three records were kindly provided to us from the
ongoing Cochrane update review. An additional 2934 records were identified from our update searches
from April to May 2012 and from July to December 2015. In total, 2954 records were identified from all
sources. After removing duplicates, 2204 records remained. Sifting of these records revealed six eligible
articles26,40,81–83 representing four RCTs, all involving two study arms. These four RCTs, together with the
Id
en
fi
ca
ti
o
n
Sc
re
en
in
g
El
ig
ib
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ty
In
cl
u
d
ed
Full-text articles assessed for eligibility
(n = 28)
Excluded at full-text screening
(n = 22)
Reasons for exclusion 
• Observational study, n = 4
• Non-randomised, n = 1
• No comparator, n = 10
• Ineligible population, n = 1
• Not a comparison of interest, n = 1
• Ineligible intervention, n = 1
• No data of interest, n = 1
• Editorial review, n = 1
• Ongoing study, n = 2
Records remaining after removing
duplicates
(n = 2204)
Articles included in this review
(n = 6)
(representing four studies)
Records excluded following title and
abstract screening
(n = 2176)
Total number of studies included in this review (n = 5)
This includes the SAFE study (the only study included in the original Cochrane review) with two reference articles
From the list of studies
included, excluded or
marked as ongoing in the
Cochrane review
(n = 17)
From the list of studies
excluded or marked as
ongoing in the Cochrane
update review (update
searched for RCTs only)
(n = 3)
Records identified from April–May
2012 and July–December 2015
(n = 2934)
• MEDLINE/PreMEDLINE, n = 1160
• EMBASE, n = 1415
• The Cochrane Library’s CENTRAL 
   (2012 and 2015), n = 334
• CINAHL (by publication date), n = 25
FIGURE 14 The PRISMA flow chart: review of RCTs of screening strategies. CINAHL, Cumulative Index to Nursing
and Allied Health Literature.
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previously identified RCT from the original Cochrane review involving three study arms (with two reference
articles),19,84 were included in this review.
We also found one ongoing study and one study that has yet to publish its results (described in Table 8).85,86
Study characteristics
Table 9 provides a summary of the characteristics of the five included RCTs. All of the RCTs were conducted
in Europe, with two each conducted in the UK19,82 and Spain81,83 and one conducted in Sweden.40 Four
studies19,26,81,82 were multicentre RCTs and one was a single-centre RCT.83 Four RCTs involved individuals
aged ≥ 65 years19,81–83 and one RCT involved individuals aged 75 and 76 years.40 All five RCTs involved both
sexes. Two RCTs involved only individuals without a previous diagnosis of AF.81,83 Three RCTs each evaluated
systematic population screening19,40,82 and systematic opportunistic screening,19,79,82 one RCT evaluated
systematic targeted screening directly,83 and one RCT evaluated systematic targeted screening indirectly
by using results from those individuals identified at ‘high risk’ among those randomised to systematic
population screening.19 Screening tests employed across the RCTs were mainly pulse palpation and ECG
with AF diagnosis predominantly by ECG. However, it was clear in only one RCT that ECG interpretation
was by a cardiologist.19 The primary outcome across a majority of the included RCTs was the number of
new cases of AF in the study arms. The duration of study follow-up varied across the RCTs, ranging from
1 year to 5 years.
TABLE 8 Ongoing RCTs and RCTs yet to publish results that compared screening strategies
Study and study
design
Population
and setting Intervention Control Primary outcome
Estimated
completion date
IDEAL-MD;85
two-arm cluster-
randomised,
multicentre trial
People aged
≥ 65 years,
general
practice
Opportunistic screening
with single-lead ECG
(MyDiagnostick). When
the device indicates a
positive result, the single-
lead ECG will be assessed
to confirm/reject the
diagnosis
No
screening/
usual care
Difference in yield of
newly detected cases
of AF in 1 year
between intervention
and control practices
March 2017
(no results
available to date)
D2AF;
86 two-arm
cluster-randomised,
multicentre trial
People aged
≥ 65 years
without
previously
documented
AF, general
practice
Opportunistic screening
with single-lead ECG
(MyDiagnostick), pulse
palpation and a modified
blood pressure monitor
with an algorithm for
irregular beat detection
(WatchBP Home A).
Patients with a positive
result on at least one of
the tests and a random
sample of patients with
negative tests will have
their AF status confirmed
by 12-lead ECG and if
this is negative they will
additionally be tested
with a 2-week Holter
monitor. Patients tested
with the 2-week Holter
monitor will concurrently
use the MyDiagnostick
three times per day
No
screening/
usual care
Difference in yield of
newly detected cases
of AF in 1 year
between intervention
and control practices
January 2018
D2AF, Detecting and Diagnosing Atrial Fibrillation; IDEAL-MD, Improving DEtection of Atrial fibriLlation in Primary Care With
the MyDiagnostick.
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Overview of the five included studies
The SAFE study19,84
This study compared systematic population screening, systematic opportunistic screening and no screening.
The study employed a two-stage randomisation process. The first step was a balanced cluster randomisation
(stratified based on Townsend score quartiles and practice size) of 50 practices in the UK to either the
intervention (screening) arm or the control (no screening) arm. This was then followed by a random
assignment of individuals aged ≥ 65 years in the intervention centres to either systematic opportunistic or
systematic population screening. Individuals aged ≥ 65 years were also identified in the control arm.
Individuals randomised to systematic opportunistic screening had a flag placed in their notes to encourage
practice staff to take a pulse recording during routine consultation. If their pulse was found to be irregular
individuals were invited to attend a screening clinic. Individuals in the systematic population screening arm
were all invited by post to attend a screening clinic. The screening clinic was the same for both screening
arms (i.e. they differ only in how individuals were selected for invitation to the screening clinic). At the
screening clinic consent was obtained, baseline characteristics were recorded and a 12-lead ECG was
performed, which was interpreted by two blinded cardiologists, with interpretation by a third blinded
cardiologist in the case of disagreement. An acceptability questionnaire was also delivered to patients.
This study also identified ‘high-risk patients’ with cardiac failure, hypertension, rheumatic heart disease,
previous MI, angina, diabetes mellitus, hyperthyroidism, previous stroke or previous TIA (using practice
disease registers) among the individuals randomised to systematic population screening. If these patients
were selectively invited to screening, this would represent a targeted screening programme. The results of
targeted screening (using the whole population screening as the denominator) were compared with the
results of no screening.
Patients with previously diagnosed AF were included in the study, but the number of such patients was
reported so that the number of newly diagnosed cases could be ascertained. To identify previously
diagnosed cases of AF, patient notes were searched for ‘G573 AF/flutter’, ‘327 ECG supraventricular
arrhythmia’, ‘181 palpitations’, ‘digoxin’, ‘amiodarone’, ‘verapamil’, ‘sotalol’, ‘metoprolol’, ‘warfarin’ and
‘aspirin’. Case notes of patients identified were reviewed and a diagnosis of AF was accepted if there were
hospital letters referring to AF or confirmatory ECGs within the previous 5 years.
The primary study outcome was the number of newly diagnosed cases of AF during the 12 months of follow-up.
Newly diagnosed cases were identified using the same computer searches as performed at baseline.
The STROKESTOP study26,40
The STROKESTOP study aims to test the hypothesis that screening 75- and 76-year-olds for AF will reduce
stroke incidence cost-effectively. All 75- and 76-year-olds in two regions of Sweden were randomised to
either the systematic population screening arm or the no screening arm.
Participants who were randomised to the screening arm were sent an invitation by post. At the screening
centre, participants were asked about their medical history and an index ECG (using a hand-held single-lead
ECG) was taken. Participants without a history of AF who were in sinus rhythm were given a hand-held
single-lead ECG and instructed to use it twice daily and whenever palpitations were felt over a period of
2 weeks. The ECG transmitted the results to a database where they were interpreted by a nurse. All abnormal
ECGs were referred to the investigating cardiologist. When results were unclear, referral for interpretation by
a consensus group was used.
An interim publication has reported the AF detection rates in individuals in the screening arm who
presented at the screening clinic.40 Both the number of people with known AF and the number of people
with newly detected AF were reported. Results for the control arm will be obtained from a National Patient
Registry (Emma Svennberg, Danderyds Sjukhus AB, Stockholm, Sweden, 2015, personal communication)
but are not available currently.
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The primary outcome of this study is stroke prevention resulting from early identification of AF through
screening, and subsequent treatment, with 5 years’ follow-up. However, the study is still ongoing and not
due to report until 2019. Because the results are currently available only for the screening arm, this study
did not contribute data to our statistical analysis.
The Morgan and Mant82 study
This study compared systematic opportunistic screening with systematic population screening. Four general
practices in the UK were chosen to represent each quartile of the small area standardised mortality ratio
of the geographical area served and approximately 750 individuals aged ≥ 65 years from each practice
were randomly selected and then randomised to either the systematic opportunistic or the systematic
screening arm.
In the systematic opportunistic screening arm a flag was inserted into the patients’ notes so that if they
consulted with their GP or nurse for any reason during the duration of the study their pulse was taken. If
their pulse was found to be irregular the nurse or GP could choose to request a confirmatory ECG. In the
reported results from this study it was assumed that there was a clinical diagnosis of AF if the pulse was
irregular but a confirmatory ECG was not requested. In the systematic screening arm, all individuals were
invited by post to a screening appointment with a nurse who took a radial pulse reading for at least
20 seconds to record evidence of irregularity. A two-lead ECG reading interpreted by a GP was used for
validation. The primary study outcome was the number of AF cases after 6 months’ follow-up, but the
study also reports the number of cases with no previous evidence of AF in their medical records. However,
the number of people with and without AF in their medical records at baseline was not reported.
The two arms differed in the validation of AF cases: in the systematic screening arm, a two-lead ECG
interpreted by a GP was used for the validation of new cases of AF, whereas in the systematic
opportunistic screening arm ECG validation took place at the discretion of the nurse or GP taking the
pulse, with some cases identified by clinical diagnosis only and others based on an ECG (number of leads
and interpreter unspecified). This difference in validation could have influenced the reported results.
The DOFA-AP study81
This study compares systematic opportunistic screening with a control group (termed ‘usual care’). Details of
the study are currently only available in the protocol81 and in an unpublished abstract shared with us by
the ongoing Cochrane update review authors (P Moran, Health Information and Quality Authority, Ireland,
4 November 2015, personal communication). Eligibility criteria for the study were participant aged ≥ 65 years
and attending their health centre in Spain for any reason without a previous diagnosis of AF.
In the systematic opportunistic screening arm, it is reported that individuals underwent ‘active screening for
AF, regardless of the reason of their visit’ (p. 4).81 In the control arm an individual’s pulse was measured if
he or she presented with symptoms of sequelae associated with AF. AF was confirmed using an ECG, but
the ECG type and the information regarding the interpreter were not provided.
However, we have concerns about the interpretation of the results of the study. It is possible that to be
eligible for inclusion in the control group individuals had to be symptomatic, as the protocol reports that
individuals presenting with AF symptoms (dyspnoea, chest pain palpitations or dizziness) or AF-induced
sequelae (stroke, TIAs, peripheral embolism, heart failure or other associated health disorders) were eligible.
Another statement in the protocol that supports this suggestion is ‘since the probability of finding patients
meeting the eligibility criteria is much lower for the [control group (usual care arm)] than for the [intervention
arm], stratified randomization will be used to assign at least 200 primary care health professionals to the two
groups, in the ratio of a 2 : 3 ratio’ (p. 4).81 This suggests that the study may in fact be better described as a
comparison of targeted testing of symptomatic individuals (control arm) with systematic opportunistic
screening (intervention arm).
From the reported results in the abstract, the denominators are also not clear from the information available.
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The study result is also unintuitive (the authors reported more AF cases in the control arm than in the
screening arm), although this could be explained by differential inclusion criteria for each arm. Because of
the lack of information about the denominator for the control arm (both the actual number and what it
represents, i.e. the number randomised or the number randomised who presented with symptoms or
sequelae), the results from this study were excluded from our analysis.
The EARLY study83
This study compared targeted screening for AF with usual care (no systematic screening). Individuals in a
primary health-care centre in Spain were selected from electronic records on the basis of not having a
diagnosis of AF but having at least one of the main risk factors for AF. Individuals were then randomised
to either an early detection programme or the control arm. Individuals in the early detection programme
arm were invited by telephone to participate in the study. The early detection programme involved visits
every 6 months over a 2-year period, at which an ECG, a physical examination and a medical history were
taken/performed. On the first visit, advice on pulse taking was also given. The primary end point of the
study was the proportion of individuals with newly diagnosed AF at 6 months. A secondary outcome was
the number of individuals diagnosed with AF during the 2-year follow-up. Cases of AF were determined
from the medical records system.
Many individuals were excluded from each arm for different reasons. Of the 2000 people randomised to
screening, 616 were not found, 425 declined to participate, 78 were no longer assigned to the health
centres, three were deceased, 153 fulfilled at least one exclusion criterion (were disabled, had a pacemaker,
did not really have a risk factor, had AF at baseline) and 262 were not contacted. Of the 2000 people
randomised to the control group, 42 were no longer assigned to the health centres, six were deceased,
38 fulfilled at least one exclusion criterion and 1449 were not contacted.
Although the study reported that an intention-to-treat analysis was performed, it considered only the
individuals included in the study. In the intervention group, individuals could decline to participate, but in
the control group they could not. The study actually compared the incidence of AF in all people eligible for
screening but who received usual care with the incidence of AF in a self-selecting subgroup of people who
both were eligible and attended screening.
On the basis of these methodological limitations, we felt that it was inappropriate to include the results
from this study in our statistical analysis.
Risk of bias within the included studies
Table 10 and Figure 15 show the risk-of-bias assessments for the included studies. A complete assessment
of the STROKESTOP study26,40 could not be made as the results for only one arm of the study have been
published. None of the studies was assessed to be at low risk of bias across all of the domains. None of the
studies could blind participants and personnel to which arm they had been randomised to and therefore
they were all judged to be at high risk of bias for this domain. The SAFE study,19,84 on which the results of
most of this review are based, was judged to be at low or unclear risk of bias for the other domains.
Study results and meta-analysis
Newly diagnosed cases of atrial fibrillation among individuals without atrial
fibrillation at baseline
Of the five RCTs included in this review, only one (the SAFE study19,84) provided usable data on the relative
effects of screening on the proportion of newly diagnosed cases of AF among individuals without AF at
baseline. The results of this study are presented in Table 11.
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This SAFE study examined systematic population screening and systematic opportunistic screening compared
with no systematic screening (usual practice). Both systematic population screening and systematic
opportunistic screening increased the odds of detecting new cases of AF among individuals without known
AF at baseline compared with usual practice (systematic population screening OR 1.57, 95% CI 1.09 to
2.26; p = 0.017; systematic opportunistic screening OR 1.59, 95% CI 1.10 to 2.29; p = 0.013). The NNS
for one screened individual with newly diagnosed AF to be identified by 12 months was 173 individuals for
systematic population screening and 167 individuals for systematic opportunistic screening.
The study also modelled a targeted screening strategy, considering what would happen if only individuals
at high risk in the systematic population screening arm were invited for screening. Targeted screening of
high-risk individuals had a similar odds of detecting AF as usual practice (OR 1.12, 95% CI 0.75 to 1.66;
p = 0.58), and the NNS was 833 individuals. These numbers were calculated from the number of people
identified through screening who were at high risk plus the number of people in the systematic screening
arm who were identified as having AF outside the screening programme. As this was a modelled outcome,
it is possible that other cases of AF in low-risk individuals who were detected by the screening programme
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FIGURE 15 Risk-of-bias assessment of all included studies. Blank cells indicate fields that were not applicable.
TABLE 11 Number of newly diagnosed AF cases among individuals without AF at baseline
Study Screening strategy Cases
No.
randomised
Proportion
(95% CI) (%)
OR (95% CI;
p-value) NNS
SAFE19,84 Control 47 4547 1.03
(0.71 to 1.29)
Systematic population screening 74 4594 1.61
(1.24 to 1.96)
1.57 (1.09 to 2.26;
p= 0.017)
173
Systematic opportunistic screening 75 4593 1.63
(1.24 to 1.96)
1.59 (1.10 to 2.29;
p= 0.013)
167
Targeted screening 53 4594 1.15
(0.8 to 1.4)
1.12 (0.75 to 1.66;
p= 0.58)
833
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would have been identified outside the screening programme if a systematic population screening
programme had not been in place and therefore the odds of detecting AF in a targeted screening
programme could be slightly higher.
Results from Morgan and Mant,82 who compared systematic opportunistic screening with systematic
population screening, could not be used because the number of people with AF at baseline was not
reported. However, if we assume that the number of people with a previous diagnosis of AF was balanced
between the groups we can assess the relative merits of systematic opportunistic screening compared with
systematic population screening. Of the 1502 people randomised to systematic opportunistic screening
there were seven newly identified cases of AF over the 6 months of follow-up, whereas of the 1499
people randomised to systematic population screening there were 12 new cases of AF (OR systematic
population vs. systematic opportunistic 1.72, 95% CI 0.68 to 4.39; p = 0.25).
Although the SAFE study provides strong evidence that screening identifies more cases of AF than usual
care, neither the SAFE study19,84 nor the study by Morgan and Mant82 provides strong evidence that one
screening approach is superior to another.
Prevalence of atrial fibrillation at baseline
The prevalence of AF in the absence of screening could be calculated from only one RCT (the SAFE study19,84).
Averaging across the study arms, the prevalence of AF before screening was 7.22% (95% CI 6.80% to 7.63%).
Prevalence of diagnosed atrial fibrillation at the end of screening and the change in
prevalence of diagnosed atrial fibrillation
The change in prevalence of diagnosed AF after screening could be calculated only from the one RCT from
which the baseline prevalence of AF could be calculated (the SAFE study).19 The prevalence of diagnosed
AF increased after the trial in all arms, including the control arm (Table 12), reflecting incident AF over the
trial period. Compared with the control arm, the prevalence of diagnosed AF changed by approximately an
additional 50% in the systematic opportunistic and systematic population screening arms, but targeted
screening saw a similar change in diagnosed prevalence to that in the control arm.
Acceptability of systematic population screening programmes
In screening programmes that sent invitations to a defined population, one measure of the acceptability of
screening is the uptake of screening among those invited. Table 13 shows the uptake in studies that
investigated systematic population and systematic targeted screening (number who attended screening
divided by the number sent invitations). Studies with methodological or reporting limitations that
precluded inclusion in other parts of this review have been included here. The fact that patients with a
previous diagnosis of AF were not excluded from the SAFE,19,84 STROKESTOP26,40 and Morgan and Mant82
TABLE 12 Prevalence of diagnosed AF after systematic screening and change in prevalence of diagnosed AF
Study Screening strategy
Baseline prevalence
(n with AF/n randomised) (%)
Prevalence after screening
(n with AF/n randomised) (%)
Change
(%)
SAFE19,84 Control 389/4936 (7.88) 436/4936 (8.83) 0.95
Systematic opportunistic
screening
340/4933 (6.89) 415/4933 (8.41) 1.52
Systematic population
screening
339/4933 (6.87) 413/4933 (8.37) 1.50
Targeted screening 339/4933 (6.87) 392/4933 (7.95) 1.07
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studies should be considered when interpreting these results. With the exception of the study by Morgan
and Mant,82 uptake of screening was fairly consistent across the studies, with approximately 50% of those
invited attending for screening. In Chapter 5 (see Uptake of systematic population screening) we report
uptake rates for single-arm studies as well as RCTs and combine the results in a meta-analysis.
It is more difficult to judge the acceptability of systematic opportunistic screening, as systematic opportunistic
screening relies on the person visiting the GP/screening centre, the nurse/GP offering the screening test and
the individual consenting to it. In the SAFE study, 69.2% (3278/4738) of people randomised to systematic
opportunistic screening who had their notes flagged had their pulse palpated.19,84 Of the 361 people found
to have an irregular pulse, 238 (65.9%) attended the screening clinic, where a 12-lead ECG was performed,
although it should be noted that, of the 123 individuals who had an irregular pulse who did not attend for
an ECG, 56 (45.5%) had already been diagnosed with AF.19,84 The SAFE study also reports that there was
variation at the practice level in both the proportion of individuals who had a pulse taken (from 33.5% to
93.0%) and the uptake of ECGs when the pulse was found to be irregular (from 14.3% to 87.5%).
In the study by Morgan and Mant,82 30.5% (439/1437) of people randomised to systematic opportunistic
screening who had their notes flagged had their pulse palpated. In this study, the number of individuals
who had their pulse palpated also varied by practice, from 8.0% in one practice to 52.1% in another.
In both studies it is unclear how many eligible individuals visited their GP.
Only the SAFE study19,84 reported the reasons why individuals refused to participate in systematic screening.
Of the 904 individuals who replied to decline screening, 38.9% gave no reason, 9.4% replied ‘can’t get to
surgery’, 9.2% replied that they were ‘already in NHS’, 7.9% had ‘had a recent ECG’, 6.9% did not attend
because of illness, 6.4% did not attend because of ‘old age’, 4.2% were ‘not interested’, 3.0% had
‘mental health problems’ and the remainder gave other reasons. All individuals undergoing an ECG in the
SAFE study were asked to complete a screening acceptability questionnaire. Of those who completed the
questionnaire, 94.4% felt that the letter/information sheet explained the tests properly, 3.7% considered
screening to be inconvenient, 95.4% thought that health screening was important, 4.8% would have
liked someone to discuss it more with first, 3.2% would have liked to talk about the tests with a GP first
and 4% would have liked to come to a clinic appointment for more information.
The SAFE study recorded private individual costs associated with attending for screening, reporting a mean
cost of £3.13 (95% CI £2.97 to £3.29) (2005 price year). Converting to 2016 prices (inflation factor 1.37,
source ONS)87 gives a mean cost of £4.29 (95% CI £4.07 to £4.51).
Characteristics of all screened individuals and screen-identified atrial
fibrillation patients
Of the five included RCTs, four19,40,82,83 reported the characteristics of the individuals who participated in the
screening processes and the individuals who were identified as having AF through screening. The reported
characteristics varied across studies, for both the individuals invited to screening and those identified as
TABLE 13 Uptake of systematic screening
Study
Systematic population, % (number who
attended screening/number sent invitations)
Systematic targeted, % (number who
attended screening/number sent invitations)
SAFE19,84 53.2 (2357/4433) –
STROKESTOP26,40 53.8 (7173/13,331) –
Morgan82 73.3 (1099/1499) –
EARLY83 – 52.1 (463/888)
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having AF through screening. Tables 14 and 15 show the characteristics of all screened individuals and
screen-detected AF patients in the included studies respectively.
The mean age and sex distributions of the individuals invited to screening were comparable in the three
studies that reported these individual characteristics. None of the reported characteristics of the patients
identified to have AF through screening was comparable across the studies.
Adverse events with systematic screening
Few data were reported on adverse events associated with systematic screening, the rate and severity of
complications or adverse events associated with the ECG or other forms of AF testing, psychological
distress, change in quality of life and impact on well-being measured using a validated scale. The SAFE
study19,84 was the only study that reported these outcomes.
A random sample of individuals randomised to the screening arms of the trial was sent the postal version
of the EuroQol-5 Dimensions (EQ-5D) (to measure quality of life)88 and the shortened Spielberger anxiety
questionnaire89 on study entry and again at the end of the screening period (approximately 17 months
later), when it was also sent to all participants who had screened positive. In addition, all participants were
asked to complete the Spielberger anxiety questionnaire immediately after screening.
The EQ-5D scores were similar across the systematic population screening and systematic opportunistic
screening arms at baseline and also at 12 months’ follow-up. Similar results were found for anxiety scores.
TABLE 14 Characteristics of individuals invited to screening
Characteristic SAFE19,84 STROKESTOP26,40 Morgan82 DOFA-AP81 EARLY83
Mean age (years) 73.5 – 75.5 – 69
Mean weight (kg) – 79.2 – – –
Mean BMI (kg/m2) – 26.7 – – –
Mean CHA2DS2-VASc
score
– 3.6 – – –
% female 53.1 53.7 58.8 – 51
% hypertensive – 49.7 – – 72
% diabetes – 11.1 – – 18
% CHF – 3.4 – – 15
% stroke/TIA – 9 – – –
% vascular disease – 9.4 – – –
% IHD – – – – 11
% VHD – – – – 5
% on aspirin – 22.7 – – –
% on anticoagulants – 8.7 – – –
% other characteristics PRA 11, previous
AF 7.2
Previous AF 9.3 – – One RF 38, two RFs 44,
three RFs 15, four RFs
1.7, five RFs 0.2
BMI, body mass index; CHF, congestive heart failure; IHD, ischaemic heart disease; PRA, pulse reading abnormality; RF, risk
factor; VHD, valvular heart disease.
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However, based on the end-of-study questionnaire, individuals who were screen positive had a higher
mean anxiety score (38.1, 95% CI 35.9 to 40.4) than individuals who were screen negative (34.6, 95% CI
32.4 to 36.8). EQ-5D scores were also significantly different, with screen-positive individuals reporting a
lower quality of life score.
Cost-effectiveness of screening
Two RCTs19,82 reported the cost-effectiveness of systematic screening. The SAFE study19 reported the
incremental cost per additional newly diagnosed AF case for systematic opportunistic, targeted and systematic
population screening relative to no screening. The Morgan and Mant study82 reported the incremental cost
per additional newly detected AF case for systematic population screening relative to systematic opportunistic
screening. The results are shown in Table 16 in 2015 prices (using inflation factor 1.67 to convert the costs in
the SAFE study19 from 2003 prices and inflation factor 1.77 to convert the costs in the Morgan and Mant82
study from 2002 prices (source ONS Consumer Price Index: Medical Services).87 It should be noted that the
SAFE study19 conducted a detailed cost assessment, whereas the Morgan and Mant82 study calculated the
cost for the time of a short appointment with a nurse as £6 (2002 prices), which is £10.62 in 2015 prices.
The SAFE study also included costs incurred by individuals attending for screening.
Subgroup and sensitivity analyses
The SAFE study19,84 provides results by sex and age (65–74 years and ≥ 75 years). Table 17 shows the
proportion of newly diagnosed AF cases among those undiagnosed at baseline by age and sex. In the
control arm, the rate of newly diagnosed AF was similar for men and women. For men, all screening
TABLE 15 Characteristics of patients identified as having AF through screening
Characteristics aSAFE19,84 bSTROKESTOP26,40 cMorgan82 DOFA-AP81 bEARLY83
Mean age (years) – – – – –
Mean weight (kg) – 81.4 – – –
Mean BMI (kg/m2) – 27.3 – – –
Mean CHA2DS2-VASc score – 3.5 – – –
Mean CHADS2 score
d 1.4 – – – –
% female – 45.4 – – 18.2
% hypertensive 37.6 52.1 57 – 63.6
% diabetes 9.4 13.3 12 – 36.4
% CHF 11.4 2.8 – – 9.1
% stroke/TIA 7.4 9.6 21 – –
% vascular disease – 14.3 – – –
% IHD – – – – 36.4
% VHD – – – – 9.1
% on aspirin – 24.8 39 – –
% on anticoagulants – 2.3 (oral) 25 – –
% other characteristics – – One RF 70,
previous PRA 49,
previous AF 82
– One RF 9.1, two
RFs 36.4, three
RFs 54.5
BMI, body mass index; CHF, congestive heart failure; IHD, ischaemic heart disease; PRA, pulse reading abnormality; RF, risk
factor; VHD, valvular heart disease.
a The SAFE study characteristics are based on 149 cases.
b Denotes characteristics of only new AF cases.
c Characteristics for the study by Morgan and Mant82 are for the systematic population screening arm only.
d CHADS2 is constructed as a sum of the following risk factors: cardiac failure, hypertension, age, diabetes, stroke (× 2).
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strategies had a higher odds of newly diagnosed AF than usual practice and this was higher for systematic
opportunistic and systematic population screening than for targeted screening. For women, there is no
clear evidence that that there are any differences in new AF diagnoses under any of the screening
strategies compared with usual practice. The ratio of ORs for women compared with men measures the
‘interaction’ effect of sex on the relative efficacy of the different screening arms. There is clear evidence of
an interaction effect, with the ORs for the screening strategies compared with usual practice much closer
to 1 for women than for men. This effect is stronger in the systematic population screening and targeted
screening arms and less strong in the systematic opportunistic screening arm.
TABLE 17 Proportion of newly diagnosed AF cases among those undiagnosed at baseline and ORs compared with
the control arm for male/female and age 60–74 and ≥ 75 years subgroupsa
Subgroup Control
Systematic
opportunistic
screening
Systematic
population
screening Targeted screening
Sex
Men
Proportion, n/N (%) 16/1896 (0.8) 38/1947 (2.0) 44/1968 (2.2) 32/1968 (1.6)
OR versus control (95% CI) 2.31 (1.28 to 4.16) 2.64 (1.48 to 4.71) 1.92 (1.05 to 3.52)
Women
Proportion, n/N (%) 31/2651 (1.2) 37/2646 (1.4) 30/2626 (1.1) 21/2626 (0.8)
OR versus control (95% CI) 1.19 (0.73 to 1.93) 0.97 (0.58 to 1.61) 0.68 (0.39 to 1.19)
Women versus men
Ratio of ORsb 0.50 (0.24 to 1.05) 0.36 (0.16 to 0.75) 0.34 (0.15 to 0.78)
Age (years)
65–74
Proportion, n/N (%) 18/2479 (0.7) 31/2637 (1.2) 30/2573 (1.2) 28/2573 (1.1)
OR versus control (95% CI) 1.61 (0.9 to 2.9) 1.6 (0.89 to 2.88) 1.49 (0.82 to 2.71)
≥ 75
Proportion, n/N (%) 29/2068 (1.4) 44/1956 (2.2) 44/2021 (2.2) 35/2021 (1.7)
OR versus control (95% CI) 1.6 (0.99 to 2.57) 1.55 (0.96 to 2.49) 1.23 (0.75 to 2.02)
≥ 75 versus 65–74
Ratio of ORsb 0.97 (0.45 to 2.00) 0.99 (0.44 to 2.05) 0.84 (0.37 to 1.84)
a Ratios of ORs comparing subgroups are given with 95% CIs. All results are from the SAFE study.
b Ratio of ORs: posterior medians and 95% CrIs from a Bayesian analysis.
TABLE 16 Cost-effectiveness of systematic screening strategies: study incremental cost (£, 2015 prices) per
additional case detected
Study
Systematic opportunistic
screening vs. no screening
Systematic population
screening vs. no screening
Targeted
screening vs.
no screening
Systematic population
screening vs. systematic
opportunistic screening
SAFE19,84 562 2528 5879 Dominated (costs an
additional £52,527, but 22
fewer cases detected)
Morgan82 NA NA NA 329 (95% CI 245 to 531)
NA, not applicable.
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For age, there is clearly an increase in the proportion of newly diagnosed AF cases in the ≥ 75 years
subgroup compared with those aged 65–74 years. However, the relative effectiveness (ORs) for the different
screening interventions compared with the control was very similar for the different age ranges, with ratios
of ORs estimated as close to 1, indicating no interaction between screening efficacy and age.
These analyses were also performed in the Cochrane review, which found strong evidence of a difference
between sexes for systematic population screening (χ2 = 6.64, p = 0.001) but not for systematic opportunistic
screening (χ2 = 2.95, p = 0.09). There was no strong evidence of a difference in AF detection between the
two age groups. These findings are in line with our results.
There were too few data to perform any other subgroup or sensitivity analyses.
Discussion
Summary of findings
Both systematic population and systematic opportunistic screening strategies were found to be effective
compared with no screening. Both systematic population and systematic opportunistic screening had
similar efficacy with an estimated 170 individuals needed to screen to detect one additional AF case
compared with usual practice. Systematic screening targeted to high-risk individuals found a similar
number of new cases as usual practice. One reason for this may be that individuals with comorbidities are
more likely to undergo an increased number of visits to primary care and, as part of investigating and
managing these conditions, will be screened in earnest or by default for AF.
Uptake of systematic population screening was typically around 50% although it was as high as 70% in
one study. There was variability in uptake between practices, with uptake being between 22% and 70% in
the SAFE study.19 Reasons for not attending for screening were varied, although older age and decreased
mobility were common themes. The proportion of individuals having their pulses checked under systematic
opportunistic screening varied across studies (30% and 66%) and between practices within studies (from
8% to 93%). The proportion of individuals consulting with their GP was not reported and so it is unclear
how much these uptake rates are driven by consultation rates, GPs offering pulse palpation and uptake of
pulse palpation by individuals. Of those with an irregular pulse who did not have a previous diagnosis of AF,
approximately 18% did not attend for an ECG test, although again this was variable across practices.
Subgroup analyses based on the SAFE study19,84 indicated that both systematic population and systematic
opportunistic screening were more effective for men than for women, and this was especially the case for
systematic screening. The Cochrane review49 discusses possible explanations for this, concluding that
‘differences in effect observed between the subgroups of men and women could be due to a combination
of higher prevalence and greater rates of participation among men’ (p. 14).49 The efficacy of screening was
not found to vary with age, despite AF prevalence being strongly associated with age group.
The findings from the subgroup analyses have implications for a screening programme, in particular
whether such a programme would be effective in women and whether or not there are interventions
that could encourage women to participate in screening. Reasons given for not attending for screening
included poor mobility, thus provision of transport to and from practices may increase participation.
Systematic opportunistic screening (when a journey to the GP has already been arranged) appeared to be
more effective for women, and this may be a consideration in determining the format of a population-
based screening programme. Most evaluations of population-based screening have included individuals
aged ≥ 65 years. The results of the subgroup analysis for age suggest that the relative efficacy of screening
is likely to be unchanged if the age threshold is increased. However, the absolute rate of detection of new
cases (per person screened) and cost-effectiveness are likely to increase with age if the proportion of
screened individuals with undiagnosed AF increases with age.
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Strengths and limitations
Although five studies were identified, because of studies having reported only interim results or concerns
over methodology, only two had data extracted, with only one reporting the number of people with AF
at baseline and therefore used to study the primary outcome. The SAFE study19,84 therefore remains the
primary source of evidence for a comparison of different screening strategies. This situation should change,
as three ongoing studies26,40,85,86 are due to report within the next 3 years. In particular, the STROKESTOP
study26,40 aims to report the impact of screening on long-term outcomes (stroke and mortality), for which
there is currently no robust evidence.
The SAFE study, on which most of our results are based, was a well-conducted study at low risk of bias
on all domains except blinding of participants/personnel (which is not possible) and blinding of outcome
assessment (unclear risk of bias). One issue with the SAFE study was that the baseline prevalence of AF
was slightly higher in the control group than in the screening group. This could potentially introduce bias
because, if more AF cases were previously diagnosed in the control practices, there may be fewer cases
that could be diagnosed subsequently through screening or routine care. This was explored in the SAFE
study using an individual participant analysis controlling for differences in baseline prevalence, which
showed that the conclusions of the SAFE study were robust to adjustments to baseline prevalence.19,84
The SAFE study19,84 found the incidence and 12-month prevalence of diagnosed AF to be similar between
systematic opportunistic and systematic population screening. However, it should be noted that a large
proportion of AF cases in the systematic opportunistic arm were detected outside the screening programme
(i.e. in primary care but not as a result of activating the flag). Of the 74 new cases of AF identified in the
systematic population screening arm, 22 (30%) were diagnosed outside the screening programme over
the 12 months of the study. This proportion was greater for the systematic opportunistic screening arm,
in which of the 75 newly identified cases, 44 (59%) were diagnosed outside the screening programme. One
explanation for this is that GPs in the systematic opportunistic screening arm changed their usual practice to
check for AF more frequently (the ‘Hawthorne effect’, where behaviour changes when under observation).
If this is the case, then the full benefits seen in the systematic opportunistic arm may not be realised outside
the context of a RCT. In contrast, Morgan and Mant82 concluded that systematic population screening is
superior to systematic opportunistic screening, although there is no strong evidence to support this based on
comparisons of new cases of AF. The Morgan and Mant study82 is complicated by the fact that an unreported
number of patients with a previous diagnosis of AF were included. Also, only approximately 30% of people
randomised to systematic opportunistic screening had their pulse assessed and, of those with an irregular pulse
not referred for an ECG, it was assumed that a clinical diagnosis was made (which could have introduced
detection bias).
In a screening programme it is likely that screening is offered repeatedly at given intervals (e.g. every 5 years).
However, none of the RCTs identified in our review considered repeated screening, only a one-off screen.
We therefore do not have any evidence on the effectiveness of such a screening strategy.
Findings in the context of previous research
A systematic review90 of cohort studies (including 26 prospective cohorts, two retrospective cohorts and two
RCTs) that used an ECG or pulse palpation to identify AF in the general ambulant population (excluding
studies performed in people with specific comorbidities such as stroke, hypertension or cardiac disease) found
that the overall incidence of previously unknown AF was 1.0% (95% CI 0.89% to 1.04%), increasing to
1.4% (95% CI 1.2% to 1.6%) in those aged ≥ 65 years. The authors observed that incidence was similar in
GP/outpatient clinics and community-based populations. The AF prevalence was 2.3% (95% CI 2.2% to
4.4%), increasing to 4.4% (95% CI 4.1% to 4.6%) in those aged ≥ 65 years. The denominator for these
estimates was the number screened and not the number randomised (even for the RCTs), as used in our
review. Despite this difference, the SAFE study19,84 found the 12-month incidence of unknown AF, with either
opportunistic or systematic screening, to be a comparable 1.6% for individuals aged ≥ 65 years. However,
the prevalence of AF after screening in the SAFE study19,84 was 8.8% in the control group and 8.4% in the
screening groups, much higher than in the systematic review by Lowres et al.90
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Chapter 5 Methods for the economic evaluation
of atrial fibrillation screening
Introduction
In this chapter we set out the methods used in the economic evaluation of systematic screening strategies
for AF. We begin by defining the decision question that our economic model addressed, the modelling
approach taken and the outputs reported. We then present the results of a review of previous economic
models evaluating population-based screening strategies for AF. This is followed by a description of the
structure of our model and the inputs required to populate it. Next, we describe a supplementary literature
review of observational studies that we used to identify evidence on the natural history of AF, to provide
inputs to the model, and present the results from this review. We then summarise all of the evidence used
for inputs to the model and describe the sensitivity analyses that we conducted.
Decision question
The economic evaluation aimed to assess the cost-effectiveness of different population-based screening
strategies for AF (including no screening) in a primary care setting in England and Wales. We took the
perspective of the NHS, excluding costs incurred by individuals, employers and other agencies.
Screening strategies
We assumed the presence of an established screening programme, with cohorts of individuals invited to
attend for screening when they reach a certain age.
We compared the following population-based screening strategies in the base case:
l no systematic screening (current practice)
l single systematic population screen, inviting all individuals meeting the screening criteria
l single systematic opportunistic screen, inviting individuals meeting the screening criteria when they
consult with their GP.
We did not include a targeted strategy in which high-risk individuals are screened, based on the findings from
the SAFE study,19 which found that this strategy did not perform any better than no systematic screening.
In the base case, we report the results for one-off screening at ages 55, 60, 65, 70, 75 and 80 years,
exploring various different screening tests (see Screening tests).
In sensitivity analyses, we explored repeated screening every 5 years for various initial screening ages
(55, 60, 65, 70, 75 and 80 years) and final screening ages (55, 60, 65, 70, 75 and 80 years), which gave a
total of 21 repeat screening strategies. We assumed that the optimal screening test and recruitment
method (systematic opportunistic or systematic population) would be used for the repeat screening.
Population
The target population for systematic screening was the general population in England and Wales of a
given age without a diagnosis of AF.
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Screening tests
We included all screening tests identified in the systematic review (see Tables 2 and 3) for which we had
sensitivity and specificity estimates compared with a gold standard (12-lead ECG interpreted by at least one
cardiologist). The exception was the two-stage screening tests because we assumed that a diagnostic test
would be given to those testing positive on a screening test, and so in effect all of the strategies represent
two-stage screening. We acknowledge that this gold standard is appropriate only for persistent/permanent
AF; however, we felt that persistent/permanent AF is likely to be the primary target of a population-based
screening programme. Furthermore, estimates of the costs and benefits of anticoagulation are based on
trials that do not generally include paroxysmal AF patients. However, we acknowledge that some
paroxysmal AF cases may be detected and treated and we included this in our model.
We assumed that all individuals with a positive screening test result would receive a 12-lead ECG
diagnostic test to confirm the diagnosis. The 12-lead ECG is likely to be performed in primary care, with a
diagnosis being made in primary care when the result is clear and referral to a cardiologist made in a
proportion of cases when the result is unclear.
Screening tests were defined according to the technology used and the interpreter (including algorithms).
The following diagnostic tests were compared in the model (see Tables 2 and 3):
l 12-lead ECG:
¢ interpreted by GP
¢ interpreted by nurse
¢ interpreted by algorithm
l single-lead ECG (including iPhone and other hand-held devices):
¢ interpreted by cardiologist
¢ interpreted by GP
¢ interpreted by nurse
¢ interpreted by algorithm
l > 1- but < 12-lead ECG:
¢ interpreted by cardiologist
¢ interpreted by algorithm
l pulse palpation (various methods):
¢ interpreted by nurse
l modified blood pressure monitor (various devices):
¢ interpreted by algorithm
l photoplethysmography:
¢ interpreted by algorithm.
Although we have included tests interpreted by a cardiologist (as they were included in the DTA review),
we note that cardiologists are unlikely to interpret screening tests in a primary care setting.
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Outcomes of the economic evaluation
The economic model was evaluated using a probabilistic analysis in which the model inputs were simulated
from distributions that reflected parameter uncertainty in the model.91 Results from the model are averages
(means) over these simulations. We present the mean total incremental costs, mean total incremental
quality-adjusted life-years (QALYs) and mean incremental net benefit (INB) at a willingness to pay of
£20,000 per QALY92 for each strategy relative to no screening (current practice). The INB is calculated as
the incremental QALYs multiplied by £20,000 minus the incremental costs. Positive values of the mean INB
indicate strategies that are cost-effective at the £20,000 per QALY threshold. We aimed to maximise the
mean INB. We also present the incremental cost-effectiveness ratio (ICER), which is the mean incremental
costs divided by the mean incremental QALYs. The INB and ICER are related, so that a positive mean INB
would have an ICER of < £20,000 and would be considered cost-effective at a willingness to pay of
£20,000 per QALY. Conversely, a negative mean INB would have an ICER of > £20,000 and would not be
considered cost-effective at a willingness to pay of £20,000 per QALY. Uncertainty in the optimal strategy
is represented using cost-effectiveness acceptability curves (CEACs) and by displaying the simulations in the
incremental cost-effectiveness plane (incremental QALYs plotted against incremental costs). The CEAC
plots the probability that each strategy is most cost-effective against willingness to pay per QALY. For
clarity we omit strategies from the CEAC plots that have a < 10% probability of being most cost-effective
at any willingness-to-pay threshold. To compare different screening strategies by age at first screen, and
number of repeated screens, we multiply the per-person INB by the population size that will benefit (for a
given age cohort). Costs and outcomes over a lifetime time horizon were included because treatment for
AF aims to reduce future events. Future costs and benefits are discounted at an annual rate of 3.5% in line
with recommendations of the UK treasury.93
Review of previous economic models of screening strategies for
atrial fibrillation
We searched the NHS Economic Evaluation (NHS EED) and HTA databases from inception until close
(end of December 2014 for NHS EED and end of December 2015 for HTA databases) using the search
terms Atrial Fibrillation AND Screening to identify economic evaluations of screening strategies. This
identified 15 references, of which seven studies19,21,25,94–97 were considered relevant after title and abstract
screening (reviewed by NJW).
Because NHS EED stops at the end of December 2014, we ran Cochrane AF screening review searches49 in
EMBASE and MEDLINE with CRD economic filters98 from January 2015 to the end of December 2015. This
identified 261 records, of which eight papers99–106 not previously identified were considered relevant after title
and abstract screening and a further four papers107–110 were highlighted as providing information on costs.
We also searched the Cost-Effectiveness Analysis (CEA) Registry on 19 January 2016, using the search term
Atrial Fibrillation. This resulted in 76 hits but did not identify any other studies on the cost-effectiveness of AF
screening. However, it did identify two studies on the cost-effectiveness of diagnostic tests for AF.111,112
The search for studies of the natural history of AF and AF screening (in EMBASE and MEDLINE, search dates from
1 January 2000 to 20 January 2016) (seeModel inputs) identified three further cost-effectiveness studies.113–115
Finally, hand-searching reference lists of papers and reports that we were aware of identified three
further studies.116–118
In total, after title and abstract screening we identified 27 studies for which full-text articles were obtained
and screened. After screening the full texts, nine studies19,21,25,96,99,100,116,117 of economic evaluations of
population-based screening strategies were identified.
Figure 16 shows a diagram illustrating the literature searches.
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In the following section, we summarise the nine economic evaluations of population-based screening for
AF, which are also described in Table 18. The quality of these economic evaluations was assessed using the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.119 These assessments are
provided in Appendix 8.
Summary of previous economic evaluations of screening for atrial fibrillation
Hobbs et al.19
Hobbs et al.19 (the SAFE study) present results from (1) a within-trial cost-effectiveness analysis that reports
cost per additional true-positive AF case detected and (2) a longer-term economic model that captures costs
and benefits beyond the follow-up period of the trial and reports cost per QALY. Both analyses assume
screening with a 12-lead ECG interpreted by a cardiologist, although this is relaxed in sensitivity analyses.
Results from the within-trial analysis comparing systematic opportunistic screening, systematic population
screening, screening targeted at high-risk individuals according to stroke risk and no screening have
previously been described (see Chapter 4, Cost-effectiveness of screening). The systematic population and
targeted screening strategies were dominated (cost more for the NHS and identified fewer new cases) by
systematic opportunistic screening. The incremental cost per case detected for opportunistic compared
with no screening was £337 (2003 prices).
The model-based analysis compared different screening intervals, screening tests and interpreters and screening
methods (systematic opportunistic and systematic population screening) for 65-year-olds. A discrete event
simulation model was used to describe patient pathways. If a patient is not identified through screening he or
NHS EED and HTA, inception 
– 31 December 2014
(15 records)
EMBASE and MEDLINE
Economic filters
1 January 2015–31 December 2015
(261 records)
The CEA Registry
(76 records)
• Title and abstract screening identified 21 records
• Natural history review identified three additional records
• Hand-searching reference lists identified three records
Full-text screening identified nine
studies on economic
evaluation of population-based
screening for AF
FIGURE 16 Flow chart for the literature search for studies of economic evaluations of population-based screening.
TABLE 18 Summary of economic evaluations of population-based screening for AF identified in our review
Study Setting Screening methods Screening tests Model structure Outcomes
Hobbs
200519
UK general
population, based
on 50 general
practices, West
Midlands, UK
Systematic
opportunistic
screening when
individuals consult
with their GP.
Systematic population
screening of the
general population.
Aged ≥ 65 years
Compared different
index tests (12-lead
ECG, limb-lead
rhythm strip ECG,
single-lead ECG),
interpreters
(consultant, GP,
nurse, automatic)
and screening
intervals
Discrete event
simulation model
Cost per QALY with
results presented for
both a NHS and a
societal perspective
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TABLE 18 Summary of economic evaluations of population-based screening for AF identified in our review
(continued )
Study Setting Screening methods Screening tests Model structure Outcomes
Moran
201525
Ireland, primary
care
Systematic
opportunistic screening
when individuals
present to their GP.
Various age thresholds
(base-case ≥ 65 years)
Pulse palpation
with individuals
with an irregular
pulse referred for
an ECG
Decision tree
for screening
outcomes followed
by a Markov model
for long-term costs
and benefits
Cost per QALY with
results presented for
both payer and
societal perspectives
Aronsson
2015100
Sweden, general
population (two
regions)
Systematic population
screening of 75- and
76-year-olds
Intermittent hand-
held ECG twice
daily (or when
palpitations) for
2 weeks
Decision tree
for screening
outcomes followed
by a Markov model
for long-term costs
and benefits of
screen-detected AF
Cost per QALY;
societal perspective
reported but only
health service costs
included
Lowres
201421
Australia, 10
pharmacies
(Sydney)
Systematic
opportunistic
screening of people
visiting the pharmacies
aged ≥ 65 years
Pulse palpation and
hand-held iPhone-
based single-lead
ECG, interpreted by
a nurse and
cardiologist
Not reported
explicitly
Cost per QALY and
cost per stroke
prevented from a
health service
perspective
Maeda
200496
Japan general
population
Systematic population
screening of 65-year-
olds annually until
age 85 years
Compared a
12-lead ECG with
pulse palpation
followed by a
12-lead ECG
Decision tree
for screening
outcomes followed
by a Markov model
for long-term costs
and benefits of
screen-detected AF
Cost per QALY from
a health service
perspective
Lord
2013116
England and
Wales
Not applicable Suspected AF in
primary care
referred to a
specialist for an
ECG. Ambulatory
monitoring may be
used if paroxysmal
AF is suspected
after a negative
ECG
Discrete event
simulation model
Cost per QALY from
a NHS perspective.
No results reported
comparing screening
methods
Gordon
2012118
35 general
practices in
north-east Essex
Systematic
opportunistic
screening in individuals
aged ≥ 65 years
without known AF
and attending for
influenza vaccination
Pulse palpation
followed by a
12-lead ECG in
individuals with an
irregular pulse
Decision tree Cost per screen-
detected case and
cost of preventing
one stroke in the
following year from
a NHS perspective
Rhys
2013117
Single general
practice in Leek,
UK
Systematic
opportunistic
screening in individuals
aged ≥ 65 years
attending for influenza
vaccination
Pulse palpation
followed by a
12-lead ECG in
individuals with an
irregular pulse
Decision tree Cost per screen-
detected case and
cost of preventing
one stroke in the
following year from
a NHS perspective
Aronsson
201599
Not reported 1,073,741,824
different screening
designs compared
Not reported Not reported Cost per QALY;
perspective not
reported
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she may be diagnosed at a later date through routine care (on average 3 years) or after an event (e.g. ischaemic
stroke). Incidence data were used to model the development of AF. The sensitivity and specificity of the tests
were taken from the SAFE trial, along with the uptake of screening and costs of screening. It was assumed that
all AF patients would be prescribed warfarin, although a sensitivity analysis was reported assuming that all
patients received aspirin instead. Rate and rhythm control were not included in the model. The results showed
that QALYs gained were very similar across all strategies (including no screening), with differences seen only in
costs. However, differences in costs were small, with slightly lower costs for systematic opportunistic screening
than for no screening.
Moran et al.25
Moran et al.25 reported a HTA of a national screening programme for AF in primary care in Ireland.
The model compared systematic opportunistic screening with no screening for men and women aged
≥ 65 years. The screening test was pulse palpation followed by an ECG read by a GP and an algorithm if
an irregular pulse was detected. The uptake and effectiveness of screening were taken from the SAFE
study,19 prevalence and incidence were taken from the Irish Longitudinal Study on Ageing (TILDA)120 and a
Markov model was used to capture the costs and benefits of treatment over the long term (until age
90 years). Patients were assumed to take DOACs, warfarin, antiplatelets or no therapy in proportions
estimated from the TILDA study and other routine data sources in Ireland and the UK. The ICER for
screening compared with no screening was €20,271 per QALY. The ICER was sensitive to the start age of
screening, varying from €50,578 if screening was started at age 50 years to €14,594 if screening was
started at age 70 years. The ICER was also sensitive to the screening interval, decreasing as the interval
between screens increased.
Aronsson et al.100
The study by Aronsson et al.100 was a cost-effectiveness analysis of systematic population screening for AF
in 75- and 76-year-olds in Sweden using intermittent ECG recording based on data from the ongoing
STROKESTOP study.40 Future consequences were tracked over a patient’s lifetime using a Markov model,
depending on CHA2DS2-VASc score and treatment. For patients eligible for anticoagulation it was assumed
that a proportion were contraindicated (based on data from the STROKESTOP study) and the remainder
used a DOAC (assumed to be apixaban). Use of warfarin rather than apixaban was considered in a
sensitivity analysis. The model predicted a cost of €4313 per QALY gained and €6583 per stroke avoided
compared with no screening.
Lowres et al.21
The study by Lowres et al.21 was a prospective study evaluating the effectiveness and cost-effectiveness of
community screening for AF in those aged ≥ 65 years visiting one of 10 pharmacies in Sydney, Australia.
Screening was by pulse palpation and hand-held iPhone-based single-lead ECG interpreted by a nurse and
cardiologist. Individuals with suspected AF were referred to their GP. The economic model followed a
cohort of 65- to 84-year-olds for 10 years, using stroke risk information from studies on asymptomatic
incidentally detected AF. Patients were assumed to be treated with warfarin. The model structure is unclear,
although it is likely to be a decision tree for screening outcomes followed by a Markov model to reflect
annual stroke and mortality risk and costs. Sensitivity and specificity of the iECG were taken from the
authors’ study. The ICER was €3142 per QALY and €15,993 per stroke prevented compared with no
screening. Results were most sensitive to treatment adherence.
Maeda et al.96
This study compared three community-based screening strategies for 65-year-olds in Japan: annual
screening with an ECG, annual screening with pulse palpation with referral for an ECG in patients with
arrhythmias and no screening. A Markov model was used to estimate costs and outcomes for AF patients
up to age 85 years. The two screening strategies gave similar results, with ICERs compared with no
screening of approximately US$8000 and US$10,000 per QALY in men and women respectively. The results
were sensitive to the proportion prescribed anticoagulants and the incidence of ischaemic stroke, with
screening being more cost-effective as the proportion of patients prescribed anticoagulants increased and
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also as the incidence of ischaemic stroke increased. Increasing the interval between repeat screenings to
every 5 years decreased the costs but had very little impact on the QALYs gained, suggesting that 5-yearly
repeated screening tests would be adequate.
Lord et al.116
This study developed a model to reflect the course of a cohort of AF patients diagnosed and treated
following the NICE clinical guidelines for AF that were available at that time (CG36121). The model tracks
care pathways for AF but does not compare the cost-effectiveness of screening strategies. Of interest to
our project, the model includes a diagnostic pathway with outcomes modelled separately for true positives,
true negatives and false negatives (figures 15 and 17 in Lord et al.116).
Other studies
Rhys et al.117 and Gordon et al.118 estimated the cost per stroke prevented over the coming 12 months based
on primary data collected while screening individuals aged ≥ 65 years attending for influenza vaccination
in UK general practice. The report by Aronsson et al.99 was a conference abstract detailing the results of
an economic evaluation of > 1000 million screening designs, concluding that the most cost-effective
programme is an initial screen at age 75 years with a repeat screen at 80 years.
Summary
The study by Hobbs et al.19 is the most relevant study to our study in that it used an economic model to
obtain lifetime costs per QALY for different screening tests and strategies in a UK population. The study was
conducted before DOACs were in routine use. The model therefore needs updating to incorporate this new
class of therapy and also to reflect up-to-date evidence on the natural history of AF in a contemporary UK
population. The HIQA model25 is also very relevant, using recent evidence in an Irish population. However,
the HIQA report considered only systematic opportunistic screening using pulse palpation. Most models
used a decision tree for the screening part of the model followed by a Markov model for subsequent
treatment, although the study by Hobbs et al.19 used a discrete event simulation model. Our model provides
a comparison of various screening tests and methods using contemporary evidence relevant to a UK
population and including anticoagulation therapy options currently available in the NHS.
Model structure
We developed a model to compare the cost-effectiveness of population-based screening strategies, drawing on
the models previously reported in the literature (described in the previous section) and also based on guidance
from our expert advisory group. Our model has many features in common with previous models. An initial
decision tree describes screening attendance, screening test findings and diagnostic test results. Then a Markov
model tracks AF-related events and mortality conditional on anticoagulant therapy. Our previously published
Markov model (DOAC model)37 was based on a network meta-analysis of all trials comparing DOACs with
warfarin (INR range 2–3) to capture the lifetime costs and benefits of anticoagulation therapy in AF.
Figure 17 illustrates the decision tree used to compare population (S1) and opportunistic (S2) screening with
current practice (S0, no screening). The model structure, costs of care post diagnosis and utilities remain the
same for each strategy; however, the sensitivity and specificity parameters depend on the screening test.
For systematic population screening, a cost is incurred for the screening invitation, which depends on the
population size invited and the proportion of individuals who do not initially respond and who are sent a
reminder letter. A certain proportion will not attend for screening and do not incur any further costs or
receive any further health benefits. We assumed that individuals with a known AF diagnosis will not be
invited for screening and that the cost of identifying and excluding these individuals using computer
records is small and can be ignored. For opportunistic screening, we assumed that, during a 12-month
period, a proportion of individuals who are flagged for screening will have an unrelated GP appointment
and will be opportunistically tested during the appointment.
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Of those who are screened, all will incur the cost of the screening test. We assumed that a proportion of
individuals with AF would have detectable AF at the time of the screening test. This proportion consists of
individuals with persistent and permanent AF and a smaller proportion of paroxysmal AF individuals who
happen to be in AF at the time of screening. We assumed that individuals who test positive on the screening
test will receive a gold standard diagnostic test (12-lead ECG interpreted in primary care with cardiologist
interpretation in a proportion of cases that are unclear), which is assumed to have 100% accuracy. We
assumed that all of those offered a 12-lead ECG diagnostic test agree to have the test (but varied this
assumption in sensitivity analysis) and that all unclear ECGs are resolved by cardiologist interpretation.
Further details are provided in Test costs. We assumed no quality of life benefit or decrement as a result of
administration of the screening test itself or the confirmatory ECG.
True positive on the initial screening test
Of those who are tested, a proportion will be true positives (screen-positive results that are confirmed
using a 12-lead ECG gold standard diagnostic test), and these individuals may benefit from early detection
of AF. All of these individuals will accrue the cost of the initial screening test plus a gold standard 12-lead
ECG test interpreted by a GP, except a proportion of unclear cases that are additionally interpreted by
a cardiologist.
For those individuals with a stroke risk CHA2DS2-VASc score of ≥ 2, anticoagulation therapy is recommended
unless contraindicated (bleeding risk using the HAS-BLED score, dementia, epistaxis, frailty or patient
preference). However, in a proportion of cases, individuals not contraindicated for anticoagulation are
not prescribed anticoagulants by their GP. In the base case we assumed that all of the individuals not
contraindicated and prescribed anticoagulation therapy use DOACs. We assumed that the most cost-effective
treatment (apixaban) in the DOAC model37 is used for all patients who receive DOACs, although it should be
noted that similar results would be obtained using other DOACS.37 In the sensitivity analyses we assumed
that 50% use DOACs and the remainder use warfarin (INR range 2–3). We assumed that individuals with a
CHA2DS2-VASc score of ≤ 1, in whom OACs are not recommended,11 and patients contraindicated to, not
prescribed or choosing not to take OACs, would receive aspirin. This was based on clinical advice, confirmed
by Quality and Outcomes Framework (QOF) statistics,3 that these patients will likely receive aspirin in practice,
despite aspirin not being recommended in the latest NICE clinical guidelines.11
Regardless of anticoagulation therapy, we assumed that all symptomatic patients would receive a standard
beta-blocker for rate control, which incurs a cost and improves quality of life benefit. The costs and benefits
of rate control were assumed to be independent of anticoagulation therapy. Rhythm control is not currently
recommended except for patients younger than those who would be invited to a screening programme,
and so we did not include it in our model.
True negative on the initial screening test
Of those tested, a proportion will be true negatives on the initial screening test. These individuals incur the
cost of the initial screening test but do not receive any further incremental benefits or costs from the
screening strategy compared with current practice (S0, no screening).
False positive on the initial screening test
We assumed that individuals with a false-positive result on the initial screening test will be given a
diagnostic 12-lead ECG test, which correctly identifies that they do not have AF (i.e. the confirmatory test
is 100% specific). All of these individuals incur the cost of the initial screening test plus the cost of the
diagnostic 12-lead ECG test interpreted by a GP and, in a proportion of unclear cases that are additionally
interpreted by a cardiologist, an additional expense will be incurred. As with the true negatives, these
individuals do not receive any further incremental benefits or costs from the screening strategy compared
with current practice (S0, no screening). It should be noted that some false positives may be diagnosed
with another condition (e.g. atrial flutter) and may receive some benefit from an AF screening programme.
However, we do not capture this benefit in our model.
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False negative on the initial screening test
Of those tested, a proportion will be false negatives on the initial screening test, that is, they have AF but
are not referred for a diagnostic 12-lead ECG test and gain no benefits from treatment. This includes
individuals with paroxysmal AF who are not in AF at the time of the screening test. These patients incur
the cost of the initial screening test but no future incremental costs and benefits compared with current
practice (S0, no screening).
Model inputs
In this section we describe the inputs used for the parameters required to populate the economic model.
The sensitivity and specificity of the screening tests came from our systematic review of DTA studies
(see Chapter 3, Statistical modelling results). The information on screening came from the studies
identified in our systematic review of comparative studies of screening strategies (see Chapter 4), together
with supplementary searches (see below) to identify observational studies of screen-detected AF. The
cost-effectiveness of anticoagulation therapy is based on our recently published DOAC model.37 The cost
parameters came from our review of economic evaluations, NHS reference costs122 and Personal Social
Services Research Unit (PSSRU) unit costs123 and primary studies reporting costs and resource use identified
in our review. Supplementary searches were conducted to identify evidence sources for the remaining
parameters in the model, primarily information on the natural history of AF and its management in the NHS.
We searched for longitudinal, observational and cross-sectional studies to identify, ideally in a population-
based screening population:
1. the prevalence of AF in England and Wales by age and sex
2. population size eligible for screening by age and sex
3. uptake of systematic population screening and the proportion requiring a reminder letter
4. the proportion of eligible patients who have their pulses taken
5. the proportion of 12-lead ECGs interpreted by a GP that are unclear and require further interpretation
by a cardiologist
6. the rate of diagnosis in the absence of screening
7. the proportion AF that is undiagnosed
8. the proportion of AF that is paroxysmal, persistent or permanent
9. the proportion of AF that is asymptomatic (by AF type)
10. disease progression through AF types
11. hazard ratios (HRs) for stroke and mortality risk by AF type and whether asymptomatic or not
12. the proportion of screen-detected AF with a CHA2DS2-VASc score of ≥ 2, previous stroke (or TIA),
previous MI and moderate (HAS-BLED score of 2) or high (HAS-BLED score of ≥ 3) risk of bleeding
13. the proportion of eligible patients prescribed DOACs, warfarin and aspirin/no anticoagulation therapy
and the proportion of patients contraindicated to anticoagulation therapy
14. incremental quality of life benefits and costs from rate control compared with no rate control.
We searched MEDLINE and EMBASE between 1 January 2000 and 22 January 2016 (search strategy is
provided in Appendix 9). In total, 2126 references were identified after deduplication. After abstract and
title screening, 134 references were identified as potentially relevant. For the prevalence of AF we restricted
inclusion to UK or Irish populations, unless the study was conducted in a community or general practice
screening setting. For all other model inputs we did not restrict the population. This identified 56 papers.
In addition, we identified a further 22 studies as follows: (1) seven studies found in the reference lists of the
Lowres et al.90 and Xiong et al.124 systematic reviews, (2) eight studies found in the economic evaluations
review and citations in the identified studies, (3) three studies found in the NICE clinical guideline CG18011
report and the associated consensus report (www.nice.org.uk/guidance/cg180/resources/nic-consesus-
statement-on-the-use-of-noacs-243733501), (4) three studies found in the DOACs review37 and associated
review and (5) one recently published study brought to our attention by the HIQA team (P Moran, Health
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Information and Quality Authority, Ireland, 2016, personal communication). After screening the full texts,
we included 48 studies that reported data relevant to at least one of the model inputs listed above. A flow
chart summarising the literature search is provided in Figure 18. In the following sections, we describe the
evidence sources for each model input in turn and provide a rationale for the values and distributions
assumed in our model.
Prevalence of atrial fibrillation in the UK by age and sex
The prevalence of AF strongly depends on both age and sex.31 We searched for studies reporting
prevalence in a general population (both diagnosed and undiagnosed) broken down by age and sex in
Western European countries, with data collected from 2000 onwards. Table 19 summarises the studies
identified and Figure 19 shows plots of prevalence against age for men and women separately. All studies
show similar patterns, although there are some differences between studies, with, in particular, the study
by Baena-Díez et al.129 finding a lower prevalence of AF in older people than the other studies. We chose
to use the prevalence estimates from Norberg et al.2 as this was the most recent and largest study
providing the most detailed results. The prevalence estimates from Norberg et al.2 are shown in Table 20.
Population size eligible for screening at each age
The size of population eligible for screening at each age was estimated as the total number of men and
women in the associated 5-year age range as reported by the Office for National Statistics (ONS)130 for
England and Wales in 2014 divided by 5. These estimates are reported in Table 21.
Uptake of systematic population screening
Seven studies reported the uptake of systematic screening in which individuals were invited to screening by
letter. These studies are summarised in Table 22. Uptake of screening varied between 53% and 76%
across studies/populations, with both the minimum and the maximum uptake seen in UK general practice
populations. We pooled the data from all seven studies using a random-effects meta-analysis, reported in
Table 22. However, uptake of screening is likely to depend on age. The only study that reported uptake by
age is the SAFE study19 (Table 23). The results for the < 75 years age group are in line with the results from
the studies reported in Table 22, whereas uptake in the older age group is lower. We used the figures in
Table 23 to inform beta distributions for use in our model.
Full-text screening identified 48 records 
Details of studies providing data for 
each outcome are described in the
accompanying text
EMBASE and MEDLINE
1 January 2000–22 January 2016
(2126 records)
Title and abstract screening
identified 134 records including
two systematic reviews, which
identified a further
seven studies
Other sources
• Studies found in economic evaluations review, 
   n = 8
• Studies found in NICE CG180 and consensus 
   report, n = 3
• Studies found in DOACs report, n = 3
• Study found via personal communication, n = 1
FIGURE 18 Flow diagram showing the literature search to find evidence on the natural history of AF.
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FIGURE 19 Estimated prevalence of AF by age and sex plotted for the studies identified in our literature review
relevant to a contemporary Western European population. (a) Men; and (b) women.
TABLE 19 Summary of studies providing information on the prevalence of AF by age and sex in Western
European populations
Study Population Comments
Fitzmaurice 200784 Prevalence at 12 months following randomisation to
screening (systematic opportunistic or systematic
population screening); 50 UK general practice centres
randomised in 2001 (n= 4915 and 4906 respectively)
Schnabel 2012125 Population-based Gutenberg Health Study random
sample of people from the Mainz region, from 2007
onwards (n= 5000)
Used in Irish HIQA HTA25 of AF
screening
Norberg 20132 General population in Skelleftia, Sweden (2010), with
extensive searching of multiple databases with ECG
validation (n = 38,142)
Used in Public Health England
report1
Frewen 2013126 Irish community sample from the TILDA study (n= 8175)
Krijthe 2013127 Two general population cohorts in Rotterdam, the
Netherlands (2002) (n= 6934)
Gómez-Doblas 2014128 Spain, general population aged ≥ 40 years in 47
hospitals across 46 provinces (2010) (n = 8343)
Baena-Díez 2014129 Pooled data from six population-based studies in Spain
and nearby islands (1999–2011) (n= 8149)
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TABLE 21 Population size eligible for screening derived from ONS 2014 estimates for England and Wales130
Screening age
(years)
ONS range
(years)
Male population
in range, n
Female population
in range, n
Screening age
population, n
55 55–59 1,670,449 1,708,826 675,855.0
60 60–64 1,517,771 1,583,693 620,292.8
65 65–69 1,540,906 1,627,388 633,658.8
70 70–74 1,110,603 1,222,424 466,605.4
75 75–79 873,540 1,026,027 379,913.4
80 80–84 595,901 801,284 279,437.0
TABLE 20 Prevalence of AF (diagnosed and undiagnosed combined) by age and sex
Age
(years)
Men Women
Population, n
Cases of
AF, n Prevalence (95% CI) Population, n
Cases of
AF, n Prevalence (95% CI)
50–54 2575 53 0.021 (0.015 to 0.026) 2575 10 0.004 (0.001 to 0.006)
55–59 2710 86 0.032 (0.025 to 0.038) 2549 17 0.007 (0.004 to 0.010)
60–64 2736 115 0.042 (0.035 to 0.050) 2596 43 0.017 (0.012 to 0.021)
65–69 2383 164 0.069 (0.059 to 0.079) 2450 83 0.034 (0.027 to 0.041)
70–74 1874 212 0.113 (0.099 to 0.127) 1957 112 0.057 (0.047 to 0.068)
75–79 1405 228 0.162 (0.143 to 0.182) 1797 183 0.102 (0.088 to 0.116)
80–84 1015 206 0.203 (0.178 to 0.228) 1478 231 0.156 (0.138 to 0.175)
≥ 85 731 174 0.238 (0.207 to 0.269) 1350 281 0.208 (0.186 to 0.230)
Source: adapted from data published in Norberg et al.2 © 2013 Norberg et al. published by Dove Medical Press Limited,
and licensed under Creative Commons Attribution – Non Commercial (unreported, v3.0) License.
TABLE 22 Summary of studies reporting information on the uptake of systematic population screening
Study Population Method Uptake, n Invited, n
Proportion
uptake
Morgan
200282
Four UK general practices, aged ≥ 65
years, either systematic population or
systematic opportunistic screening
Pulse palpation +
optional ECG
1099 1499 0.733
Hobbs 200519 50 UK general practice centres, aged
≥ 65 years, systematic population,
systematic opportunistic or no
screening
ECG 2357 4433 0.532
Davis 2012131 English general practices 1995–9,
aged ≥ 45 years invited for screening
12-lead ECG 3960 6286 0.630
Engdahl
201322
75- and 76-year-olds in a region of
Sweden invited to screening
12-lead ECG+ 2 weeks
hand-held ECG,
systematic
848 1330 0.638
Gómez-Doblas
2014128
Spain, general population aged
≥ 40 years, 47 hospitals across
46 provinces
ECG 8400 11,055 0.760
continued
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Proportion of initial invitees requiring a reminder letter
Two studies reported the proportion of reminder invitations sent during systematic screening (Table 24).
This proportion varied from 0.4 to 0.6. We used the results from the SAFE study as being the most
representative of a UK population and a normal distribution was used to reflect uncertainty in this estimate.
Pulse taking in flagged individuals in opportunistic screening
Two studies reported the number of flagged individuals who had pulse palpation under a systematic
opportunistic screening strategy (Table 25). There is a large discrepancy between these results. We used the
results from Hobbs et al.19 to inform beta distributions in our base-case model as this was the more recent,
larger study and the results were broken down by age group (< 75 and ≥ 75 years). Both of these studies
used paper flags, whereas in current practice computerised flags are likely to be more feasible and sustainable
for recurrent opportunistic screening; however, GPs may be less likely to respond to computerised flags
because of ‘alert fatigue’.133 We used the results from Morgan and Mant82 in a sensitivity analysis (assuming
the same rate in both age groups as the rates were not reported separately), to represent a lower uptake of
systematic opportunistic screening.
The proportion of 12-lead electrocardiograms interpreted by a general
practitioner that require further interpretation by a cardiologist
We did not identify any information on the proportion of 12-lead ECGs read by a GP that would require
further interpretation by a cardiologist and so took advice from our clinical experts. On the basis of this,
we assumed that 10% of ECGs read by a GP would require a cardiologist interpretation to confirm the
diagnosis. We assumed a 95% CI from 1% to 20%.
TABLE 23 Summary of studies reporting information on the uptake of systematic population screening by age
Study Population
Age group
(years) Uptake, n Invited, n
Proportion uptake
(95% CI)
Hobbs 200519 50 UK general practice centres,
aged ≥ 65 years, systematic
population, systematic
opportunistic or no screening
< 75 1471 2418 0.608 (0.589 to 0.628)
≥ 75 741 1726 0.429 (0.406 to 0.453)
TABLE 22 Summary of studies reporting information on the uptake of systematic population screening
(continued )
Study Population Method Uptake, n Invited, n
Proportion
uptake
Bury 2015132 25 Irish general practice centres, aged
≥ 70 years invited for screening
3-lead ECG, systematic 639 1003 0.637
Svennberg
201540
Individuals aged ≥ 65 years invited to
screening in two locations in Sweden
Hand-held ECG over
2 weeks (24 hours of
continuous monitoring if
unclear result), systematic
7173 13,331 0.538
Pooled random-effects posterior mean (95% CrI) 0.641 (0.543 to 0.730)a
a Pooled using random-effects analysis on a log-odds scale in WinBUGS version 1.4.3 (convergence checked using
Brooks–Rubin–Gelman diagnostic, n= 10,000 burn-in, n= 20,000 sample) (MRC Biostatistics Unit, Cambridge, UK).
Results converted to probabilities for presentation.
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Rate of diagnosis of atrial fibrillation in the absence of screening
The SAFE study compared systematic and opportunistic screening against a no screening control.19 Table 26
shows the diagnosis rate in the SAFE study no screening arm. The rate of detection in the absence of
screening is low and it is likely that in many cases diagnosis of AF occurs only after a stroke or another acute
event. Our DOAC model37 already tracks the incidence of adverse events in individuals with AF not on
anticoagulation therapy and assumes that anticoagulation therapy is initiated following a stroke in those
who are not contraindicated. Therefore, to avoid double counting a diagnosis of AF following acute events,
we assumed that there would be no ‘serendipitous’ diagnosis of AF in the no screening arm.
The proportion of atrial fibrillation that is undiagnosed
It is possible to estimate the proportion of AF that is undiagnosed from screening studies (Table 27).
However, these estimates are not directly comparable with each other because different screening tests are
used. Furthermore, we might expect these to be underestimates because a one-off ECG is unlikely to
detect paroxysmal AF. In the two studies with prolonged monitoring,22,40 higher undiagnosed proportions
were seen than in many studies with one-off monitoring. A recent report by Public Health England1 used
prevalence estimates from a Swedish study2 (that comprehensively searched ECG records in a variety of
sources together with patient records) and applied these estimates to the demographics of GPs in England
to obtain predicted AF cases in England. Comparing this prediction with the figures reported in the QOF3
for England GPs gives an estimate of the proportion of AF that is undiagnosed of 0.348. Given that this
estimate is in line with the most intensive screening study,22 it has been adjusted to match demographics
in England and prevalence estimates are available broken down by age and sex, and we used this estimate
of the proportion of undiagnosed AF in our model.
TABLE 24 Summary of studies reporting the proportion of patients invited to screening who required a
reminder letter
Study Population Arm/group Invited, n
Proportion reminder
(95% CI)
Hobbs 200519 50 UK general practice centres, aged
≥ 65 years, systematic population,
systematic opportunistic or no screening
Systematic 4433 0.45 (0.435 to 0.465)
Svennberg
201540
Individuals aged ≥ 65 years invited to
screening in two locations in Sweden
Stockholm 10,908 0.6
Halland 2345 0.4
TABLE 25 Summary of studies reporting the proportion of patients with flagged notes who have their
pulses checked
Study Population
Age group
(years)
Pulses taken on
consultation, n
Notes
flagged, n
Proportion pulses
taken (95% CI)
Hobbs 200519 50 UK general practice centres,
aged ≥ 65 years, systematic
population, systematic
opportunistic or no screening
< 75 1806 2585 0.699 (0.681 to 0.716)
≥ 75 1224 1828 0.670 (0.648 to 0.691)
Morgan 200282 Four UK general practices,
aged ≥ 65 years, either
systematic population or
systematic opportunistic
screening
439 1437 0.305 (0.282 to 0.329)
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TABLE 27 Summary of screening studies for AF
Study Population Method
Number
screened
with
known AF
Number
with screen-
detected AF
Number
screened
with AF
Proportion
AF is
undiagnosed
Public Health
England1
England – diagnosed AF
from QOF. Total AF
estimated using
prevalence by age and
sex from Swedish
database data2 applied
to demographics from
the QOF
Estimated using
patient
demographics in
England and
Swedish database
889,383 473,938 1,363,321 0.348
Engdahl
201322
75- and 76-year-olds in
a region of Sweden
invited to screening
12-lead ECG
+ 2-week hand-
held ECG
81 40 121 0.331
Svennberg
201540
Individuals aged
≥ 65 years invited to
screening in two
locations in Sweden
Hand-held ECG
over 2 weeks
(24 hours of
continuous
monitoring if
unclear result)
666 218 884 0.247
Hobbs 200519 50 UK general practice
centres, aged ≥ 65 years,
systematic population,
systematic opportunistic
or no screening
Systematic: ECG 339 52 391 0.133
Hobbs 200519 50 UK general practice
centres, aged ≥ 65 years,
systematic population,
systematic opportunistic
or no screening
Opportunistic:
pulse palpation +
ECG
340 31 371 0.084
Bury 2015132 25 Irish general practice
centres, individuals aged
≥ 70 years invited for
screening
3-lead ECG 23 12 35 0.343
Claes 2012134 Aged ≥ 40 years,
Belgium, nationwide
volunteers
Single-lead ECG 771 228 999 0.228
Kaasenbrood
2016135
10 general practices
in the Netherlands,
individuals aged
≥ 60 years invited to
screening during flu
vaccination
Single-lead ECG 84 37 121 0.306
Lowres
201421
Australia, individuals
aged ≥ 65 years
attending 10 community
pharmacies invited to
screening
Pulse palpation+
iECG (checked by
cardiologist)
104 15 119 0.126
TABLE 26 Summary of the study reporting the diagnosis rate of AF in the absence of screening
Study Population Incident AF, n Population, n
1-year incident AF
diagnosis rate (95% CI)
Hobbs 200519 25 UK general practice centres, aged
≥ 65 years, control (no screening)
47 4936 0.0095 (0.0068 to 0.0122)
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The proportion of atrial fibrillation that is paroxysmal, persistent and permanent
Although several studies provided information on the proportion of patients with paroxysmal, persistent and
permanent AF, these were primarily studies of diagnosed patients, which will underestimate the proportion
of paroxysmal patients quite dramatically. Instead, we were interested in the proportion of paroxysmal AF
in a systematic screening population (Table 28). The proportion of AF of each type varied widely across
screening studies. Engdahl et al.22 and Arronnson et al.100/Svenberg et al.40 used a continuous monitoring
screening test in population-based screening that was able to detect paroxysmal AF. Both of these studies
detected a higher proportion of paroxysmal AF than persistent or permanent AF, suggesting that paroxysmal
AF is more prevalent in people with undiagnosed AF, but that most screening studies are not able to detect it.
For example, among the new AF cases detected by Sanmartín et al.,138 only 6% were paroxysmal AF. In our
model we assumed that 6% of screen-detected AF is paroxysmal AF and the remaining 94% is permanent or
persistent AF. In sensitivity analysis, we varied the proportion of paroxysmal AF that can be detected.
For the proportion of all undiagnosed AF that is paroxysmal we pooled the data from Engdahl et al.22 and
Arronsson et al.100/Svenberg et al.40 using a fixed-effects meta-analysis (see Table 28).
The proportion of atrial fibrillation that is asymptomatic (by atrial fibrillation type)
We were interested in the proportion of patients, by AF type, who are asymptomatic in a population-based
screening population (Table 29). Two of the studies136,139 gave results for screen-detected AF based on
electrocardiography (and hence mostly persistent and permanent AF). These studies found a high
proportion of AF that is asymptomatic (0.8 and 0.49 respectively), as would be expected in a screening
context. Another study14 reporting 1 year of follow-up of newly diagnosed AF patients found a similarly
high proportion of asymptomatic patients (0.87). In patients with diagnosed chronic AF (persistent or
permanent), there was a consistent finding of approximately 30% of patients being asymptomatic.14,140,141
The proportion of paroxysmal AF that was asymptomatic was higher (estimates of 0.4142 and 0.714).
We pooled the data from Deif et al.,136 Smyth et al.139 and Nieuwlaat et al.14 in our model using a
fixed-effects meta-analysis (see Table 29).
TABLE 27 Summary of screening studies for AF (continued )
Study Population Method
Number
screened
with
known AF
Number
with screen-
detected AF
Number
screened
with AF
Proportion
AF is
undiagnosed
Deif 2013136 Australian hospital,
individuals aged
≥ 65 years attending for
minor surgery invited for
screening
ECG in hospital 98 10 108 0.093
Rhys 2013117 Individuals aged
≥ 65 years attending for
flu vaccination in a
single centre in the UK
Pulse + ECG 21 2 23 0.087
Gómez-
Doblas
2014128
Spain, general
population aged
≥ 40 years, 47 hospitals
across 46 provinces
ECG 369 41 410 0.1
Panisello-
Tafalla
2015137
Spanish AF registry of
those aged > 60 years
Unclear 0.309
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TABLE 29 Summary of studies providing information on the proportion of screen-detected AF that is asymptomatic
(by AF type)
Study Population
Proportion
asymptomatic in
paroxysmal AF
Proportion
asymptomatic in
permanent AF
Proportion
asymptomatic in
persistent and
permanent AF
Proportion
asymptomatic
in newly
diagnosed AF
Deif
2013136
Australian hospital,
individuals aged
≥ 65 years attending for
minor surgery invited for
screening
8/10= 0.8
Smyth
2016139
37 GPs in rural Ireland,
individuals aged
≥ 65 years flagged for
opportunistic screening
27/55= 0.491
Nieuwlaat
200814
Euro Heart Survey,
1-year follow-up of AF
patients
821/1170 = 0.702 686/2012 = 0.341 615/708= 0.869
Senoo
2014142
Shinken database,
paroxysmal AF from a
single hospital in Japan
468/1176 = 0.398
Rienstra
2014140
Permanent AF patients in
the RACE trial,
33 centres, the
Netherlands
157/522= 0.301
Frykman
2001141
Swedish hospital
outpatients with
permanent or persistent
AF
91/282 = 0.323
Pooled fixed-effects estimate posterior mean (95% CrI) 0.841 (0.814 to 0.866)a
RACE, RAte Control versus Electrical cardioversion for persistent atrial fibrillation.
a Data from Deif et al., Smyth et al. and Nieuwlaat et al. were pooled using a fixed-effects meta-analysis (insufficient
number of studies to estimate a random-effects model) on a log odds scale in WinBUGS version 1.4.3 (convergence
checked using the Brooks–Rubin–Gelman diagnostic, n= 10,000 burn-in, n= 20,000 sample). Results converted to
probabilities for presentation.
TABLE 28 Summary of screening studies providing information on the proportion of patients with paroxysmal,
persistent or permanent AF
Study Population
Proportion
paroxysmal AF
Proportion
persistent or
permanent AF
Engdahl 201322 75- and 76-year-olds in a region of Sweden invited for
screening, 12-lead ECG+ 2-week hand-held ECG
30/40= 0.75 10/40 = 0.25
Arronsson 2015100/
Svennberg 201540
Individuals aged ≥ 65 years invited for screening in two
locations in Sweden; 2-week hand-held ECG
182/218 = 0.835 36/218 = 0.165
Sanmartín 2013138 Individuals aged ≥ 65 years invited for screening, three
Spanish health centres, pulse palpation+ 12-lead ECG
1/17 = 0.059 16/17= 0.941
Pooled fixed-effects estimate posterior mean (95% CrI) 0.822 (0.773 to 0.865)a
a Data from Engdahl et al.22 and Arronnson et al.100/Svenberg et al.40 were pooled using a fixed-effects meta-analysis
(insufficient number of studies to estimate a random-effects model) on a log odds scale in WinBUGS version 1.4.3
(convergence checked using the Brooks–Rubin–Gelman diagnostic, n= 10,000 burn-in, n= 20,000 sample). Results
converted to probabilities for presentation.
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Disease progression from paroxysmal atrial fibrillation to persistent/permanent
atrial fibrillation
Table 30 summarises studies reporting information on the rate at which paroxysmal AF patients progress
to persistent and permanent AF. The majority of the studies report the rate at which paroxysmal AF
progresses to permanent AF. The results are fairly consistent across studies, with the only UK study143
giving a very similar estimate to the largest study conducted in the US (Holmqvist144). Holmqvist144 also
provides the figures to estimate the rate that individuals progress from paroxysmal to chronic (persistent or
permanent) AF, which is what is required in our model. Given the agreement between Holmqvist144 and
the UK study, we chose to use Holmqvist144 to estimate the rate of progression from paroxysmal to chronic
AF in the economic model.
Hazard ratios for stroke and mortality risk by whether asymptomatic or not
Xiong et al.124 presented a systematic review of studies comparing mortality and stroke outcomes in
symptomatic and asymptomatic patients. Because symptomatic patients may receive different anticoagulation
therapy and other treatments from asymptomatic patients, we present here the results from the RCTs
included in the study by Xiong et al.,124 in which allocation of symptomatic and asymptomatic patients across
trial arms should have been balanced. The results from these two RCTs35,140 included in the study by Xiong
et al.124 are summarised in Table 31.
TABLE 30 Summary of studies providing information on disease progression from paroxysmal (Px) to persistent(Ps)/
permanent (Pm) AF
Study Population
Mean
follow-up
(years) Px, n
Px→ Ps
(but not Pm), n Px→ Pm, n
Px→ Ps or
Pm, n
Holmqvist
2015144
ORBIT-AF registry of
outpatients aged ≥ 18 years,
centres across the USA
1.5 4697 556
(rate = 0.079)
476
(rate = 0.068)
1032
(rate = 0.146)
Ruigomez
2005143
UK General Practice
Research Database (GPRD)
2.7 418 70
(rate = 0.062)
Nieuwlaat
200814
Euro Heart Survey 1 1170 234
(rate = 0.200)
Kato 2004145 Patient records at a single
hospital, Japan
14 171 132
(rate = 0.055)
Al-Khatib
2000146
Patients of a single
cardiologist, NC, USA
4 231 42
(rate = 0.045)
TABLE 31 Summary of studies providing information on stroke and mortality risk in symptomatic compared with
asymptomatic AF
Study Population
All-cause mortality,
HR symptomatic vs.
asymptomatic (95% CI)
Composite outcome
(mortality+ events),
HR symptomatic vs.
asymptomatic (95% CI)
Rienstra 2014140 Permanent AF patients in the RACE
trial, 33 centres, the Netherlands
1.96 (1.09 to 3.45)
Flaker 200535 AFFIRM RCT AF patients, USA Unadjusted: 1.29
(0.99 to 1.68); adjusted:
1.07 (0.79 to 1.46)
Unadjusted: 1.31
(1.04 to 1.65); adjusted:
1.14 (0.87 to 1.50)
AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; RACE, RAte Control versus Electrical
cardioversion for persistent atrial fibrillation.
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Both studies show that symptomatic patients are more likely to have a composite outcome of mortality
and other events than asymptomatic patients; however, Flaker et al.35 show that, when adjusted for other
risk factors, this effect diminishes (HR 1.14, 95% CI 0.87 to 1.50). Flaker et al.35 found a similar result for
all-cause mortality, with an adjusted HR of 1.07 (95% CI 0.79 to 1.46). Because the risk of stroke and
mortality in our model already accounts for risk factors (CHA2DS2-VASc score, previous MI, previous
stroke), the adjusted estimates are of relevance to our model and, as these suggest that there is no
evidence that risk is any different in asymptomatic patients from symptomatic patients, we do not allow
for differential risk according to symptomatic status in our base case. In sensitivity analysis, we assumed
that the event rate in screen-detected patients is lower than that for routinely detected AF using the
unadjusted HR for symptomatic AF (representing non-screen-detected AF) compared with asymptomatic AF
(representing screen-detected AF) found by Flaker et al.35 of 1.31 (95% CI 1.04 to 1.65).
Hazard ratios for stroke and mortality risk by atrial fibrillation type
To obtain estimates of the HRs for events for different AF types, we need to avoid confounding by
treatment, as permanent AF is more likely to be treated than paroxysmal AF. We selected studies in which
treatment allocation was the same across AF type, mostly post hoc analyses of pooled RCT arms, but also
one study in which the results were broken down by treatment (Table 32). Only one study147 gave the HR
for mortality for persistent relative to paroxysmal AF, but this was in close agreement with the HR for stroke
in that same study, which supports an assumption that the HRs are the same for both stroke and mortality
outcomes. The majority of the studies gave results for stroke comparing persistent with paroxysmal AF,
showing in general an increased risk of stroke in persistent compared with paroxysmal AF. Vanassche et al.9
also presented the HR for permanent compared with paroxysmal AF, which suggested that there is a
‘dose–response relationship’, with risk increasing from paroxysmal to persistent to permanent AF. We
pooled the HRs from the studies reporting HRs (and CIs) for stroke in persistent compared with paroxysmal
AF. Because there were only three such studies, we pooled them using a fixed-effects model. In our model
we do not distinguish between persistent and permanent AF; for at least one of the studies, the result for
persistent AF also included permanent AF. We therefore used the HR for persistent compared with
paroxysmal AF in our model. We assumed that the HR is the same for mortality as it is for stroke.
TABLE 32 Summary of studies providing information on stroke and mortality risk for persistent (Ps) or permanent
(Pm) AF compared with paroxysmal (Px) AF
Study Population
Stroke HR, Ps vs. Px
(95% CI)
Stroke HR,
Pm vs. Px
(95% CI)
Mortality
HR, Ps vs. Px
(95% CI)
Steinberg 2015147 AF patients in the ROCKET-AF RCT of
rivaroxaban vs. warfarin; arms pooled
1.28 (1.01 to 1.64) 1.27
(1.06 to 1.49)
Vanassche 20159 Two RCT AF populations; one or more
risk factors for stroke, contraindicated
for OACs, on aspirin
1.43 (1.04 to 1.96) 2.04
(1.6 to 2.61)
Friberg 2010148 All patients treated for AF in a Swedish
hospital in 2002
Not on warfarin 1.53,
on warfarin 1.11
Hohnloser 2007149 RCT AF population, both arms pooled;
patients with one or more risk factors
for stroke
1.15 (0.77 to 1.69)
Pooled fixed-effects estimate posterior mean (95% CrI) 1.3 (1.09 to 1.54)a
ROCKET-AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention
of Stroke and Embolism Trial in Atrial Fibrillation.
a Data from Steinberg et al.147, Vanassche et al.9 and Hohnloser et al.149 were pooled for the outcome of stroke in
persistent relative to paroxysmal AF using a fixed-effects meta-analysis on a log HR scale in WinBUGS version 1.4.3
(convergence checked using the Brooks–Rubin–Gelman diagnostic, n= 10,000 burn-in, n= 20,000 sample). Results
converted to HRs for presentation.
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The proportion of screen-detected atrial fibrillation with a CHA2DS2-VASc
score of ≥ 2
Table 33 details the results from six studies providing information on the proportion of AF patients with a
CHA2DS2-VASc score of ≥ 2 in a screening or community population. The results are given separately for
known (diagnosed) AF patients and screen-detected AF patients. We pooled the data from all four studies
reporting results for screen-detected AF using a fixed-effects meta-analysis for use in our model.
The proportion of screen-detected atrial fibrillation cases with a previous
history of myocardial infarction
Table 34 shows the results from studies reporting the proportion of screen-detected AF cases with a
previous history of MI. We also show the results for studies of newly diagnosed AF; however, it should
be noted that these patients are more likely to be symptomatic at diagnosis than screen-detected AF
patients. This is reflected in the results, with a much higher proportion of newly diagnosed AF cases having
a previous history of MI than screen-detected or asymptomatic AF cases. The proportion of patients with
a previous MI was 5.4%135 and 0%138 in the two studies of screen-detected AF. We pooled the data
from both studies reporting results for screen-detected AF using a fixed-effects meta-analysis for use in
our model.
TABLE 33 Summary of studies reporting the proportion of screen-detected AF with a CHA2DS2-VASc score of ≥ 2
Study Population
P(CHA2DS2-VASc
score of ≥ 2), known
and screen-detected AF
P(CHA2DS2-VASc
score of ≥ 2),
known AF
P(CHA2DS2-VASc
score of ≥ 2),
screen-detected AF
Claes 2012134 Aged ≥ 40 years, Belgium,
nationwide volunteers
0.72
Kaasenbrood
2016135
10 GPs in the Netherlands,
individuals aged ≥ 60 years
invited to screening during flu
vaccination
73/84 = 0.869 29/37= 0.784
Smyth 2016139 37 GPs in rural Ireland,
individuals aged ≥ 65 years
flagged for opportunistic
screening
37/39= 0.949
Lowres 201421 Australia, individuals aged
≥ 65 years attending 10
community pharmacies invited
to screening
15/15= 1
Deif 2013136 Australian hospital, individuals
aged ≥ 65 years attending
for minor surgery invited
for screening
11/12= 0.91
Frewen 2013126 Irish community sample 81/119 = 0.681
Pooled fixed-effects estimate posterior mean (95% CrI) 0.750 (0.699 to 0.797)a
a Data from Kasenbrood et al.,135 Smyth et al.,139 Lowres et al.21 and Deif et al.136 were pooled using a fixed-effects
meta-analysis (insufficient number of studies to estimate a random-effects model) on a log odds scale in WinBUGS
version 1.4.3 (convergence checked using the Brooks–Rubin–Gelman diagnostic, n = 10,000 burn-in, n= 20,000
sample). Results converted to probabilities for presentation.
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The proportion of screen-detected atrial fibrillation cases with a previous
history of ischaemic stroke (or transient ischaemic attack)
Table 35 shows the results from studies reporting the proportion of screen-detected AF cases with a
previous history of ischaemic stroke or TIA. We also show the results for studies of newly diagnosed AF.
The results do not show a consistent pattern of previous stroke risk in newly diagnosed AF patients
compared with screen-detected AF. The results are variable even when restricting to screen-detected AF.
We pooled the data from all seven studies (eight arms) reporting results for screen-detected AF using a
random-effects meta-analysis to account for heterogeneity, reported in Table 35. However, the most
relevant study to a UK screening population is the SAFE study,153 the estimate for which is only just
TABLE 34 Summary of studies reporting the proportion of screen-detected AF cases with a previous history of MI
Study Population
Proportion
with previous
MI, diagnosed
paroxysmal AF
Proportion
with previous
MI, diagnosed
persistent/
permanent AF
Proportion
with previous
MI, all
diagnosed
Proportion with
previous MI,
asymptomatic
diagnosed AF
Proportion
with prior
MI, screen-
detected AF
Kaasenbrood
2016135
Screen-detected
AF, 10 GPs in
the Netherlands,
invited a subset
of those
attending for flu
vaccination
2/37= 0.054
Sanmartín
2013138
Screen-detected
AF, aged ≥ 65
years, three
Spanish health
centres
0/17 = 0
Martinez
2014150
UK Clinical
Practice Research
Datalink
incidentally
detected AF
patients
232/5555= 0.042
Avgil Tsadok
2012151
Patients admitted
to hospitals in
Quebec province,
Canada, with
newly diagnosed
AF, identified
from hospital
records
Women:
5826/44,115=
0.132; men:
8192/39,398=
0.208
Kerr 2005152 Canadian
Registry of Atrial
Fibrillation
(CARAF) – newly
diagnosed AF by
type
99/588= 0.168 30/169= 0.178
Pooled fixed-effects estimate posterior mean (95% CrI) 0.037 (0.005 to 0.099)a
a Data from Kasenbrood et al.135 and Sanmartin138 were pooled using a fixed-effects meta-analysis (insufficient number of
studies to estimate a random-effects model) on a log odds scale in WinBUGS version 1.4.3 (convergence checked using the
Brooks–Rubin–Gelman diagnostic, n= 10,000 burn-in, n= 20,000 sample). Results converted to probabilities for presentation.
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contained in the CrI around the random-effects mean. We elected to estimate the history of previous
stroke in a UK screen-detected AF population by pooling the systematic population and systematic
opportunistic arms of the SAFE study for use in our economic model (reported in Table 35). We assumed a
normal distribution for this history of previous stroke. In sensitivity analysis, we used the random-effects
mean across all studies reporting screen-detected AF.
TABLE 35 Summary of studies reporting the proportion of screen-detected AF cases with a previous history of
ischaemic stroke (or TIA)
Study Population
Proportion with
previous stroke,
diagnosed AF
Proportion with
previous stroke,
asymptomatic
diagnosed AF
Proportion
with previous
stroke, screen-
detected AF
Fitzmaurice
2014153
50 UK GP centres, aged ≥ 65 years,
systematic screen-detected AF
7/74 = 0.095
Fitzmaurice
2014153
50 UK GP centres, aged ≥ 65 years,
opportunistic screen-detected AF
4/75 = 0.053
Svennberg
201540
Two locations in Sweden, aged
≥ 65 years, systematic screen-detected
AF, hand-held ECG over 2 weeks
(24 hours of continuous monitoring if
unclear result)
137/666 = 0.206 21/218 = 0.096
Claes 2012134 Aged ≥ 40 years, Belgium, nationwide
volunteers, single-lead ECG screen-
detected AF
27/228 = 0.118
Kaasenbrood
2016135
10 GPs in the Netherlands, invited a
subset of those attending for flu
vaccination. Results for diagnosed and
screen-detected AF
9/84 = 0.107 7/37 = 0.189
Sanmartín
2013138
Aged ≥ 65 years, three Spanish health
centres, screen-detected AF
4/17 = 0.235
Gómez-Doblas
2014128
Spain, general population aged
≥ 40 years, 47 hospitals across
46 provinces
7/41 = 0.171
Lowres 201421 Australia, individuals aged ≥ 65 years
attending 10 community pharmacies.
Results for diagnosed and screen-
detected AF
2/15 = 0.133
Martinez
2014150
UK Clinical Practice Research Datalink
incidentally detected AF patients
509/5555= 0.092
Avgil Tsadok
2012151
Patients admitted to hospitals in Quebec
province, Canada, with newly diagnosed
AF, identified from hospital records
Women: 3511/
44,115 = 0.08;
men: 2733/
39,398 = 0.069
Pooled random-effects mean posterior mean (95% CrI) 0.116 (0.080 to 0.168)a
SAFE study only 0.074 (0.032 to 0.116)
a Data from the seven screening studies (eight arms) were pooled in a random-effects meta-analysis on a log odds scale in
WinBUGS version 1.4.3 (convergence checked using the Brooks–Rubin–Gelman diagnostic, n= 20,000 burn-in,
n= 40,000 sample). Results converted to probabilities for presentation.
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Anticoagulation therapy for screen-detected atrial fibrillation with a
CHA2DS2-VASc score of ≥ 2
Our model required information on the proportions of screen-detected AF patients with a CHA2DS2-VASc
score of ≥ 2 who are prescribed OACs, who are contraindicated to or who decline OACs and who simply do
not have OACs prescribed. The studies providing information relevant to this are summarised in Table 36. Only
one study126 provided information on the HAS-BLED bleeding risk score in AF patients with a CHA2DS2-VASc
score of ≥ 2, finding 2.49% with a HAS-BLED score of ≥ 3. It should be noted that, although the HAS-BLED
score can inform clinical decision making on whether or not a patient is suitable for OACs, other factors will
also be taken into account. A more practical measure of those who are not suitable for OACs is the reported
proportion contraindicated to, or preferring not to take, OACs. Three studies3,118,154 reported this information in
patients with a high stroke risk (albeit using the CHADS2 rather than the CHA2DS2-VASc risk score), with
all three studies giving very similar estimates (see Table 36). The QOF report3 represents the most recent
evidence covering the majority of GPs in England, with an estimated 12.94% of patients contraindicated or
declining OACs (‘exceptions’ rate from the QOF report3), which we used in our model.
There is a wide variation in the proportion of AF patients with a CHA2DS2-VASc score of ≥ 2 who are
prescribed OACs (see Table 36). Again, we used the figures from the QOF report3 as they provide the most
contemporary relevant evidence in England, giving an estimated 74.30% of AF patients who are prescribed
OACs. It should be noted that this leaves 12.76% of patients who are not contraindicated but who do
not receive OACs. In our model base case, we assumed that all patients not prescribed OACs (12.94%
contraindicated or declining OACs plus 12.76% not prescribed OACs for other reasons) receive aspirin.
It may be that patients with screen-detected AF are less likely to be prescribed OACs than patients with
AF detected routinely, in which case the uptake of OACs may be lower than 74.30%. Alternatively,
implementation activities may lead to an increase in uptake of OACs in the future. We explored the
robustness of our results to this in sensitivity analyses, with the uptake of OACs reduced to 50% or
increased to 87.0% (so that all who are not contraindicated or declining OACs receive OACs).
TABLE 36 Summary of studies reporting the proportion of patients contraindicated or declining OACs and the
proportion prescribed OACs
Study Population
HAS-BLED
score of ≥ 3)
Contraindicated
or declining
OACs Prescribed OACs
Health and Social
Care Information
Centre 20153
England, GP reports, CHADS2 score of ≥ 1 0.1294 0.743
Cowan 2013154 GRASP-AF registry, voluntary GPs in
England, results for CHADS2 score of ≥ 2
12,128/87,198 =
0.139
72,211/87,198 =
0.828
Gordon 2012118 Individuals aged ≥ 65 years attending for
flu vaccination, 35 general practices in
Sussex, screen-detected AF, CHADS2
score of ≥ 2
10/84= 0.119 41/84 = 0.488
Apenteng
2014155
UK subpopulation of GARFIELD-AF, an
international registry of newly diagnosed
AF, CHA2DS2-VASc score of ≥ 2
0.472
Deif 2013136 Patients aged ≥ 65 years attending for
minor surgery, single hospital in Australia,
known AF with CHADS2 score of ≥ 2
52/82 = 0.634
Frewen 2013126 Irish community sample, known and
screen-detected AF with a CHA2DS2-VASc
score of ≥ 2
2/81 = 0.025
GARFIELD, Global Anticoagulant Registry in the FIELD.
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Uptake of DOACs has been slow, with some studies reporting that DOACs represent as little as 3.79%156
of all OACs prescribed for AF. Figure 20 shows the trends in prescribing of OACs in England over time.
It can be seen that there has been a steady trend of increased prescribing of DOACs. Figure 20 includes
all patients prescribed OACs. We hypothesise that the trend towards increased DOAC use is driven by
prescribing in newly diagnosed patients, rather than by switching treatment in patients who have historically
been prescribed warfarin. This view is supported by the STROKESTOP study,40 which found that, of those
with newly diagnosed AF who were started on OACs, 73% were prescribed DOACs. For our model we
therefore assumed in the base case that the proportion of OACs that are DOACs in newly diagnosed AF
patients is 75%. We varied this to 50% and 100% in sensitivity analyses. We assumed that the OAC
received is apixaban (most cost-effective in the DOAC model37) but note that the results would be similar if
other DOACs were used instead.
Incremental quality-of-life benefits and costs from rate control compared
with no rate control
Incremental lifetime costs and QALYs associated with rate control (compared with no rate control) are
assumed to be fixed costs and benefits obtained by patients who are prescribed rate control as a result of
screening. In practice, some of these patients would eventually have been detected with AF and given rate
control, so our model will overestimate these benefits. We performed a sensitivity analysis assuming an
annual rate of detection of AF in the absence of screening or an AF-related stroke.
The model developed by Lord et al.116 provides information on the incremental costs and QALYs over a
lifetime for rate control compared with no rate control for persistent AF. The authors found an incremental
cost of –£260 (i.e. cost saving), which we inflated to –£274.55 at 2015 prices, and incremental QALYs
of 0.0133 for rate control. We assumed these values in our model for symptomatic patients detected
by screening.
Sensitivity and specificity of the screening tests
The assumed values for the sensitivity and specificity of the screening tests were the mean values from our
HSROC model reported in the systematic review of DTA studies (see Tables 4 and 5).
Screening costs
The costs of the screening tests consist of the capital cost of any equipment required, the cost of consumables
for each test performed and the cost of clinician time to administer and interpret the test results. In the case of
systematic population screening there will also be costs associated with the screening invitation.
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FIGURE 20 Trends over time in the proportion of OACs prescribed that are warfarin or DOACs in England, using
data from Powell-Smith A, Goldacre B, OpenPrescribing.net, EBM DataLab, University of Oxford, 2017.
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Equipment costs vary widely across screening tests, from approximately £1500 for a 12-lead ECG to £100 for a
modified blood pressure monitor, £24 for photoplethysmography and no cost for pulse palpation. The capital
cost per patient will depend on, among other factors, the lifespan of the device and the throughput of patients
for AF screening. Patient throughput will, in turn, depend on practice size and demographics, screening uptake
and the frequency of screening. The calculation is further complicated for multipurpose devices such as ECG
machines, which will not be used solely for AF screening. In practice, even the relatively high purchase cost of an
ECG machine will be spread widely over the large number of patients who use it. In our base-case analysis, we
assumed that the capital cost of equipment per patient screened is zero and that the screening test costs consist
of invitation costs, the costs of consumables and the costs of clinician and administrative time taken to administer
and interpret the test results. We discuss the likely impact of this assumption and the issue of investment in
equipment, particularly for screening strategies (e.g. photoplethysmography, modified blood pressure monitors)
for which GPs do not currently have the equipment, in the discussion section of the next chapter.
We used the results from the SAFE study19 to inform the costs of systematic population and systematic
opportunistic screening. The cost of invitation to systematic population screening consists of the costs of the
invitation letter, postage and 1 minute of administrator time. Estimates for these costs are based on the trial
data from Hobbs et al.,19 but we inflated from 2003 prices to quarter 1 2015 prices using the ONS Consumer
Price Index for Medical Services (DKC3).157 The quarter 1 2015 prices were chosen to maintain consistency,
with costs used to generate the results of the DOAC model.37 These costs are summarised in Table 37.
Test costs
We used PSSRU 2014/15 data123 to estimate staff costs for administering and interpreting the screening
and diagnostic tests. An hour of face-to-face contact with a nurse was assumed to cost £56 (including
TABLE 37 Summary of the costs of screening assumed in the economic model
Activity Resource required Source
Administrative time per individual per invitation letter 1 minute, administrator Estimate19
Time to take pulse 1 minute, nurse or other health
professional
Trial data19
Administrative time per individual attending for ECG 2 minutes, administrator Trial data19
Nurse time per ECG (without interpretation) 12 lead: 7 minutes; limb lead:
3 minutes; single lead: 4 minutes
Trial data19
Interpretation of ECG 1 minute Trial data19
Resource required Cost (£) Source and comment
Electrode pad 0.10 Hobbs et al.19 (inflated from
£0.3 in 2003 to 2015 prices)
Stationery and postage per ECG 0.50 Hobbs et al.19 (inflated from
£0.3 in 2003 to 2015 prices)
Invitation letter 0.50 Hobbs et al.19 (inflated from
£0.3 in 2003 to 2015 prices)
Administrator cost for invitation (1 minute) 0.30 Hobbs et al.19 (cost per hour of
£10.93 in 2003 prices inflated
to £18.22 in 2015 prices giving
a cost per minute of £0.30)
Total systematic invitation cost 1.31
Rate control –274.55 Lord et al.116 (inflated from
£260 in 2013 to 2015 prices)
Nurse (1 hour) 56 PSSRU123
GP (1 hour) 129 PSSRU123
Cardiologist (1 hour) 137 PSSRU123
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qualification costs) (see Table 37). An hour of general medical services activity by a GP was assumed to cost
£129 (including qualification costs but excluding direct care staff costs). An hour of cardiologist time was
taken as the cost of 1 hour of ‘consultant medical’ time, which was £137 (including qualification costs).
We used the times for each test estimated by Hobbs et al.19 for the times to complete systematic opportunistic
screening. We also used their estimated interpretation time of 1 minute for all ECGs interpreted by a nurse, GP
or cardiologist. Systematic population screening would require a dedicated appointment with a nurse. A typical
practice nurse consultation is estimated to last approximately 15 minutes;123 however, for routine screening
the consultation time could be considerably less. Staff times assumed for each test are provided in Table 38.
TABLE 38 Summary of screening test costs assumed in the economic model
Test name
Opportunistic
screening, staff
required
Population
screening, staff
required
Consumables
required
Total cost
opportunistic
screening (£)
Total cost
population
screening (£)
Modified blood pressure
monitor
1 minute nurse 5 minutes nurse 1.54 5.27
Pulse palpation – nurse 1 minute nurse 5 minutes nurse 1.54 5.27
Photoplethysmography 1 minute nurse 5 minutes nurse 1.54 5.27
Single-lead ECG –
automatic/algorithm
4 minutes nurse 8 minutes nurse 1 pad 4.44 8.17
Single-lead ECG – nurse 4 minutes nurse
(administration) +
1 minute nurse
(interpretation)
8 minutes nurse
(administration) +
1 minute nurse
(interpretation)
1 pad 5.37 9.11
Single-lead ECG – GP 4 minutes nurse
(administration) +
1 minute GP
(interpretation)
8 minutes nurse
(administration) +
1 minute GP
(interpretation)
1 pad 6.59 10.32
Single-lead ECG –
cardiologist
4 minutes nurse
(administration) +
1 minute
cardiologist
(interpretation)
8 minutes nurse
(administration) +
1 minute
cardiologist
(interpretation)
1 pad 6.72 10.46
> 1- and < 12-lead ECG –
automatic/algorithm
5.5 minutes nurse
(administration)
9.5 minute nurse
(administration)
2.5 pads 5.99 9.72
> 1- and < 12-lead ECG –
cardiologist
5.5 minutes nurse
(administration) +
1 minute
cardiologist
(interpretation)
9.5 minute nurse
(administration) +
1 minute
cardiologist
(interpretation)
2.5 pads 8.27 12.01
12-lead ECG – automatic/
algorithm
7 minutes nurse
(administration)
11 minutes nurse
(administration)
12 pads 8.34 12.07
12-lead ECG – nurse 7 minutes nurse
(administration) +
1 minute nurse
(interpretation)
11 minutes nurse
(administration) +
1 minute nurse
(interpretation)
12 pads 9.27 13.01
12-lead ECG – GP 7 minutes nurse
(administration) +
1 minute GP
(interpretation)
11 minutes nurse
(administration) +
1 minute GP
(interpretation)
12 pads 10.49 14.22
12-lead ECG – cardiologist 7 minutes nurse
(administration) +
1 minute
cardiologist
(interpretation)
11 minutes nurse
(administration) +
1 minute
cardiologist
(interpretation)
12 pads 10.62 14.36
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If the initial screening test was a 12-lead ECG then the diagnostic test cost would be only the cost of the
1-minute interpretation by a GP or cardiologist, which is £2.15 and £2.28 respectively. If the initial
screening test was something else (e.g. photoplethysmography) then the diagnostic test cost would be the
full cost of a 12-lead ECG with administrator and nurse appointment time. We did not include the cost of
a follow-up appointment with a GP or cardiologist for a true-positive 12-lead ECG diagnostic test as this
was included in the management costs of the long-term model (see Long-term costs and benefits).
Following Hobbs et al.,19 all test costs included 2 minutes of administrator time. Administrator time was
priced at £10.93 per hour in Hobbs et al.19 and was inflated to £18.22 (quarter 1 2015 prices) using the
ONS Consumer Price Index for Medical Services (DKC3),157 giving a cost of £0.61 for 2 minutes for each test.
We assumed that each lead of the ECG machine required one pad and that a > 1- and < 12-lead ECG,
with an average of 2.5 leads, required 2.5 pads. Following clinical advice we assumed that no alcohol
wipes were used for the ECGs.
The total estimated costs and their underlying assumptions for systematic opportunistic and systematic
population screening are reported in Table 38.
Long-term costs and benefits
Anticoagulation therapy (directly acting oral anticoagulant model37)
A previously developed Markov model37 was used to estimate the long-term costs and outcomes for patients
with screen-detected AF (true positives on initial screen, confirmed by 12-lead ECG). The model includes a
HR for events (stroke, systemic embolism, TIA) affected by AF type (paroxysmal relative to persistent or
permanent). We combined persistent and permanent AF in the model because the RCTs informing the
efficacy of anticoagulation therapy predominantly combined persistent and permanent AF patients.
The model depends on age, sex, previous history of ischaemic stroke or TIA and previous history of MI.
The discrete-time Markov multistate model used a cycle length of 3 months, as in other recent models.158–160
We ran the model for a cohort for a given starting age and using a lifetime time horizon. The model
structure is illustrated in Figure 21. Each treatment strategy has the same model structure but different
costs, utilities and event probabilities. From any state, a patient can have a clinically relevant (extracranial)
bleed, an intracranial haemorrhage, an ischaemic stroke or a MI, all of which have long-term consequences
AF well
Stroke
MI + S
B + S
ICH + S
B + MI
ICH + MI
B + ICH
B + ICH
 + MI
B + ICH
 + S
B + MI
 + S
S + B +
MI + ICH
ICH + MI
 + S
MI
Major
bleed
ICH
D
ea
d
FIGURE 21 Discrete-time Markov model structure for screen-detected AF patients. B, major bleed; ICH, intracranial
haemorrhage; S, stroke.
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that are modelled. Patients can also experience a TIA or systemic embolism, which are transient states, or
can discontinue or switch treatment because of any event, or die. Patients on apixaban who experience a
bleed or intracranial haemorrhage will be switched to warfarin (INR range 2–3); patients experiencing a
further bleed or intracranial haemorrhage are then switched to no treatment. Patients initially on no
treatment or aspirin who experience a stroke and who are not contraindicated to DOACs and have no
history of a bleed or intracranial haemorrhage are assumed to initiate apixaban treatment.
Transition probabilities were derived using HRs for apixaban and aspirin relative to warfarin estimated from
a systematic literature review.37 The warfarin arms were used to estimate baseline hazards. We relied on
previous meta-analyses to estimate the relative effect of warfarin (INR range 2–3) compared with no
treatment.161 Evidence from the literature was used to estimate the effect of previous events on stroke,
mortality, MI, systemic embolism, TIA and bleed risk.162,163 Average drug costs were based on the British
National Formulary March 2015 update,164 and it was assumed that oral apixaban and aspirin incurred no
monitoring or administration costs. Acute management costs for systemic embolism, MI, TIA and clinically
relevant bleeding were obtained from 2013/14 NHS reference costs.165 Acute and long-term management
costs for ischaemic stroke and intracranial haemorrhage were taken from a study of AF patients on a UK
stroke registry.166 Utilities were identified from a previous NICE technology appraisal submission on
rivaroxaban,159 which included a systematic literature search for evidence on EQ-5D utility index scores in
health states related to AF.
The model was modified to include management costs for AF reported published in the literature.110 Costs
were available for a 12-week initialisation period and annual ‘maintenance’ periods thereafter, summarised
in Table 39. These costs included the costs of blood testing, medication, primary and secondary care visits,
further diagnostic testing and inpatient visits. We adjusted the costs by removing the blood testing and
medication costs, which were already accounted for in our model. We also inflated costs to quarter 1 2015
prices157 to maintain consistency with the other model costs. We used a log-normal distribution with the
mean and SD in Table 39 (‘adjusted total’) for the initialisation and maintenance periods.
Summary of model inputs
Table 40 summarises the model parameters and assumed values and distributions and the evidence
sources used for each.
Sensitivity analyses
In sensitivity analyses, we used the optimal screening test and screening method identified in the base case
unless otherwise stated.
TABLE 39 Assumed non-anticoagulation therapy costs in the economic modela
Component
Initialisation period (£) Maintenance period (£)
Mean SD Mean SD
Blood testing 5.12 9.22 7.17 11.27
AF medications 9.22 10.25 50.20 50.20
Total 964.14 1120.90 436.48 611.68
Adjusted total 949.80 1120.99 379.10 613.84
a Costs are provided for a 12-week initialisation period and subsequent annual ‘maintenance’ time periods, based on
Kassianos et al.110
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TABLE 40 Summary of input parameter distributions and sources used in the cost-effectiveness model
Model Input Value Evidence source and distribution
Prevalence of AF (diagnosed and undiagnosed) by
age and sex
See Table 20 Norberg et al.,2 Public Health
England1
Population size eligible for screening at each age See Table 21 ONS130
Uptake of systematic population screening < 75 years: 0.608 (0.589 to
0.628); ≥ 75 years: 0.429
(95% CI 0.406 to 0.453)
Hobbs et al.,19 beta distribution
Proportion of initial invitees sent a reminder letter 0.45 (95% CI 0.435 to 0.465) Hobbs et al.,19 normal distribution
Proportion of flagged individuals who have their
pulses checked
< 75 years: 0.699 (95% CI
0.681 to 0.716); ≥ 75 years:
0.670 (95% CI 0.648 to 0.691)
Hobbs et al.,19 beta distribution
Proportion of AF undiagnosed 0.348 Public Health England1
Proportion of screen-detected AF that is
asymptomatic
0.841 (95% CI 0.814 to 0.866) Meta-analysis (see Table 29),
Bayesian posterior
Proportion of undiagnosed AF that is paroxysmal 0.822 (95% CI 0.773 to 0.865) Meta-analysis (see Table 28),
Bayesian posterior
Proportion of screen-detected AF that is
paroxysmal
0.06 Assumption based on Sanmartín
et al.138
Rate of progression from paroxysmal to chronic AF 0.146 (95% CrI 0.138 to 0.156) Holmqvist et al.,144 Bayesian posterior
Proportion of 12-lead ECGs referred to a
cardiologist
0.1 (95% CI 0.01 to 0.2) Expert opinion, normal distribution
Proportion of screen-detected AF with a
CHA2DS2-VASc score of ≥ 2
0.750 (95% CrI 0.699 to 0.797) Meta-analysis (see Table 33),
Bayesian posterior
Proportion of screen-detected AF cases with a
previous history of MI
0.037 (95% CrI 0.005 to 0.099) Meta-analysis (see Table 34),
Bayesian posterior
Proportion of screen-detected AF cases with a
previous history of stroke
0.074 (95% CI 0.032 to 0.116) Fitzmaurice et al.,153 normal
distribution
Proportion of screen-detected AF with a
CHA2DS2-VASc score of ≥ 2 contraindicated to OACs
0.129 QOF report3
Proportion of screen-detected AF with a
CHA2DS2-VASc score of ≥ 2 prescribed OACs
0.743 QOF report3
Proportion of prescribed OACs that are DOACs 1 Assumption
HR for event rates in symptomatic vs.
asymptomatic AF
Assumed 1 after adjusting for
other risk factors
Flaker et al.35
HR for stroke/mortality in persistent vs.
paroxysmal AF
1.3 (95% CrI 1.09 to 1.54) Meta-analysis (see Table 32),
Bayesian posterior
Incremental costs and benefits of rate control
compared with no rate control in symptomatic
patients
Incremental cost: –£274.55;
incremental QALYs: 0.0133
Lord et al.116
Cost of screening invitation See Table 37 Hobbs et al.19
Cost of initial screening tests See Table 38 Hobbs et al.,19 NHS reference costs
Sensitivity and specificity of tests See Tables 4 and 5 DTA review meta-analysis
Cost of confirmatory ECG interpreted by a GP See Tables 37 and 38 Hobbs et al.,19 NHS reference costs
Cost of ECG referral to a cardiologist See Tables 37 and 38 Hobbs et al.,19 NHS reference costs
Long-term treatment costs and benefits from the
DOAC model
Depends on age, sex and
stroke risk
Sterne et al.37
Non-anticoagulation costs of AF See Table 39 Kassianos et al.110
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Screening test
We found that results from the evidence synthesis of the DTA studies were robust to the various sensitivity
analyses that we performed. However, there was a high degree of uncertainty in the estimates of sensitivity
and specificity. Also, the photoplethysmography screening test was based on a single study that did not
take place in a primary care setting and the study was rated as being at high risk of bias for the index test.
Furthermore, photoplethysmography and modified blood pressure monitors are not currently available in
most primary care settings. We therefore performed a sensitivity analysis of the comparison between age
at screening, using the most cost-effective screening test and omitting (1) photoplethysmography and
(2) photoplethysmography and modified blood pressure monitors.
Repeat screening
In sensitivity analyses, we explored repeated screening every 5 years for various initial screening ages
(55, 60, 65, 70, 75 and 80 years) and final screening ages (55, 60, 65, 70, 75 and 80 years), giving a total
of 21 repeat screening strategies. The model structure and input parameters were as for the base case;
however, the total proportion of diagnosed or undiagnosed AF at each age (see Table 40) was adjusted to
allow for the AF detected at previous screening rounds. We considered a single-age cohort that may be
screened at various ages as it gets older. We assumed that total (diagnosed and undiagnosed) prevalence
increases with age in this cohort according to the patterns reported in Table 20, which reflects increasing
incidence with age. We subtracted from this total prevalence the proportion of patients diagnosed in
previous screening rounds and also the proportion of patients diagnosed in the absence of screening,
assumed to be a 1% diagnosis rate per year based on the control arm of the SAFE study19 (see Rate of
diagnosis of atrial fibrillation in the absence of screening), which was varied to 5% in sensitivity analysis.
Comparisons across different screening strategies related to this age cohort and therefore we needed to
consider the cost and QALY implications for the cohort as a whole to make fair comparisons. This was
achieved by using population estimates reported in Table 21 to obtain population costs and QALYs for
each screening interval, discounted at 3.5% back to the time of the initial screen. The total population
costs and QALYs for each strategy were the sum of the costs and QALYs for each screening interval for a
given strategy, with the last screening interval representing the remaining lifetime time horizon.
Uptake of systematic opportunistic screening
In a sensitivity analysis, we used a lower uptake of systematic opportunistic screening (0.305, 95% CI
0.282 to 0.329), as reported in Morgan and Mant,82 which was assumed to be the same for all age
groups; this compares to the base case in which we used the results from the SAFE study19 (< 75 years age
group: 0.699, 95% CI 0.681 to 0.716; ≥ 75 years age group: 0.670, 95% CI 0.648 to 0.691).
Uptake of electrocardiograms in those with a positive screening result
In the base case, we assumed that all those with a positive screening test result would be offered and
would accept a diagnostic ECG to confirm the diagnosis. The SAFE study19 found that only 72.5% of those
with an irregular pulse and no previous AF diagnosis agreed to have an ECG test. We therefore conducted
a sensitivity analysis assuming that only 72.5% of those with a positive screening test result will agree to
have an ECG. The remaining 27.5% are assumed to be a mixture of true positives and false positives
(in the same proportion as for those who agree to have an ECG).
Diagnosis in the absence of screening or atrial fibrillation-related stroke
In the base case, we included an annual rate of diagnosis in the absence of screening of 1% based
on the control arm of the SAFE study.19 We increased this to 5% in sensitivity analysis, as assumed by
Aronsson et al.100
Previous history of stroke in UK screen-detected atrial fibrillation
We investigated the robustness of our conclusions to using an estimate of the previous history of stroke in
UK screen-detected AF based on the random-effects meta-analysis of screening studies (0.112, 95% CrI
0.072 to 0.170); in the base case we used the estimate of the previous history of stroke from the SAFE
study19 alone (0.074, 95% CI 0.032 to 0.116).
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Proportion of oral anticoagulants prescribed that are directly acting
oral anticoagulants
In the base case, we assumed that 75% of OACs prescribed are DOACs. Prescribing practice is changing,
with the DOACs becoming the OACs of choice for newly diagnosed AF. However, warfarin is still
prescribed, with some patients/practitioners preferring the regular monitoring of warfarin. We performed a
sensitivity analysis of the proportion of OACs that are DOACs, using assumed values of 50% and 100%.
Uptake of oral anticoagulants
In the base case, 74% of patients who are eligible for OACs receive them, 13% are contraindicated or do
not wish to take them and the remaining 13% do not receive OACs but could do. In sensitivity analyses,
we explored the impact of a reduced uptake of OACs of 50% and also an improvement in the uptake
of OACs, so that all 87% of patients who are not contraindicated or who prefer not to take OACs
receive OACs.
Hazard ratios for stroke and mortality risk for routine-detected atrial
fibrillation compared with screen-detected atrial fibrillation
In sensitivity analysis, we assumed that the event rate in screen-detected patients was lower than that for
routinely detected AF using the unadjusted HR for symptomatic AF (representing non-screen-detected AF)
compared with asymptomatic AF (representing screen-detected AF) found by Flaker et al.35 of 1.31
(95% CI 1.04 to 1.65), instead of a HR of 1, as assumed in the base case.
Discussion
Summary of results from the review of studies on the natural history of atrial
fibrillation screening
We identified several studies that estimated the prevalence of AF by age and sex. All showed similar
trends, although there was variation in the overall prevalence level, most likely because of the method of
measurement used together with population differences. The studies with the most intensive ascertainment
of AF diagnosis gave the highest estimates of prevalence and were in line with each other.2,125 We used the
estimates from the most comprehensive and recent of these studies2 in our model to represent the overall
prevalence of AF (both diagnosed and undiagnosed) by age and sex.
Uptake of systematic population screening was fairly consistent across studies, with a mean estimate of
64% (95% CrI 54% to 73%), although there was a strong effect of age seen in the SAFE study,19 with a
lower uptake of screening in the ≥ 75 years age group of 43% (95% CI 41% to 45%) compared with
uptake in the < 75 years age group of 61% (95% CI 59% to 63%). In contrast, there was a high degree
of variability across studies in the uptake of systematic opportunistic screening, ranging from 30% to 70%
(regardless of age), raising concern that the high level of opportunistic screening achieved in the SAFE
study19 may not be seen in practice. Furthermore, with the introduction of computerised flags for a range
of health issues, GPs may be less likely to respond to computerised flags as a result of ‘alert fatigue’.133
The proportion of AF that is undiagnosed was estimated to be 35%; however, this estimate was very
variable across screening studies, reflecting the method of screening and test used as well as differences
in populations. As expected, the higher estimates came from studies with more intensive screening tests
(e.g. long-term continuous monitoring). It is clear that if the objective is to detect paroxysmal AF then
long-term continuous monitoring is necessary. Whether or not this is feasible in a population-based
screening setting, however, is unclear.
As expected, our results suggest that a high proportion of screen-detected AF is likely to be asymptomatic.
Asymptomatic AF has a lower risk of stroke and mortality; however, after adjusting for other risk factors,
there is no evidence that the risk of stroke or mortality depends on whether AF is asymptomatic or not.35
We explored the robustness of our conclusions to this assumption in a sensitivity analysis.
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We estimated that paroxysmal AF progresses to chronic (persistent or permanent) AF at a rate of 0.15 per
year. There is evidence of a ‘dose–response’ relationship, with stroke and mortality risk increasing as AF
progresses from paroxysmal to persistent to permanent AF.
Strengths and limitations
Our review of the natural history of AF and of AF screening covered a very broad set of review questions
to identify evidence relevant to our economic model. Our review focused on evidence relevant to screening
populations in a primary care setting in the UK. When appropriate, we pooled results from studies in
meta-analysis. We also took care to account for ‘confounding by treatment’ in estimating mortality and
stroke risk according to type of AF and whether symptomatic or not.
Because of the scale and scope of this review, it was only possible for a single reviewer (NJW) to review
the literature, and so it was not possible to discuss inclusion with another reviewer. We ran searches from
2000 onwards only, and so we may have missed relevant evidence published before this date. However,
our focus was on understanding the epidemiology of AF and screening for AF in 2016, and so we wished
to find the most contemporary evidence available.
Many inputs for the economic model relied on a single trial (the SAFE study19). Our model tracks AF
diagnosed as a result of acute events, such as stroke, but does not estimate serendipitous detection of AF
in the absence of screening in the base case. There was no evidence on the proportion of 12-lead ECGs
interpreted by a GP that are referred to a cardiologist to help with interpretation, and we had to rely on
expert opinion. There was scant information on patient characteristics of screen-detected AF cases, and
there was no data on the joint distribution of different risk factors; we therefore had to assume that they
were independent (which is unlikely, as, for example, those with a previous history of MI may be more
likely to have a previous history of stroke as well).
We assumed that the HR for stroke comparing chronic AF with paroxysmal AF was the same as that for
mortality, although there was evidence that this assumption was reasonable.147 We assumed that the
stroke and mortality rates were the same in screen-detected AF as in routinely detected AF, once risk
factors have been accounted for, based on the results from Flaker et al.35 We explored the robustness of
our conclusions to this assumption in a sensitivity analysis.
If primary care screening were to be adopted by the NHS, then it would be necessary for all practices to
acquire and maintain an ECG machine. We did not include this capital cost in the model, but we note that
this would be a consideration in the decision to introduce a national screening programme. We took a
NHS perspective, excluding the costs of participants, carers and other agencies. Attending for screening is
likely to have a financial impact on participants in terms of travel and time to attend screening, particularly
if they have to take time off work to attend.
Findings in the context of previous research
The Irish HIQA study25 used a German study125 to estimate AF prevalence, whereas we used a Swedish
study;2 however; as noted, the results from the two studies were very similar (see Prevalence of atrial
fibrillation in the UK by age and sex).
Previous systematic reviews were identified for only two of our review questions (prevalence of AF90 and
cardiovascular risk for symptomatic vs. asymptomatic AF124). Our findings were in line with the results from
these reviews.
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Chapter 6 Results of the economic evaluation
Base-case results
We ran our economic evaluation using 10,000 simulation samples for a single screen invitation at one of
various different ages: 55, 60, 65, 70, 75 and 80 years. The results are presented for each of these ages in
Tables 41–46 respectively. These tables show, for each of the screening strategies and screening tests, the
mean incremental costs, incremental benefits (QALYs), INB and ICER (see Outcomes of the economic
evaluation). All results are presented per 1000 individuals eligible for screening. The results are ordered
according to mean INB, so that strategies that are closer to the top of the table are more cost-effective
than strategies lower down the table. In nearly all cases, screening for AF has a positive INB at a
willingness-to-pay threshold of £20,000, suggesting that a population-based screening programme is likely
to be a cost-effective use of resources compared with no screening. The exception was using 12-lead ECG
as a systematic population screening test in 55-year-olds. Regardless of age and screening test, systematic
opportunistic screening has lower mean incremental costs and higher mean incremental QALYs and hence
a higher INB than systematic population screening. As age at screening increases, incremental costs
increase, but this is outweighed by the increase in incremental benefits, leading to an increase in INB and a
reduction in the ICER. By age 70 years, all CrIs around the INB are positive, indicating very little uncertainty
that screening is cost-effective compared with current practice (whatever format the screening takes). The
CIs around the incremental costs and QALYs for individual screening strategies are quite wide. However,
the INB is highest for photoplethysmography, closely followed by modified blood pressure monitors and
then nurse pulse palpation and 12-lead ECG (as a screening test).
We explored the uncertainty in our findings using CEACs, which display the probability of different
screening strategies being most cost-effective at a range of willingness to pay per QALY thresholds.
Figures 22–24 show the CEACs for each age at invitation to screening. Uncertainty in the results can also
be seen in the cost-effectiveness planes presented in Appendix 10.
For all age groups and for all willingness-to-pay thresholds > £10,000, systematic opportunistic screening
has a higher probability of being cost-effective than systematic population screening, and is also superior
to no screening. Systematic opportunistic screening using photoplethysmography as the screening test had
the highest probability of being cost-effective at all thresholds > £10,000, and this result becomes more
certain (higher probability) as the age at screening increases.
To inform a decision about which age to screen (if we were to choose a single age at which to screen) we
considered a specific age cohort (e.g. 55-year-olds in 2016) and computed the total population incremental
costs and QALYs for this cohort by multiplying the incremental costs and QALYs by the population size at
each candidate screening age (those still alive and eligible for screening). Table 47 shows the age cohort
population attributable mean incremental costs, QALYs and net benefits for different screening ages (all
under opportunistic screening with photoplethysmography). Mean incremental costs increase with age until
age 75 years and begin to fall at age 80 years. Mean incremental QALYs increase with age at screening, as
does the INB. Figure 25 shows the CEACs comparing different ages at screening for a single one-off screen.
The cost per screen-detected case decreases from £55,637 to £31,135 as the age of screening increases
from 55 to 80 years (see Table 47). Note that these costs include lifetime treatment costs and lifetime event
costs, as well as the costs of the screening strategy, We should be cautious in interpreting results for the
older and younger age groups, as many of the model inputs are based on studies with individuals aged
65–75 years, and we have assumed that some model inputs (such as the proportion undiagnosed) apply
across all age ranges. Of course, these results assume that we screen only once, whereas the format of
many screening programmes is to screen at repeated intervals. We present the results for repeated
screening in the sensitivity analyses (see Screening test).
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TABLE 41 Base-case results for a single screen at age 55 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic opportunistic
photoplethysmography
8078
(4232 to 15,401)
0.89
(0.43 to 1.5)
9700
(1835 to 19,135)
9511
(6000 to 17,053)
Systematic opportunistic modified
blood pressure monitor
7459
(3900 to 14,485)
0.85
(0.41 to 1.5)
9546
(2313 to 18,741)
9155
(5990 to 15,927)
Systematic opportunistic pulse
palpation – nurse
8129
(4329 to 15,012)
0.81
(0.38 to 1.4)
8152
(1026 to 17,007)
10,509
(6635 to 18,043)
Systematic opportunistic single-lead
ECG – automatic/algorithm
9607
(5997 to 16,549)
0.86
(0.41 to 1.5)
7603
(375 to 16,797)
11,824
(7751 to 19,385)
Systematic opportunistic single-lead
ECG – nurse
9845
(6264 to 16,512)
0.83
(0.39 to 1.4)
6661
(–445 to 15,784)
12,710
(8246 to 20,850)
Systematic opportunistic single-lead
ECG – GP
10,326
(6698 to 17,119)
0.83
(0.38 to 1.5)
6353
(–943 to 15,739)
13,284
(8609 to 22,020)
Systematic opportunistic single-lead
ECG – cardiologist
10,884
(7378 to 17,717)
0.85
(0.41 to 1.5)
6187
(–1029 to 15,361)
13,594
(8895 to 22,016)
Systematic opportunistic > 1- and
< 12-lead ECG – cardiologist
11,659
(8055 to 18,769)
0.89
(0.43 to 1.5)
6129
(–1272 to 15,646)
13,985
(9168 to 22,536)
Systematic opportunistic > 1- and
< 12-lead ECG – automatic/algorithm
9176
(5848 to 15,376)
0.73
(0.29 to 1.3)
5520
(–1278 to 14,137)
13,563
(8620 to 23,626)
Systematic opportunistic 12-lead
ECG – automatic/algorithm
11,153
(7867 to 17,655)
0.8
(0.39 to 1.4)
4942
(–1762 to 13,479)
14,838
(9665 to 24,157)
Systematic opportunistic 12-lead
ECG – nurse
12,389
(8821 to 19,339)
0.86
(0.41 to 1.5)
4840
(–2465 to 14,017)
15,451
(9997 to 25,220)
Systematic opportunistic 12-lead
ECG – GP
13,295
(9685 to 20,413)
0.89
(0.43 to 1.5)
4493
(–2936 to 14,076)
16,032
(10,388 to 26,067)
Systematic population
photoplethysmography
8882
(6256 to 13,741)
0.57
(0.28 to 0.98)
2517
(–2747 to 8664)
16,740
(10,565 to 28,320)
Systematic population modified blood
pressure monitor
8405
(6050 to 12,989)
0.55
(0.27 to 0.95)
2498
(–2166 to 8430)
16,559
(10,594 to 27,166)
Systematic population pulse palpation
– nurse
9040
(6418 to 13,506)
0.52
(0.25 to 0.91)
1400
(–3321 to 7078)
18,721
(11,633 to 31,544)
Systematic population single-lead
ECG – automatic/algorithm
9813
(7431 to 14,313)
0.55
(0.27 to 0.95)
1222
(–3461 to 7121)
19,200
(12,086 to 31,768)
Systematic population single-lead
ECG – nurse
9933
(7532 to 14,356)
0.53
(0.25 to 0.92)
651
(–3948 to 6524)
20,396
(12,661 to 34,726)
Systematic population single-lead
ECG – GP
10,154
(7798 to 14,608)
0.53
(0.24 to 0.94)
540
(–4176 to 6596)
20,770
(12,763 to 35,776)
Systematic population > 1- and
< 12-lead ECG – cardiologist
10,969
(8624 to 15,539)
0.57
(0.28 to 0.98)
436
(–4312 to 6530)
20,804
(13,104 to 34,228)
Systematic population single-lead
ECG – cardiologist
10,587
(8248 to 14,985)
0.55
(0.27 to 0.94)
359
(–4306 to 6220)
20,939
(13,164 to 34,802)
Systematic population > 1- and
< 12-lead ECG – automatic/algorithm
9401
(7238 to 13,381)
0.47
(0.19 to 0.85)
22
(–4334 to 5553)
22,244
(13,222 to 41,982)
Systematic population 12-lead
ECG – automatic/algorithm
10,644
(8496 to 14,872)
0.52
(0.25 to 0.89)
–324
(–4617 to 5210)
22,393
(13,942 to 37,455)
Systematic population 12-lead
ECG – nurse
11,437
(9111 to 15,908)
0.55
(0.27 to 0.96)
–390
(–5064 to 5479)
22,536
(13,940 to 37,489)
Systematic population 12-lead
ECG – GP
12,018
(9662 to 16,578)
0.57
(0.28 to 0.98)
–612
(–5352 to 5494)
22,850
(14,240 to 37,953)
a All results are per 1000 eligible individuals. Results are ordered by the highest INB.
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TABLE 42 Base-case results for a single screen at age 60 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic opportunistic
photoplethysmography
11,797
(5750 to 24,270)
1.4
(0.68 to 2.3)
15,638
(2774 to 30,431)
8991
(5492 to 17,158)
Systematic opportunistic modified
blood pressure monitor
11,004
(5313 to 22,795)
1.3
(0.65 to 2.3)
15,238
(2891 to 29,365)
8755
(5472 to 16,976)
Systematic opportunistic pulse
palpation – nurse
11,566
(5764 to 23,047)
1.3
(0.61 to 2.2)
13,567
(1685 to 27,470)
9667
(5993 to 18,138)
Systematic opportunistic single-lead
ECG – automatic/algorithm
13,285
(7552 to 25,169)
1.3
(0.66 to 2.3)
13,273
(908 to 27,424)
10,555
(6755 to 19,031)
Systematic opportunistic single-lead
ECG – nurse
13,398
(7662 to 24,914)
1.3
(0.6 to 2.2)
12,073
(101 to 26,218)
11,153
(7092 to 19,897)
Systematic opportunistic > 1- and
< 12-lead ECG – cardiologist
15,537
(9705 to 27,601)
1.4
(0.68 to 2.3)
11,913
(–948 to 26,533)
12,015
(7794 to 20,997)
Systematic opportunistic single-lead
ECG – GP
13,934
(8208 to 25,553)
1.3
(0.59 to 2.2)
11,800
(–566 to 26,271)
11,540
(7380 to 20,672)
Systematic opportunistic single-lead
ECG – cardiologist
14,591
(8940 to 26,301)
1.3
(0.65 to 2.3)
11,751
(–504 to 25,843)
11,751
(7599 to 20,567)
Systematic opportunistic 12-lead
ECG – nurse
16,193
(10,468 to 28,095)
1.3
(0.65 to 2.3)
10,394
(–2126 to 24,573)
13,002
(8362 to 22,447)
Systematic opportunistic > 1- and
< 12-lead ECG – automatic/algorithm
12,359
(6991 to 22,974)
1.1
(0.46 to 2.0)
10,315
(–883 to 23,836)
11,741
(7368 to 21,430)
Systematic opportunistic 12-lead
ECG – GP
17,243
(11,388 to 29,314)
1.4
(0.68 to 2.3)
10,207
(–2657 to 24,809)
13,395
(8669 to 22,881)
Systematic opportunistic 12-lead
ECG – automatic/algorithm
14,688
(9402 to 25,639)
1.2
(0.61 to 2.1)
10,149
(–1429 to 23,486)
12,589
(8133 to 21,762)
Systematic population
photoplethysmography
14,727
(9256 to 25,626)
1.2
(0.59 to 2.1)
9160
(–2219 to 22,214)
13,132
(8305 to 22,912)
Systematic population modified blood
pressure monitor
13,925
(8904 to 24,257)
1.1
(0.56 to 2.0)
8924
(–1840 to 21,240)
12,981
(8337 to 22,279)
Systematic population pulse palpation
– nurse
14,704
(9450 to 24,990)
1.1
(0.53 to 1.9)
7180
(–3178 to 19,283)
14,401
(9015 to 24,951)
Systematic population single-lead
ECG – automatic/algorithm
15,954
(10,885 to 26,343)
1.2
(0.57 to 2)
7170
(–3613 to 19,633)
14,772
(9429 to 25,119)
Systematic population > 1- and
< 12-lead ECG – cardiologist
17,690
(12,571 to 28,279)
1.2
(0.59 to 2.1)
6211
(–4991 to 18,974)
15,882
(10,165 to 26,777)
Systematic population single-lead
ECG – nurse
16,007
(10,912 to 25,963)
1.1
(0.52 to 1.9)
6171
(–4273 to 18,549)
15,539
(9754 to 26,641)
Systematic population single-lead
ECG – GP
16,350
(11,316 to 26,385)
1.1
(0.51 to 2.0)
6057
(–4735 to 18,665)
15,793
(9904 to 27,341)
Systematic population single-lead
ECG – cardiologist
17,028
(12,039 to 27,279)
1.1
(0.57 to 2.0)
5909
(–4779 to 18,249)
15,942
(10,150 to 26,877)
Systematic population 12-lead ECG –
nurse
18,260
(13,230 to 28,603)
1.2
(0.57 to 2.0)
4889
(–5975 to 17,305)
17,020
(10,730 to 28,633)
Systematic population > 1- and
< 12-lead ECG – automatic/algorithm
14,956
(10,255 to 24,287)
0.99
(0.4 to 1.8)
4786
(–4941 to 16,659)
16,684
(10,125 to 30,394)
Systematic population 12-lead
ECG – GP
19,174
(14,031 to 29,851)
1.2
(0.59 to 2.1)
4727
(–6460 to 17,477)
17,262
(10,984 to 28,884)
Systematic population 12-lead
ECG – automatic/algorithm
16,950
(12,291 to 26,468)
1.1
(0.53 to 1.9)
4676
(–5409 to 16,341)
16,873
(10,720 to 28,289)
a All results are per 1000 eligible individuals. Results are ordered by the highest INB.
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TABLE 43 Base-case results for a single screen at age 65 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic opportunistic
photoplethysmography
18,325
(8870 to 36,261)
2.3
(1.2 to 4.0)
28,623
(9404 to 52,829)
8065
(5253 to 14,282)
Systematic opportunistic modified
blood pressure monitor
17,250
(8250 to 34,719)
2.2
(1.1 to 3.8)
27,656
(9279 to 50,560)
7929
(5202 to 14,037)
Systematic opportunistic single-lead
ECG – automatic/algorithm
19,605
(10,561 to 37,225)
2.3
(1.2 to 3.9)
25,846
(7228 to 49,288)
8971
(6002 to 15,292)
Systematic opportunistic pulse
palpation – nurse
17,535
(8496 to 34,159)
2.1
(1.1 to 3.7)
25,463
(7515 to 48,022)
8451
(5567 to 14,713)
Systematic opportunistic > 1- and
< 12-lead ECG – cardiologist
22,077
(12,819 to 39,987)
2.3
(1.2 to 4.0)
24,898
(5692 to 49,023)
9822
(6657 to 16,325)
Systematic opportunistic single-lead
ECG – cardiologist
20,864
(11,921 to 37,995)
2.3
(1.2 to 3.8)
24,216
(5829 to 47,351)
9666
(6540 to 16,171)
Systematic opportunistic single-lead
ECG – nurse
19,458
(10,534 to 36,527)
2.2
(1.1 to 3.8)
24,121
(5883 to 47,147)
9319
(6225 to 15,790)
Systematic opportunistic single-lead
ECG – GP
20,061
(10,945 to 37,391)
2.2
(1.0 to 3.8)
23,979
(5150 to 47,476)
9546
(6385 to 16,181)
Systematic opportunistic 12-lead
ECG – GP
23,780
(14,513 to 41,664)
2.3
(1.2 to 4.0)
23,194
(4068 to 47,338)
10,621
(7207 to 17,385)
Systematic opportunistic 12-lead
ECG – nurse
22,524
(13,407 to 40,188)
2.3
(1.1 to 3.9)
22,974
(4226 to 46,757)
10,392
(7013 to 17,177)
Systematic opportunistic 12-lead
ECG – automatic/algorithm
20,602
(12,146 to 37,173)
2.1
(1.1 to 3.6)
21,900
(4447 to 43,917)
10,153
(6886 to 16,774)
Systematic opportunistic > 1- and
< 12-lead ECG – automatic/algorithm
17,764
(9168 to 33,310)
1.9
(0.82 to 3.5)
21,034
(3363 to 43,398)
9654
(6419 to 16,660)
Systematic population
photoplethysmography
20,410
(12,045 to 36,194)
2
(1.0 to 3.5)
20,469
(3666 to 41,835)
10,466
(6992 to 17,201)
Systematic population modified blood
pressure monitor
19,364
(11,487 to 34,514)
2
(0.99 to 3.3)
19,738
(3680 to 40,068)
10,380
(7018 to 17,069)
Systematic population single-lead
ECG – automatic/algorithm
21,456
(13,502 to 36,907)
2
(1.0 to 3.4)
18,119
(1885 to 38,581)
11,416
(7684 to 18,469)
Systematic population pulse palpation
– nurse
19,898
(11,904 to 34,611)
1.9
(0.92 to 3.2)
17,542
(1710 to 37,206)
11,193
(7444 to 18,464)
Systematic population > 1- and
< 12-lead ECG – cardiologist
23,385
(15,280 to 39,067)
2
(1.1 to 3.5)
17,517
(881 to 38,814)
12,065
(8129 to 19,308)
Systematic population single-lead
ECG – cardiologist
22,489
(14,718 to 37,535)
2
(1.0 to 3.4)
16,764
(734 to 37,071)
12,096
(8119 to 19,446)
Systematic population single-lead
ECG – nurse
21,283
(13,365 to 36,257)
1.9
(0.93 to 3.3)
16,663
(774 to 36,763)
11,862
(7932 to 19,369)
Systematic population single-lead
ECG – GP
21,686
(13,729 to 36,749)
1.9
(0.91 to 3.3)
16,662
(266 to 37,170)
12,014
(7957 to 19,798)
Systematic population 12-lead
ECG – GP
24,867
(16,775 to 40,497)
2
(1.1 to 3.5)
16,035
(–611 to 37,308)
12,864
(8634 to 20,516)
Systematic population 12-lead
ECG – nurse
23,773
(15,784 to 39,085)
2
(0.99 to 3.4)
15,843
(–506 to 36,866)
12,722
(8477 to 20,413)
Systematic population 12-lead
ECG – automatic/algorithm
22,099
(14,713 to 36,553)
1.9
(0.93 to 3.2)
14,908
(–221 to 34,253)
12,638
(8493 to 20,272)
Systematic population > 1- and
< 12-lead ECG – automatic/algorithm
19,663
(12,203 to 33,342)
1.7
(0.71 to 3)
14,120
(–1270 to 33,500)
12,513
(8172 to 21,451)
a All results are per 1000 eligible individuals. Results are ordered by the highest INB.
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TABLE 44 Base-case results for a single screen at age 70 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic opportunistic
photoplethysmography
28,603
(13,079 to 61,452)
4
(2 to 6.7)
50,562
(16,224 to 92,951)
7523
(4637 to 14,429)
Systematic opportunistic modified
blood pressure monitor
27,083
(12,211 to 58,475)
3.8
(1.9 to 6.4)
48,640
(15,746 to 88,859)
7444
(4593 to 14,418)
Systematic opportunistic single-lead
ECG – automatic/algorithm
29,558
(14,518 to 61,314)
3.8
(1.9 to 6.5)
47,076
(13,852 to 87,578)
8063
(5109 to 15,059)
Systematic opportunistic > 1- and
< 12-lead ECG – cardiologist
32,373
(16,989 to 65,313)
4
(2 to 6.7)
46,836
(12,335 to 89,163)
8572
(5518 to 15,663)
Systematic opportunistic pulse
palpation – nurse
26,945
(12,448 to 57,840)
3.6
(1.8 to 6.3)
45,573
(13,829 to 85,258)
7750
(4803 to 14,705)
Systematic opportunistic single-lead
ECG – cardiologist
30,738
(15,872 to 62,674)
3.8
(1.9 to 6.4)
45,278
(12,253 to 85,955)
8478
(5436 to 15,531)
Systematic opportunistic 12-lead
ECG – GP
34,074
(18,690 to 67,139)
4
(2 to 6.7)
45,135
(10,685 to 87,471)
9047
(5880 to 16,183)
Systematic opportunistic single-lead
ECG – GP
29,701
(14,709 to 61,343)
3.7
(1.8 to 6.4)
44,555
(10,831 to 85,574)
8407
(5364 to 15,407)
Systematic opportunistic single-lead
ECG – nurse
29,012
(14,214 to 60,355)
3.7
(1.8 to 6.3)
44,479
(11,909 to 84,926)
8271
(5259 to 15,343)
Systematic opportunistic 12-lead
ECG – nurse
32,497
(17,416 to 64,724)
3.8
(1.9 to 6.5)
44,225
(10,579 to 85,598)
8910
(5760 to 16,043)
Systematic opportunistic 12-lead
ECG – automatic/algorithm
29,920
(15,938 to 60,096)
3.6
(1.8 to 6.1)
41,743
(10,790 to 79,834)
8768
(5663 to 15,893)
Systematic population
photoplethysmography
29,357
(15,791 to 57,907)
3.4
(1.7 to 5.8)
39,574
(9632 to 76,378)
8951
(5757 to 16,068)
Systematic opportunistic > 1- and
< 12-lead ECG – automatic/algorithm
26,273
(11,922 to 54,546)
3.3
(1.4 to 5.8)
39,167
(7475 to 77,335)
8472
(5367 to 15,506)
Systematic population modified blood
pressure monitor
27,924
(14,994 to 55,165)
3.3
(1.6 to 5.6)
38,010
(9498 to 72,987)
8902
(5757 to 16,059)
Systematic population > 1- and
< 12-lead ECG – cardiologist
32,351
(18,920 to 61,152)
3.4
(1.7 to 5.9)
36,617
(6693 to 73,385)
9907
(6472 to 17,182)
Systematic population single-lead
ECG – automatic/algorithm
30,120
(16,922 to 57,932)
3.3
(1.7 to 5.7)
36,606
(7765 to 71,902)
9517
(6185 to 16,806)
Systematic population 12-lead
ECG – GP
33,829
(20,408 to 62,675)
3.4
(1.7 to 5.9)
35,139
(5246 to 71,843)
10381
(6800 to 17,820)
Systematic population single-lead
ECG – cardiologist
31,085
(18,078 to 58,648)
3.3
(1.7 to 5.6)
35,103
(6365 to 70,172)
9923
(6486 to 17,217)
Systematic population pulse palpation
– nurse
28,086
(15,288 to 55,043)
3.2
(1.5 to 5.4)
35,056
(7396 to 69,459)
9380
(6046 to 16,712)
Systematic population single-lead
ECG – GP
30,080
(16,933 to 57,832)
3.2
(1.5 to 5.6)
34,577
(5182 to 70,523)
9874
(6408 to 17,364)
Systematic population single-lead
ECG – nurse
29,600
(16,701 to 56,854)
3.2
(1.6 to 5.5)
34,390
(6009 to 69,425)
9783
(6339 to 17,104)
Systematic population 12-lead
ECG – nurse
32,457
(19,308 to 60,424)
3.3
(1.7 to 5.7)
34,346
(5096 to 70,369)
10,296
(6713 to 17,750)
Systematic population 12-lead
ECG – automatic/algorithm
30,213
(17,969 to 56,659)
3.1
(1.6 to 5.3)
32,185
(5184 to 65,284)
10,246
(6691 to 17,608)
Systematic population > 1- and
< 12-lead ECG – automatic/algorithm
27,073
(14,583 to 51,723)
2.8
(1.2 to 5.1)
29,908
(2297 to 63,258)
10,173
(6515 to 18,189)
a All results are per 1000 eligible individuals. Results are ordered by the highest INB.
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TABLE 45 Base-case results for a single screen at age 75 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic opportunistic
photoplethysmography
42,351
(18,662 to 91,816)
5.8
(2.9 to 9.6)
72,655
(21,084 to 130,621)
7596
(4657 to 15,271)
Systematic opportunistic modified
blood pressure monitor
40,246
(17,756 to 87,546)
5.5
(2.8 to 9.3)
69,759
(20,180 to 125,238)
7543
(4626 to 15,097)
Systematic opportunistic > 1- and
< 12-lead ECG – cardiologist
46,146
(22,584 to 95,939)
5.8
(2.9 to 9.6)
68,924
(17,348 to 126,966)
8319
(5284 to 16,001)
Systematic opportunistic single-lead
ECG – automatic/algorithm
42,870
(19,997 to 91,137)
5.6
(2.8 to 9.4)
68,466
(18,876 to 124,651)
7967
(4985 to 15,581)
Systematic opportunistic 12-lead
ECG – GP
47,842
(24,296 to 97,625)
5.8
(2.9 to 9.6)
67,228
(15,678 to 125,343)
8643
(5540 to 16,323)
Systematic opportunistic single-lead
ECG – cardiologist
43,947
(21,232 to 91,680)
5.5
(2.8 to 9.3)
66,488
(17,033 to 122,485)
8252
(5231 to 15,872)
Systematic opportunistic pulse
palpation – nurse
39,527
(17,382 to 85,450)
5.3
(2.6 to 9.0)
65,815
(17,555 to 121,716)
7749
(4803 to 15,381)
Systematic opportunistic 12-lead
ECG – nurse
45,808
(22,816 to 94,635)
5.6
(2.8 to 9.4)
65,642
(15,075 to 123,303)
8549
(5455 to 16,254)
Systematic opportunistic single-lead
ECG – GP
42,614
(19,850 to 89,237)
5.4
(2.6 to 9.2)
65,259
(15,371 to 122,622)
8205
(5178 to 15,864)
Systematic opportunistic single-lead
ECG – nurse
41,762
(19,219 to 88,078)
5.3
(2.6 to 9)
64,990
(16,451 to 120,311)
8109
(5108 to 15,768)
Systematic opportunistic 12-lead
ECG – automatic/algorithm
42,379
(20,950 to 87,750)
5.2
(2.6 to 8.7)
61,734
(15,339 to 114,630)
8453
(5402 to 16,109)
Systematic population
photoplethysmography
41,320
(20,660 to 84,674)
5
(2.5 to 8.4)
58,817
(13,680 to 109,183)
8574
(5469 to 16,333)
Systematic opportunistic > 1- and
< 12-lead ECG – automatic/algorithm
37,634
(15,917 to 80,767)
4.8
(2.0 to 8.4)
57,416
(11,266 to 111,330)
8249
(5200 to 15,889)
Systematic population modified blood
pressure monitor
39,380
(19,666 to 80,591)
4.8
(2.4 to 8.1)
56,403
(13,322 to 104,820)
8542
(5459 to 16,262)
Systematic population > 1- and
< 12-lead ECG – cardiologist
44,342
(23,815 to 87,886)
5
(2.5 to 8.4)
55,851
(10,916 to 106,209)
9234
(6003 to 17,016)
Systematic population single-lead
ECG – automatic/algorithm
41,705
(21,744 to 83,833)
4.8
(2.4 to 8.2)
55,234
(11,827 to 104,566)
8963
(5789 to 16,707)
Systematic population 12-lead
ECG – GP
45,814
(25,266 to 89,292)
5
(2.5 to 8.4)
54,378
(9342 to 104,651)
9559
(6236 to 17,374)
Systematic population single-lead
ECG – cardiologist
42,582
(22,755 to 83,758)
4.8
(2.4 to 8.1)
53,574
(10,533 to 102,432)
9242
(5996 to 17,053)
Systematic population 12-lead
ECG – nurse
44,044
(24,042 to 86,123)
4.9
(2.4 to 8.2)
52,997
(8900 to 102,859)
9500
(6184 to 17,344)
Systematic population pulse palpation
– nurse
39,032
(19,626 to 79,148)
4.6
(2.2 to 7.8)
52,691
(10,635 to 100,920)
8866
(5690 to 16,613)
Systematic population single-lead
ECG – GP
41,321
(21,383 to 82,040)
4.7
(2.2 to 8.1)
52,607
(8892 to 102,716)
9212
(5931 to 17,047)
Systematic population single-lead
ECG – nurse
40,697
(21,021 to 80,639)
4.6
(2.3 to 7.9)
52,253
(10,245 to 100,588)
9146
(5902 to 16,953)
Systematic population 12-lead
ECG – automatic/algorithm
41,058
(22,397 to 80,180)
4.5
(2.3 to 7.6)
49,593
(8894 to 95,581)
9467
(6158 to 17,244)
Systematic population > 1- and
< 12-lead ECG – automatic/algorithm
36,963
(18,056 to 75,050)
4.1
(1.7 to 7.3)
45,799
(5526 to 92,680)
9415
(6027 to 17,387)
a All results are per 1000 eligible individuals. Results are ordered by the highest INB.
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TABLE 46 Base-case results for a single screen at age 80 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic opportunistic
photoplethysmography
53,753
(23,995 to 112,770)
8
(4.0 to 14)
106,818
(39,910 to 191,259)
6954
(4317 to 13,150)
Systematic opportunistic > 1- and
< 12-lead ECG – cardiologist
57,418
(27,857 to 116,241)
8
(4.0 to 14)
103,243
(36,064 to 187,797)
7453
(4777 to 13,709)
Systematic opportunistic modified
blood pressure monitor
51,182
(22,811 to 108,233)
7.7
(3.9 to 13)
102,405
(38,226 to 183,424)
6918
(4297 to 13,065)
Systematic opportunistic 12-lead
ECG – GP
59,039
(29,484 to 117,796)
8
(4.0 to 14)
101,623
(34,536 to 186,152)
7676
(4967 to 13,965)
Systematic opportunistic single-lead
ECG – automatic/algorithm
53,837
(25,023 to 110,826)
7.8
(3.9 to 13.0)
101,607
(36,514 to 183,878)
7210
(4554 to 13,395)
Systematic opportunistic single-lead
ECG – cardiologist
54,758
(26,262 to 111,401)
7.7
(3.9 to 13.0)
99,427
(35,025 to 180,487)
7406
(4742 to 13,637)
Systematic opportunistic 12-lead
ECG – nurse
56,675
(27,746 to 115,373)
7.8
(3.9 to 13.0)
98,947
(32,867 to 182,406)
7611
(4901 to 13,916)
Systematic opportunistic single-lead
ECG – GP
53,199
(24,162 to 110,982)
7.5
(3.5 to 13.0)
97,416
(31,285 to 180,723)
7374
(4698 to 13,630)
Systematic opportunistic pulse
palpation – nurse
49,926
(22,118 to 105,397)
7.4
(3.6 to 13.0)
97,139
(34,351 to 177,397)
7057
(4409 to 13,201)
Systematic opportunistic single-lead
ECG – nurse
52,261
(24,142 to 107,827)
7.5
(3.6 to 13.0)
96,824
(32,285 to 177,826)
7308
(4644 to 13,552)
Systematic opportunistic 12-lead
ECG – automatic/algorithm
52,559
(25,599 to 106,267)
7.3
(3.7 to 12.0)
92,805
(32,174 to 169,458)
7545
(4863 to 13,805)
Systematic opportunistic > 1- and
< 12-lead ECG – automatic/algorithm
46,999
(19,703 to 100,172)
6.6
(2.7 to 12.0)
85,733
(23,800 to 163,137)
7406
(4718 to 13,591)
Systematic population
photoplethysmography
38,163
(18,936 to 76,220)
5.1
(2.6 to 8.7)
64,791
(21,700 to 119,110)
7746
(5012 to 14,112)
Systematic population > 1- and
< 12-lead ECG – cardiologist
40,317
(21,265 to 78,333)
5.2
(2.6 to 8.7)
62,695
(19,757 to 116,918)
8203
(5373 to 14,545)
Systematic population modified
blood pressure monitor
36,440
(18,215 to 73,099)
4.9
(2.5 to 8.4)
62,037
(21,019 to 113,899)
7730
(5000 to 14,022)
Systematic population 12-lead
ECG – GP
41,352
(22,289 to 79,374)
5.2
(2.6 to 8.7)
61,660
(18,688 to 115,840)
8425
(5536 to 14,868)
Systematic population single-lead
ECG – automatic/algorithm
38,170
(19,605 to 75,072)
5
(2.5 to 8.5)
61,497
(19,796 to 113,886)
8018
(5224 to 14,341)
Systematic population single-lead
ECG – cardiologist
38,718
(20,457 to 74,633)
4.9
(2.5 to 8.4)
60,141
(18,872 to 112,148)
8212
(5394 to 14,571)
Systematic population 12-lead
ECG – nurse
39,836
(21,259 to 76,963)
5
(2.5 to 8.5)
59,942
(17,652 to 112,823)
8389
(5509 to 14,917)
Systematic population single-lead
ECG – GP
37,649
(19,028 to 74,793)
4.8
(2.3 to 8.4)
58,923
(16,328 to 112,385)
8196
(5357 to 14,675)
Systematic population pulse
palpation – nurse
35,826
(17,980 to 71,026)
4.7
(2.3 to 8.1)
58,471
(18,349 to 110,096)
7955
(5161 to 14,228)
Systematic population single-lead
ECG – nurse
37,130
(19,033 to 72,996)
4.8
(2.3 to 8.2)
58,461
(16,966 to 110,431)
8152
(5316 to 14,528)
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FIGURE 22 Cost-effectiveness acceptability curves for a single screen at ages (a) 55 years and (b) 60 years. Screening
strategies that have a < 10% probability of being cost-effective at any willingness-to-pay threshold are not shown
for clarity.
TABLE 46 Base-case results for a single screen at age 80 years: mean incremental costs, incremental QALYs, INB for
a willingness to pay per QALY threshold of £20,000 and ICERa (continued )
Test/interpreter
Incremental costs
(£) (95% CrI)
Incremental
QALYs (95% CrI)
INB at £20,000
(£) (95% CrI) ICER (£) (95% CrI)
Systematic population 12-lead
ECG – automatic/algorithm
37,198
(19,847 to 71,715)
4.7
(2.3 to 7.9)
56,007
(16,998 to 105,243)
8375
(5516 to 14,807)
Systematic population > 1- and
< 12-lead ECG – automatic/algorithm
33,656
(16,073 to 67,842)
4.3
(1.8 to 7.5)
51,448
(11,798 to 101,716)
8359
(5411 to 14,964)
a All results are per 1000 eligible individuals. Results are ordered by the highest INB.
RESULTS OF THE ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
Results from sensitivity analyses
Screening test
Because the photoplethysmography screening test was based on a single study69 that did not take place
in a primary care setting, and the study was rated as being at high risk of bias for the index test, we
performed a sensitivity analysis of the comparison of different ages at screening for a single one-off screen
using the most cost-effective screening test omitting photoplethysmography, which was the modified
blood pressure monitor. The results were very similar (see Appendix 11, Using a modified blood pressure
monitor as the screening test) and the conclusions were unchanged.
Photoplethysmography and modified blood pressure monitors are not currently available in most primary
care settings. Therefore, we conducted a further sensitivity analysis using the screening test that was most
cost-effective (pulse palpation interpreted by a nurse) when restricting to tests that are currently typically
available in primary care (i.e. excluding photoplethysmography and modified blood pressure monitors).
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FIGURE 23 Cost-effectiveness acceptability curves for a single screen at ages (a) 65 years and (b) 70 years. Screening
strategies that have a < 10% probability of being cost-effective at any willingness-to-pay threshold are not shown
for clarity.
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FIGURE 24 Cost-effectiveness acceptability curves for a single screen at ages (a) 75 years and (b) 80 years. Screening
strategies that have a < 10% probability of being cost-effective at any willingness-to-pay threshold are not shown
for clarity.
TABLE 47 Age cohort population mean incremental costs, incremental QALYs, net benefit for a willingness to pay
per QALY threshold of £20,000, number of screen-detected cases and total cost per screen-detected case for
different screening ages, all using opportunistic screening with photoplethysmography relative to no screeninga
Screening
age
(years)
Population
size of age
cohort for
given ages
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Screen-
detected
cases
(95% CrI)
Cost per screen-
detected case (£)
(95% CrI)
80 279,437 15,021
(6705 to 31,512)
2243
(1130 to 3799)
29,849
(11,152 to 53,445)
445
(244 to 716)
55,637
(28,215 to 97,765)
75 379,913.4 16,090
(7090 to 34,882)
2185
(1105 to 3666)
27,603
(8010 to 49,625)
449
(249 to 723)
48,371
(24,759 to 85,931)
70 466,605.4 13,346
(6103 to 28,674)
1847
(930 to 3134)
23,593
(7570 to 43,372)
345
(190 to 560)
41,349
(19,006 to 80,786)
65 633,658.8 11,612
(5621 to 22,977)
1487
(763 to 2539)
18,137
(5959 to 33,476)
278
(152 to 448)
36,949
(15,774 to 72,064)
60 620,292.8 7317
(3567 to 15,055)
851
(421 to 1450)
9700
(1721 to 18,876)
153
(84 to 250)
34,224
(13,916 to 67,342)
55 675,855 5460
(2860 to 10,409)
601
(292 to 1031)
6556
(1240 to 12,932)
104
(56 to 173)
31,135
(12,525 to 59,556)
a Age cohort population represents England and Wales 2014.
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The results were very similar (see Appendix 11, Using pulse palpation interpreted by a nurse as the screening
test) and, although INBs were slightly lower than in the base case, the overall conclusions were unchanged.
Repeated screening
We explored the impact of repeated screening on a given age cohort by varying the initial and final
screening ages, and assuming screening every 5 years, reporting all results for the age cohort population
(see Chapter 5, Repeat screening). We found that screening every 5 years from age 65 years to age
80 years had the highest probability of being cost-effective, with screening every 5 years from age 70 years
to age 80 years having the second highest probability of being cost-effective (Figure 26). These strategies
also have the highest expected INB (Table 48). The optimal strategy from the base case (initial screen at
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FIGURE 25 Cost-effectiveness acceptability curves comparing different ages for a single one-off screen in a given
age cohort population. Screening strategies that have a < 10% probability of being cost-effective at any
willingness-to-pay threshold are not shown for clarity.
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FIGURE 26 Cost-effectiveness acceptability curves for screening strategies with repeated screening every 5 years
for various initial and final screening ages, all using opportunistic pulse palpation by a nurse as the screening test.
No screening represents no screening at any age. The results are based on incremental costs and QALYs for a
single age cohort population. Screening strategies that have a < 10% probability of being cost-effective at any
willingness-to-pay threshold are not shown for clarity.
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TABLE 48 Age cohort population mean incremental costs, incremental QALYs, net benefit for willingness to pay
per QALY thresholds of £20,000, number of screen-detected cases and total cost per screen-detected case for
repeat screening at different initial and final screening ages using opportunistic pulse palpation by a nurse as the
screening testa
Initial and final
age for repeated
screening every
5 yearsb
Age cohort
population
incremental
costs (£million)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000
(£million)
(95% CrI)
Screen-
detected
cases
(95% CrI)
Cost per screen-
detected case (£)
(95% CrI)
Initial age 65 years,
final age 80 years
38 (19 to 72) 4910
(2478 to 8286)
60 (22 to 107) 1241
(666 to 2026)
31,193
(20,886 to 50,491)
Initial age 70 years,
final age 80 years
34 (17 to 66) 4495
(2265 to 7640)
56 (21 to 101) 1048
(562 to 1706)
32,684
(21,417 to 55,016)
Initial age 60 years,
final age 80 years
38 (20 to 70) 4685
(2387 to 7903)
56 (20 to 101) 1316
(704 to 2129)
29,175
(19,732 to 46,589)
Initial age 55 years,
final age 80 years
36 (19 to 65) 4307
(2197 to 7312)
50 (18 to 91) 1349
(724 to 2189)
27,240
(18,659 to 42,579)
Initial age 65 years,
final age 75 years
31 (15 to 58) 3848
(1925 to 6516)
46 (16 to 84) 890
(475 to 1451)
34,963
(23,189 to 57,823)
Initial age 75 years,
final age 80 years
27 (13 to 52) 3578
(1788 to 6112)
45 (16 to 82) 782
(419 to 1278)
34,374
(21,781 to 59,434)
Initial age 60 years,
final age 75 years
32 (16 to 59) 3833
(1952 to 6502)
45 (15 to 82) 981
(522 to 1591)
32,892
(22,073 to 53,111)
Initial age 55 years,
final age 75 years
31 (16 to 57) 3624
(1858 to 6160)
41 (14 to 76) 1030
(553 to 1671)
30,899
(20,986 to 48,669)
Initial age 70 years,
final age 75 years
25 (12 to 49) 3170
(1584 to 5405)
39 (13 to 71) 678
(362 to 1106)
36,516
(23,330 to 64,354)
Initial age 60 years,
final age 70 years
24 (12 to 45) 2843
(1444 to 4840)
33 (11 to 61) 641
(341 to 1046)
38,082
(25,262 to 62,211)
Initial age 55 years,
final age 70 years
25 (13 to 46) 2829
(1444 to 4830)
31 (9.7 to 59) 706
(379 to 1148)
36,124
(24,342 to 57,393)
Initial age 65 years,
final age 70 years
21 (10 to 41) 2613
(1301 to 4457)
31 (9.9 to 58) 533
(283 to 874)
40,076
(25,976 to 68922)
Initial age 80 years,
final age 80 years
15 (6.5 to 30) 2063
(994 to 3549)
27 (8.7 to 49) 408
(218 to 666)
36,000
(21,583 to 66,120)
Initial age 75 years,
final age 75 years
15 (6.7 to 32) 1925
(928 to 3329)
23 (5.9 to 44) 394
(210 to 645)
38,291
(22,648 to 74,239)
Initial age 55 years,
final age 65 years
19 (9.9 to 34) 1991
(1001 to 3383)
21 (5.4 to 41) 445
(237 to 723)
42,506
(28,155 to 68,113)
Initial age 70 years,
final age 70 years
13 (5.8 to 27) 1628
(783 to 2799)
20 (5.2 to 38) 303
(161 to 497)
41,676
(25,219 to 78,271)
Initial age 60 years,
final age 65 years
16 (8.2 to 30) 1797
(899 to 3076)
20 (5.1 to 38) 367
(195 to 602)
44,250
(28,517 to 75,451)
Initial age 65 years,
final age 65 years
11 (5.4 to 22) 1309
(628 to 2269)
15 (2.8 to 29) 244
(128 to 402)
45,785
(28,021 to 86,277)
Initial age 55 years,
final age 60 years
11 (6 to 21) 1151
(570 to 1997)
12 (1.9 to 24) 223
(118 to 367)
51,966
(33,535 to 86,197)
Initial age 60 years,
final age 60 years
7.1 (3.6 to 14) 749
(355 to 1302)
7.9 (0.54 to 16) 134
(71 to 224)
53,624
(32,829 to 97,800)
Initial age 55 years,
final age 55 years
5.6 (2.9 to 11) 552
(256 to 978)
5.4 (0.02 to 12) 96
(49 to 160)
60,477
(37,044 to 106,296)
a Age cohort population represents England and Wales 2014.
b Each strategy assumes 5-yearly screening from the initial age to the final age or a single screen at the initial age (when
the initial age is equal to the final age).
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80 years with no repeat screening) had a low probability of being the most cost-effective strategy and a
relatively low INB when repeated screening strategies were included in the decision. Because the results of
a single screen were very similar for photoplethysmography, modified blood pressure monitors and pulse
palpation by a nurse (see Screening test), we present only the results for pulse palpation by a nurse when
comparing different repeated screening strategies, as nurse palpation has no capital costs and is currently
available in primary care. The conclusions were unaltered using different screening tests.
Uptake of systematic opportunistic screening
In this sensitivity analysis we assumed a lower uptake of systematic opportunistic screening, as reported in
Morgan and Mant82 (0.305, 95% CI 0.282 to 0.329), assuming that uptake was the same for all age
groups. The main impact was to change the optimal screening method from systematic opportunistic
screening to systematic population screening. All other conclusions were unchanged. This suggests that
our finding that systematic opportunistic screening is the optimal screening approach is sensitive to the
uptake of systematic opportunistic screening. The CEACs for different screening ages are shown in
Figure 27.
Uptake of an electrocardiogram in those with a positive screening result
We conducted a sensitivity analysis using the assumption that only 72.5% of those with a positive
screening test result will agree to have an ECG, compared with 100% in the base case. We found that
incremental costs, incremental QALYs and INBs were all lower than for the base case, but overall the
conclusions were robust to reducing the uptake of a diagnostic ECG (see Appendix 11, Uptake of an
electrocardiogram in those with a positive screening result).
Diagnosis in the absence of screening or an atrial fibrillation-related stroke
For the repeated screening strategies, we conducted a sensitivity analysis assuming an annual rate of
diagnosis in the absence of screening or an AF-related stoke of 5%, as assumed by Aronsson et al.,100
compared with 1% based on the control arm of the SAFE study19 used in the base case. As one would
expect, the INB decreases as the diagnosis rate in the absence of screening or AF-related stroke increases
(Table 49). When the diagnosis rate in the absence of screening or AF-relative stroke is 5%, it is
unclear whether it is more cost-effective to initiate repeated screening at age 65 years or age 70 years
No screening
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FIGURE 27 Sensitivity analysis assuming a lower uptake of systematic opportunistic screening: CEACs comparing
different ages for a single one-off screen in an age cohort population. Screening strategies that have a < 10%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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(Figure 28); this compares with the base case, in which there was a reasonably high probability that the
optimal screening strategy was to initiate repeated screening at age 65 years (see Figure 26).
Meta-analysis of previous history of stroke in UK screen-detected atrial fibrillation
In a sensitivity analysis, we used the results of a random-effects meta-analysis for the proportion of
screen-detected AF patients with a previous history of stroke (0.112, 95% CrI 0.072 to 0.170); this
compares with 0.074 (95% CI 0.032 to 0.116) based on the SAFE study19 used in the base case. We found
no change in the conclusions and only a slight decrease in the INBs (see Appendix 11, Meta-analysis of
previous history of stroke in UK screen-detected atrial fibrillation).
TABLE 49 Mean INBs for an age cohort population at the £20,000 willingness-to-pay threshold, comparing
different repeat screening strategies using opportunistic pulse palpation by a nurse as the screening testa
Diagnosis rate in the absence of screening:
1% (base case) Diagnosis rate in the absence of screening: 5%
Initial and final age for repeated
screening every 5 yearsb
Age cohort
population
INB at £20,000
(£million)
Initial and final age for repeated
screening every 5 years
Age cohort
population INB
at £20,000
(£million)
Initial age 65 years, final age 80 years 60 (22 to 107) Initial age 70 years, final age 80 years 47 (17 to 85)
Initial age 70 years, final age 80 years 56 (21 to 101) Initial age 65 years, final age 80 years 45 (16 to 83)
Initial age 60 years, final age 80 years 56 (20 to 101) Initial age 75 years, final age 80 years 41 (14 to 74)
Initial age 55 years, final age 80 years 50 (18 to 91) Initial age 65 years, final age 75 years 38 (13 to 70)
Initial age 65 years, final age 75 years 46 (16 to 84) Initial age 60 years, final age 80 years 37 (12 to 68)
Initial age 75 years, final age 80 years 45 (16 to 82) Initial age 70 years, final age 75 years 35 (12 to 65)
Initial age 60 years, final age 75 years 45 (15 to 82) Initial age 60 years, final age 75 years 32 (10 to 60)
Initial age 55 years, final age 75 years 41 (14 to 76) Initial age 55 years, final age 80 years 29 (8.5 to 54)
Initial age 70 years, final age 75 years 39 (13 to 71) Initial age 65 years, final age 70 years 28 (8.7 to 52)
Initial age 60 years, final age 70 years 33 (11 to 61) Initial age 80 years, final age 80 years 27 (8.7 to 49)
Initial age 55 years, final age 70 years 31 (9.7 to 59) Initial age 60 years, final age 70 years 26 (7.5 to 49)
Initial age 65 years, final age 70 years 31 (9.9 to 58) Initial age 55 years, final age 75 years 26 (7.3 to 49)
Initial age 80 years, final age 80 years 27 (8.7 to 49) Initial age 75 years, final age 75 years 23 (6.1 to 44)
Initial age 75 years, final age 75 years 23 (5.9 to 44) Initial age 55 years, final age 70 years 21 (5.7 to 41)
Initial age 55 years, final age 65 years 21 (5.4 to 41) Initial age 70 years, final age 70 years 20 (5.3 to 38)
Initial age 70 years, final age 70 years 20 (5.2 to 38) Initial age 60 years, final age 65 years 17 (4.3 to 34)
Initial age 60 years, final age 65 years 20 (5.1 to 38) Initial age 55 years, final age 65 years 16 (3.5 to 32)
Initial age 65 years, final age 65 years 15 (2.8 to 29) Initial age 65 years, final age 65 years 15 (2.8 to 29)
Initial age 55 years, final age 60 years 12 (1.9 to 24) Initial age 55 years, final age 60 years 10 (1.4 to 21)
Initial age 60 years, final age 60 years 7.9 (0.54 to 16) Initial age 60 years, final age 60 years 7.9 (0.45 to 16)
Initial age 55 years, final age 55 years 5.4 (0.02 to 12) Initial age 55 years, final age 55 years 5.4 (0.036 to 12)
a Results shown for different diagnosis rates in the absence of screening or AF-related stroke: 1% (base case) and 5%.
b Each strategy assumes 5-yearly screening from the initial to the final age or a single screen at the initial age (when the
initial age is equal to the final age).
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Proportion of anticoagulant patients receiving directly acting oral anticoagulants
instead of warfarin
In the base case, we assumed that 75% of patients prescribed OACs would be prescribed DOACs. We ran
sensitivity analyses on the proportion of OAC patients prescribed DOACs instead of warfarin (INR range 2–3),
assuming that 50% and 100% of patients were prescribed DOACs. We found no difference in the
conclusions and almost no difference in absolute results from the base case (see Appendix 11, Proportion of
anticoagulant patients receiving directly acting oral anticoagulants instead of warfarin).
Uptake of oral anticoagulants
In the base case, 74% of patients eligible for OACs receive them, 13% of patients are contraindicated or
do not wish to take OACs and the remaining 13% do not receive OACs but could do so. In sensitivity
analyses we explored the impact of (1) a reduced OAC uptake of 50% and (2) improving the uptake
of OACs so that all 87% of patients who are not contraindicated or who prefer not to take OACs
receive OACs. The overall INB was lower if OAC uptake was lower, but this did not alter our conclusions
(see Appendix 11, Uptake of oral anticoagulants).
Hazard ratios for stroke and mortality risk for routine-detected atrial fibrillation
compared with screen-detected atrial fibrillation
In sensitivity analysis, we assumed that the event rate in screen-detected patients was lower than that for
routinely detected AF using the unadjusted HR for symptomatic AF (representing non-screen-detected AF)
compared with asymptomatic AF (representing screen-detected AF) found by Flaker et al.35 of 1.31 (95% CI
1.04 to 1.65), instead of a HR of 1, as assumed in the base case. Our conclusions were unchanged from the
base case (see Appendix 11, Hazard ratios for stroke and mortality risk for routine-detected atrial fibrillation
compared with screen-detected atrial fibrillation).
Discussion
Summary of the results
Our results indicate that systematic screening for AF is likely to be cost-effective. This is because of the
relatively large net benefit resulting from anticoagulation therapy for patients identified with AF and the
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FIGURE 28 Cost-effectiveness acceptability curves for screening strategies with repeated screening every 5 years for
various initial and final screening ages, all using opportunistic pulse palpation by a nurse as the screening test, for
the sensitivity analysis with a 5% diagnosis rate in the absence of screening or AF-related stroke. No screening
represents no screening at any age. Results are based on incremental costs and QALYs for a single age cohort
population. Screening strategies that have a < 10% probability of being cost-effective at any willingness-to-pay
threshold are not shown for clarity.
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relatively low cost of a screening programme. We found that cheaper screening tests (such as
photoplethysmography, blood pressure monitors and pulse palpation by a nurse) were more likely
to be cost-effective than other screening tests, which is probably because these tests have good
sensitivity as well as because they are cheaper than alternative tests. It should be noted, however, that
photoplethysmography and blood pressure monitor devices are currently not typically available in primary
care, and so adoption of these tests would incur a substantial upfront capital investment (see Strengths
and limitations). Furthermore, the evidence informing the DTA of photoplethysmography was rated as
being at high risk of bias for the index test, and there was no evidence available from a primary care
context. The next most cost-effective screening test was found to be pulse palpation by a nurse. All of
these findings rely on the use of a 12-lead ECG diagnostic test interpreted by a GP (referred to a
cardiologist when the diagnosis is unclear) for individuals with a positive screening test result.
Both systematic opportunistic and systematic population screening methods were found to be cost-effective
compared with no screening (current practice); however, systematic opportunistic screening was more likely
to be cost-effective than systematic population screening in our base-case analyses. This result was found to
be sensitive to assumptions on the uptake of opportunistic screening, which, if lower than in the base case,
changes the optimal method of screening to systematic population screening.
For a given age cohort we found that, if we were to conduct a single screen, then strategies that use a
higher age at screening were more likely to be cost-effective. However, when allowing for the possibility of
repeated screening strategies with 5-year intervals, single screens were no longer found to be cost-effective.
Instead, an initial screen at age 65 years followed by repeat screens every 5 years until age 80 years was
found most likely to be cost-effective. If we assume a high (5%) diagnosis rate in the absence of screening
or AF-related stroke, then it may be more cost-effective to initiate screening at age 70 years with repeated
screens at 75 and 80 years. It should be noted, however, that the majority of the evidence informing the
model was based on individuals aged 65–75 years, and so we are less confident of our results outside
this age range.
Strengths and limitations
Our model is based on a comprehensive set of reviews of DTA studies (see Chapters 2 and 3), screening
RCTs (see Chapters 2 and 4), the natural history of AF and AF screening (see Chapter 5) and a systematic
review, network meta-analysis and cost-effectiveness model of OACs.37 This allowed us to explore a wide
range of screening tests and to incorporate net benefits of recently developed DOACs as well as warfarin.
We explored the optimal age range at which to conduct a single ‘prevalent’ screen and also assessed the
cost-effectiveness of repeat screening rounds for a given age cohort. We considered only 5-year screening
intervals for repeat screens and could have varied the screening interval in further sensitivity analyses.
However, previous studies that have investigated this have found that cost-effectiveness depends on the
interval of screening, with an interval of around 5 years found to be acceptable.25,96,99
We assumed that uptake of screening varies with age by crudely dichotomising into < 75 years and
≥ 75 years age ranges, as reported in the SAFE study,19 which found that uptake of systematic population
screening was greater in younger than older individuals. No other studies reported uptake of screening by
age. Although we incorporated the effect of age for prevalence and the uptake of screening, many other
model inputs were based on studies that primarily included those in the age range 65–70 years. We are
therefore more confident in our results for this age range than for other age ranges.
The sensitivity analysis exploring repeated screening is not as robust as the base-case analysis. We did not
directly model the incidence of new cases of AF or the progression from paroxysmal to persistent/permanent
AF or from asymptomatic to symptomatic AF in the model of repeat screening – we simply used information
on population size, prevalence and previous diagnosis of AF at each age. This assumes that the patterns of
prevalence seen in the study by Norberg et al.2 would apply to a single age cohort (i.e. no cohort or period
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effects). We assumed a 1% annual diagnosis rate in the absence of screening and assumed that this did not
change with increasing age. When we allowed a higher diagnosis rate in the absence of screening of 5%,
there was a suggestion that initiating a repeated screening strategy at 70 years rather than at 65 years
might be cost-effective. These limitations should be considered when making final decisions about repeat
screening strategies.
We considered only screening programmes based on age, rather than on other risk factors. The SAFE
study,19 however, found that systematic screening targeted at high-risk individuals had a similar rate of
identification of new cases of AF as the control (no screening), suggesting that targeted systematic
screening is unlikely to be cost-effective. An ongoing controlled before-and-after study (due to report in
2016) in Scotland has trialled the AliveCor app used in primary care to screen high-risk individuals,167 which
will provide more evidence on this question.
We have averaged over men and women in our model to enable a single decision to be made for both
sexes. The SAFE study19 found that screening was more effective in men than in women. For women, only
systematic opportunistic screening was effective, whereas for men both systematic opportunistic screening
and systematic population screening were effective. Women were less likely to accept an ECG than men. If
a systematic screening programme is introduced, individuals need to be fully informed of the consequences
of receiving an ECG to confirm the diagnosis if the screening test is positive.
We assumed that the screening test would be conducted at a single visit to primary care and therefore
would detect only a small proportion of cases of paroxysmal AF (compared with more intensive monitoring).
We made this assumption because of a lack of evidence on prolonged screening tests identified in our
systematic review of DTA studies. The proportion of paroxysmal AF detected by population-based screening
would increase if long-term monitoring devices were used, and costs might therefore increase too. It is not
clear, however, whether or not this would represent a cost-effective use of resources, as paroxysmal AF
patients may be less likely to have a CHA2DS2-VASc score of > 1 and be eligible to receive anticoagulation
therapy. Our review of natural history studies found that stroke risk is lower in patients with paroxysmal AF
than in patients with persistent or permanent AF.
It should be noted that some false positives may be diagnosed with another condition (e.g. atrial flutter),
and thus receive some benefit from an AF screening programme. We did not capture this benefit in our
model; however, incorporating this would increase the cost-effectiveness of a population-based systematic
screening programme.
We assumed that the DOAC used is apixaban because this was found to be most cost-effective in the
DOAC model.37 However, several DOACs are currently prescribed in UK practice and all licensed DOACs
were found to be similar in terms of cost and benefits.37 Our conclusions would therefore be robust to
the actual DOAC that was prescribed and we envisage that a variety of DOACs would be prescribed for
screen-detected AF, as is currently the case for incidentally detected AF. In the base case, we also assumed
that 75% of patients prescribed OACs received DOACs, but in practice more patients may receive warfarin
for various reasons, including comorbidity and tolerability. Also, in the future a higher proportion of OACs
prescribed may be DOACs. Varying the proportion of OACs that were DOACs from 75% to 50% or 100%
did not alter our conclusions on the cost-effectiveness of screening strategies.
We have not included capital costs of the screening test devices in our analyses. However, based on plausible
assumptions about the purchase costs, lifespan and patient throughput of ECG, photoplethysmography and
modified blood pressure monitor equipment (Table 50), we believe that the inclusion of the capital costs of
equipment within the screening test cost would have little impact on our conclusions. The capital cost of the
most expensive equipment (£1495 for a 12-lead ECG) is ‘spread out’ over the lifespan of the equipment
(e.g. 5 years) among patients undergoing screening for AF and patients for whom an ECG is used for other
clinical indications (Table 51). The estimated additional capital cost of an ECG per individual screened would
be approximately £1, increasing slightly with screening age as the number of patients screened declines.
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The capital costs per AF patient screened for a modified blood pressure monitor (from £0.33 to £0.87) and
photoplethysmography (from £0.08 to £0.21) were lower still if each practice purchased one device
dedicated to AF screening. Alternatively, practices might eventually choose to replace existing blood pressure
monitors with modified monitors in each consultation and treatment room and use them for screening AF
and other patients.
If a screening strategy using equipment not available in practices is selected, then investment in equipment
will be required to achieve nationwide primary care screening. This may act as a barrier to initiating screening.
A recent review found that 81% of practices have a 12-lead ECG machine available.44 Investment would
therefore be required for the 19% of practices that do not have a machine available. This would be required
under all screening strategies, because we assume that all positive screening tests would be followed by a
diagnostic 12-lead ECG. Modified blood pressure monitors or photoplethysmography devices are not typically
available in primary care and if these screening tests were adopted then this would represent a large capital
TABLE 50 Assumptions and sources for the purchase costs, lifespan and patient throughput of screening and
diagnostic tests for AF
Parameter Value Source/comment
Uptake of systematic opportunistic screening 0.692 See Table 40, proportion of flagged individuals
who have their pulses checked
Uptake of systematic population screening 0.641 See Table 40
Number of general practices 7835 Health and Social Care Information Centre168
Proportion of general practices with an ECG machine 0.81 Taggar et al.44
Non-AF patients using an ECG machine per 1000 34.7 Wolff et al.169
Average patients per practice 7267 Health and Social Care Information Centre168
ECG machine cost £1495.00 Numed Healthcare170
Photoplethysmography cost £23.88 Bonanzamarket171
Modified blood pressure monitor cost £99.95 Omron172
ECG lifespan 5 years Assumption
Photoplethysmography lifespan 5 years Assumption
Modified blood pressure monitor lifespan 5 years Assumption
Resale value (all equipment) £0 Assumption
TABLE 51 Capital cost per patient of systematic opportunistic (Opp) and systematic population (Syst) screening
strategies using photoplethysmography (PP), modified blood pressure (MBP) monitor or ECG testing
Screen
age
(years)
Eligible
patients
per
practice, n
Opp
patients
screened
per practice,
n
Syst
patients
per
practice,
n
Non-AF
screening
patients
using
ECG, n
Opp PP
cost per
patient
(£)
Syst PP
cost per
patient
(£)
Opp MBP
monitor
cost per
patient
(£)
Syst MBP
monitor
cost per
patient
(£)
Opp ECG
cost per
patient
(£)
55 86.26 59.69 55.43 252.16 0.08 0.09 0.33 0.36 0.96
60 79.17 54.79 50.87 252.16 0.09 0.09 0.36 0.39 0.97
65 80.88 55.97 51.97 252.16 0.09 0.09 0.36 0.39 0.97
70 59.55 41.21 38.27 252.16 0.12 0.13 0.49 0.52 1.02
75 48.49 33.55 31.16 252.16 0.14 0.15 0.60 0.64 1.05
80 35.67 24.68 22.92 252.16 0.19 0.21 0.81 0.87 1.08
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investment. In particular, photoplethysmography has been asessed only in a single study, which was not
carried out in a primary care context and which was at high risk of bias for the index test. Investment in such
a technology would be unwise without further research to better understand its diagnostic performance in a
primary care screening setting. We estimate that, for photoplethysmography and modified blood pressure
monitor screening strategies, for which all practices would have to purchase equipment and some practices
would also have to purchase 12-lead ECG equipment for confirmatory testing, the investment needed would
be approximately £2.4M and £3.0M respectively (Table 52). In contrast, for strategies that require only some
practices to purchase 12-lead ECG equipment for screening or confirmatory testing (e.g. pulse palpation,
ECG) the initial investment would be £2.2M.
Findings in the context of previous research
In line with other studies,19,25,96,100 we found that population-based screening is likely to be cost-effective.
We found that systematic opportunistic screening was more cost-effective than systematic population
screening, which, again, is in line with previous studies.19 The SAFE19 study is the only other study we are
aware of that looked at different screening tests. The DTA results from the SAFE study19 were included in
our review of DTA studies, along with the results from 14 other studies. Our model is therefore based on a
more comprehensive evidence base and covers a wider range of screening tests than the SAFE model.19
TABLE 52 Investment costs for photoplethysmography (PP), modified blood pressure (MBP) monitor or ECG
screening strategies
Screening strategy Investment cost (£)
PP 187,100
MBP monitor 783,108
12-lead ECG 2,225,532
PP+ 12-lead ECG 2,412,632
MBP monitor + 12-lead ECG 3,008,640
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Chapter 7 Discussion
Summary of findings
Review of diagnostic accuracy studies
We identified 15 studies of screening tests for detecting AF, including 12-lead ECG, single-lead ECG,
between 1- and 12-lead ECG, pulse palpation, modified blood pressure monitors, photoplethysmography
and two-stage testing. Screening tests varied in whether they were interpreted by a cardiologist, a GP,
a nurse or an automatic algorithm, although evidence was not available for every test and interpreter
combination. There was a high degree of variability between studies and a high level of uncertainty in the
estimates of DTA. In general, most tests had a high sensitivity, in excess of 0.9. Specificity was, in general,
lower than sensitivity for all of the tests, and was lowest for pulse palpation by a nurse (specificity 0.79),
a 12-lead ECG interpreted by a nurse (specificity 0.84) and photoplethysmography (specificity 0.87). Tests
with the highest DOR were the 12-lead ECG (regardless of interpreter), the between 1- and 12-lead ECG
(automatic or cardiologist interpretation), two-stage tests and the single-lead ECG interpreted by a GP;
all of these tests had similar DORs.
In general, for a given interpreter, the results for single-lead ECGs were less accurate and more variable
than ECGs with more than one lead. Nurse interpretation of single-lead ECGs performed similarly to
single-lead ECGs with other interpretation methods, but nurse interpretation of 12-lead ECGs did not
perform as well as 12-lead ECGs with other interpretation methods. Automatic interpretation did not have
a consistent impact on test accuracy, with automatic interpretation of single-lead ECGs having a high
sensitivity but variable specificity. In contrast, automatic interpretation of ECGs with more leads had good
specificity but variable sensitivity. The different two-stage screening strategies all had very high specificity,
but sensitivity was high only when a 12-lead ECG was used as the second-stage test.
Review of randomised controlled trials comparing screening strategies
We identified five RCTs comparing screening strategies for AF; however, only two of these provided data
that could be included in our review, and only one was included in our primary outcome (the number of
new AF diagnoses). The SAFE study19 therefore remains the main source of evidence on the comparative
efficacy of different screening strategies for AF. Systematic population (a 12-lead ECG interpreted by
a cardiologist) and systematic opportunistic (pulse palpation followed by a 12-lead ECG interpreted by a
cardiologist) screening strategies were found to be similarly effective, with an estimated 170 individuals
needed to screen to detect one additional AF case compared with no screening. There was no evidence
that systematic screening targeted to high-risk individuals was effective compared with no screening.
Uptake of systematic population screening was typically around 50%, although it was as high as 70% in
one study. There was variability in uptake between practices (between 22% and 70% in the SAFE study19).
Reasons for not attending for screening were varied, although older age and decreased mobility were
common themes. The proportion of individuals having their pulses checked under systematic opportunistic
screening varied across studies (between 30% and 66%) and between practices within studies (from 8%
to 93%). The proportion of individuals consulting with their GP was not reported, so it is unclear how
much these uptake rates are driven by consultation rates, GPs offering pulse palpation and uptake of pulse
palpation by individuals. Of those with an irregular pulse who did not have a previous diagnosis of AF,
approximately 18% did not attend for an ECG test, although, again, this varied across practices.
Subgroup analyses based on the SAFE study19,84 indicated that both systematic population screening and
systematic opportunistic screening were more effective for men than for women, and this was especially
the case for systematic population screening. The efficacy of screening was not found to vary with age,
despite AF prevalence being strongly associated with age.
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Review of the natural history of atrial fibrillation and atrial fibrillation screening
We searched for studies to inform the natural history of AF and screening for AF for use in our economic
evaluation. This comprehensive search identified 48 studies that provided data relevant to our model. The
prevalence of AF was variable across studies but showed similar trends with age and sex. The studies with
the most intensive ascertainment of AF gave the highest estimates of prevalence and were in line with each
other.2,125 The proportion of AF that is undiagnosed was estimated to be 35%; however, this estimate was
variable across screening studies, reflecting the method of screening and test used as well as differences
in populations. As expected, the higher estimates came from studies with more intensive screening tests
(e.g. long-term continuous monitoring). It is clear that, if the objective is to detect paroxysmal AF, then
long-term continuous monitoring is necessary.
Uptake of systematic population screening was fairly consistent across studies, with a mean estimate of
64% (95% CrI 54% to 73%), although this was shown to depend on age in the SAFE study.19 In contrast,
there was a high degree of variability in the uptake of systematic opportunistic screening, ranging from
30% to 70% (regardless of age), raising concern that the high level of opportunistic screening achieved in
the SAFE study19 may not be seen in practice.
As expected, our results suggest that a high proportion of screen-detected AF is likely to be asymptomatic.
Asymptomatic AF has a lower risk of stroke and mortality; however, after adjusting for other risk factors,
there is no evidence that the risk of stroke or mortality depends on whether AF is asymptomatic or not.35
We found that our results were robust to this assumption. We estimated that paroxysmal AF progresses to
chronic (persistent or permanent) AF at a rate of 0.15 per year. There is evidence of a ‘dose–response’
relationship, with stroke and mortality risk increasing as AF progresses from paroxysmal to persistent
to permanent.
Economic evaluation
Our results indicate that both systematic opportunistic screening and systematic population screening
followed by DOAC therapy when indicated are likely to be cost-effective compared with no screening
(current practice). However, systematic opportunistic screening was more likely to be cost-effective than
systematic population screening as long as the proportion of flagged individuals who have their pulses
checked observed in the SAFE study19 is realised in practice.
We found that photoplethysmography, modified blood pressure monitors and pulse palpation by a nurse
were more likely to be cost-effective than other screening tests because they are cheaper than other
screening tests while have adequate test sensitivity. This finding relies on the use of a 12-lead ECG
diagnostic test interpreted by a trained GP (with referral to a cardiologist when the diagnosis is unclear) in
individuals with a positive screening test result.
For a single screen of a given age cohort, we found that strategies that use a higher age of screening were
more likely to be cost-effective. However, when allowing for the possibility of repeated screening strategies
with 5-year intervals, single screens were no longer found to be cost-effective. Instead, an initial screen
at age 65 or 70 years followed by repeat screens every 5 years until age 80 years was found to be most
likely to be cost-effective, provided that compliance with screening and treatment does not decline with
increasing age.
Strengths and limitations
We have conducted a comprehensive set of reviews of DTA studies (see Chapters 2 and 3), screening RCTs
(see Chapters 2 and 4) and the natural history of AF and screening for AF (see Chapter 5), with inclusion
criteria designed specifically for relevance to a general population screening programme for AF. In our
economic model we also make use of a recent systematic review, network meta-analysis and cost-effectiveness
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model of OACs37 (including both DOACs and warfarin) to fully reflect the costs and benefits of anticoagulation
therapy in screen-detected AF patients.
Screening tests
Although we were able to explore screening test and interpreter combinations, we were restricted by the
evidence that we identified in our systematic review of DTA studies. Only a small number of studies met
our inclusion criteria, not all screening test and interpreter combinations were included and, when present,
few observations were reported, leading to a lack of statistical power to detect meaningful differences.
None of the included studies was assessed to be at low risk of bias across all domains and to have low
concerns with regard to applicability. In particular, only four studies were conducted in primary care.
Although we had preplanned a wide range of subgroup analyses and sensitivity analyses, enough data
were available to perform only some of these.
Although photoplethysmography had very high test sensitivity, this estimate was based on a single study69
that was not based in a primary care setting, and for which the index test was rated as being at high risk
of bias and the applicability of the patient selection was unclear. Similarly, a 12-lead ECG interpreted by a
GP was evaluated in only a single study,70 which was at high risk of bias according to patient selection.
We are therefore cautious in interpreting the results from these screening tests.
Setting
We restricted our analyses to a primary care setting, but opportunistic screening could potentially be
conducted in other settings, for example community centres, such as pharmacies,104 or in secondary care
such as in elderly patients attending for minor surgery.136
Comparative evidence
For systematic opportunistic screening, a greater proportion of the 75 newly identified cases were
diagnosed outside the screening programme (44/75, 59%) than within it (31/75, 41%). One explanation
for this is that GPs in the systematic opportunistic screening arm changed their usual practice to check for
AF more frequently (the ‘Hawthorne effect’, in which behaviour changes when under observation). If this is
the case, then the full benefits seen in the systematic opportunistic arm may not be realised outside the
context of a RCT.
None of the RCTs identified in our review considered repeated screening, only a one-off screen.
We therefore do not have any comparative evidence on the effectiveness of repeated strategies.
We have considered screening programmes based only on age, rather than on other risk factors. The SAFE
study,19 however, found that systematic screening targeted at high-risk individuals had a similar rate of
identification of new AF cases as no screening, suggesting that targeted systematic screening is unlikely to
be cost-effective. A controlled before-and-after study evaluating the AliveCor ECG app used in primary
care to screen high-risk individuals is ongoing in Scotland (due to report in 2016),167 which will provide
more evidence on this question.
Other arrhythmias
Some false-positive patients may be diagnosed with another condition (e.g. atrial flutter), and therefore receive
some benefit from an AF screening programme. We did not capture this benefit in our model; however,
incorporating this would increase the cost-effectiveness of a population-based systematic screening programme.
Paroxysmal atrial fibrillation
Continuous monitoring devices are showing promise for detecting paroxysmal AF.22 Engdahl et al.22 found
that, in patients who screened negative on a 12-lead ECG but who had two or more risk factors based on
the CHADS2 score, a period of 2-week monitoring using a hand-held monitoring device identified 7.4% of
paroxysmal AF cases. This study specifically targeted high-risk individuals, however, and so it is unclear how
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large the yield would be in a general population. In the general population, paroxysmal AF patients may be
less likely to have a CHA2DS2-VASc score of > 1 and may be eligible to receive anticoagulation therapy.
Also, our review of natural history studies found that stroke risk is lower in patients with paroxysmal AF
than in those with persistent or permanent AF. If such devices were to be used in a screening context,
there would need to be clear instructions for their use, and there would also be concerns about the
devices not being returned.
Screening age
The studies informing many model inputs were primarily carried out with those in the age range 65–70
years, and we are therefore more confident about our results in this age range than in other age ranges.
We did not directly model the incidence of new cases of AF or the progression from paroxysmal AF to
persistent/permanent AF or from asymptomatic AF to symptomatic AF in the model of repeat screening –
we simply used information on population size, prevalence and previous diagnosis of AF at each age.
This assumes that the patterns of prevalence seen in the study by Norberg et al.2 would apply to a single
age cohort (i.e. no cohort or period effects). We assumed a 1% annual diagnosis rate in the absence of
screening, and that this did not change with increasing age. When we allowed a higher diagnosis rate in
the absence of screening of 5%, there was a suggestion that initiating a repeated screening strategy at
70 years rather than 65 years might be cost-effective.
Economic model
Our review of the literature for inputs to the economic model was the most comprehensive search of the
literature to date. We combined the results from multiple studies using meta-analysis when possible.
However, despite this, many inputs to the economic model relied on the results from a single trial.19 There
was no evidence on the proportion of 12-lead ECGs interpreted by a GP that are referred to a cardiologist
to help with interpretation, and so we had to rely on expert opinion. There was scant information on
patient characteristics of screen-detected AF cases and no data on the joint distribution of different risk
factors, so we had to assume that they were independent (which is unlikely, as, for example, those with a
previous history of MI may be more likely to have a previous history of stroke as well).
We took a NHS perspective, excluding the costs of participants, carers and other agencies. Attending for
screening is likely to have a financial impact on participants in terms of travel and time to attend screening,
particularly if they have to take time off work to attend.
If a nationwide primary care screening strategy using equipment not available in practices is adopted, then
investment in equipment will be required. This may act as a barrier to initiating screening. A recent review
found that 81% of practices have a 12-lead ECG machine available.44 Investment would therefore be
required for the 19% of practices that do not have a machine available. This would be required under all
screening strategies, because we assume that all positive screening tests would be followed by a diagnostic
12-lead ECG. Modified blood pressure monitors or photoplethysmography devices are not typically available
in primary care and, if these screening tests were adopted, this would represent a large capital investment.
Investment in photoplethysmography would be unwise without further research to better understand its
diagnostic performance in a primary care screening setting. We estimate that, for photoplethysmography
and modified blood pressure monitor screening strategies, for which all practices would have to purchase
equipment and some practices would also have to purchase 12-lead ECG equipment for confirmatory
testing, the investment needed would be approximately £2.4M and £3.0M respectively (see Table 52).
For strategies that require only some practices to purchase 12-lead ECG equipment for screening or
confirmatory testing (e.g. pulse palpation, ECG), the initial investment would be £2.2M.
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Research needs
Screening test accuracy
Our study was restricted to comparing screening tests that had been evaluated in DTA studies that used a
12-lead ECG interpreted by a cardiologist as the reference standard. Only 15 studies met our inclusion
criteria, and of those only four were carried out in a primary care or community setting, which is where we
envisage screening taking place. When replicates existed of the same screening test/interpreter combination,
heterogeneity in results was observed. This suggests a need to replicate the results based on a single study or
few studies. In particular, the DTA results for photoplethysmography were based on a single study69 rated as
being at high risk of bias for the index test and conducted outside a primary care setting. Robust evidence
on the performance of this device in a primary care screening setting, for a range of cut-off values, would
be of merit. Such a study should also record information on hygiene, use in people with skin conditions, ease
of use, durability, length of test time and sensation.
We found that a 12-lead ECG interpreted by a GP had a very good diagnostic performance compared with
a 12-lead ECG interpreted by a cardiologist/specialist. However, this was based on a single study70 that
was at high risk of bias with regard to patient selection. A study to replicate this result in a screening
population in a format that reflects how screening is likely to be implemented (i.e. ECGs interpreted by a
trained GP with referral to a cardiologist/specialist in cases that are unclear) may be of value, although
resources may be better directed towards training GPs in the interpretation of ECGs for diagnosing AF.
Such a study would also be able to provide information on the proportion of ECGs that are unclear and
that would thus be referred to a cardiologist/specialist, which was an assumption in our economic model.
The development of new devices to detect AF is a fast-moving area, and a horizon-scanning exercise to
identify new literature as it becomes available, and to update our review, would be of value. It should be
noted that we assumed that only a small proportion of paroxysmal AF would be detected by the screening
strategies that we considered. However, the availability of newer technologies that allow for intensive
testing over a period of time would allow a higher proportion of paroxysmal AF cases to be detected.
More intensive screening tests are likely to be more costly and to incur initial capital investment, although
this would not necessarily be the case, for example in the case of smartphone apps. Studies comparing the
DTA of smartphone apps with that of a 12-lead ECG interpreted by a cardiologist/specialist reference
standard are needed. The benefits of detecting paroxysmal AF through screening also need to be better
understood, to help evaluate more intensive screening tests.
Comparative effectiveness of screening strategies for atrial fibrillation
The primary comparative evidence of effectiveness of screening strategies remains the SAFE study.19 This is
a well-conducted study, but it evaluates only a single screen for a given age range and does not follow up
to measure long-term outcomes of screening or the value of repeat screening. To fully evaluate the benefits
of a screening programme and change practice, there is a need for a comparative study that measures
long-term outcomes (stroke and mortality) for a screening strategy compared with a no screening strategy.
The ongoing STROKESTOP study should provide evidence on this over a longer follow-up period than
previous studies;26,40 however, the results are specific to the format of screening used (intermittent ECG over
2 weeks). Because an intensive screening test was used in the STROKESTOP study, a large proportion of those
with newly detected AF will have paroxysmal AF. This study should therefore provide valuable evidence on
the impact of screening on long-term outcomes for paroxysmal AF patients. The benefits of early detection of
AF through screening will depend on the subsequent medical care and anticoagulation therapy used. The
generalisability of the results of the STROKESTOP study will depend in part on how similar the use of
anticoagulation therapies for AF patients is between Sweden and the UK.
Given the huge number of potential screening strategies (test, interpreter, age at initial screen, screening
interval, age at final screen, systematic opportunistic screening, systematic population screening, systematic
targeted screening, setting) it is not possible to design a primary research study to evaluate all combinations.
Some form of modelling/simulation is therefore necessary to evaluate different options to identify those that
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are most likely to be effective so that they can be evaluated further in a primary research study. The design
of such a primary research study may take the form of a cluster randomised factorial trial and make use of
linked electronic health records. This is likely to be challenging because of the fast-moving development of
screening test technologies. Uncertainties in the economic model that a RCT could inform include the
uptake of screening by age and sex, patient characteristics of those with screen-detected AF (including
CHA2DS2-VASc score), the proportion of patients diagnosed in the absence of screening and reason for
diagnosis (event, symptoms or other) and anticoagulation therapies used (including the proportion of OACs
that are DOACs).
We have focused on screening in a primary care setting. Further research into alternative settings including
secondary care (e.g. outpatient clinics) and community settings (e.g. pharmacies) would be of value.
Repeat screening
To thoroughly assess repeat screening strategies, good evidence is required on the incidence of new cases
of AF (and the proportion of these that are undiagnosed), progression from paroxysmal to persistent/
permanent AF, progression from asymptomatic to symptomatic AF and the diagnosis rate in the absence of
screening that is not a result of an AF-related stroke. A large epidemiological study with linked electronic
health records may be the most efficient way to provide some of this evidence; however, such a study may
not identify undiagnosed AF that could be identified by screening. A nested follow-on study to a cluster RCT
of screening could be conducted in those who were screened and who tested negative, by randomising
individuals to a repeat screen after 5 years or not. This would provide evidence on the incidence of AF that
is diagnosed and undiagnosed and the yield of a repeat screen. All previous models of repeat screening
(including ours) use routinely collected data on the prevalence/incidence of AF, which likely underestimates
undiagnosed AF cases.
Implementation of screening
The economic model results were sensitive to the proportion of flagged individuals who have their pulses
checked. This proportion was estimated to be very different (30% and 66%) in the two studies that
reported it19,82 and a high degree of variability was seen across practices.19 Research on the effectiveness of
implementation strategies to improve the proportion of pulses that are taken among flagged individuals
would be of value if a systematic opportunistic screening strategy were recommended.
Implications for practice
Screening method
Our findings support the use of systematic opportunistic screening for AF, with evidence that a screening
strategy with an initial screen at age 65 years and repeated screens every 5 years until age 80 years is likely
to be cost-effective. Operationalising opportunistic screening would require some training of clinicians,
possibly using age-triggered prompts in the electronic medical record and simple practice-level protocols to
ensure that patients in whom AF is suspected based on the screening test are offered an ECG. The practice
protocol, based on national guidance, would need to specify who to invite, operationalised through the
Read coding of patients to exclude individuals with a previous diagnosis of AF, as it can be distressing to
patients to be invited to screening for a condition that they know they have. Similar systems are in place
for other screening programmes (e.g. breast and cervical screening), suggesting that such a system could
be implemented for AF screening.
Wright et al.173 found that a multifaceted intervention programme aimed at health professionals in primary care
led to an increase in detection of AF cases, highlighting the need for an implementation strategy to embed
screening in general practices. Several studies performed screening alongside influenza vaccination,117,118 but
yield was fairly low. Another study174 looked at changes in AF detection rates in practices that implemented the
NHS Health Checks programme compared with practices that did not implement the NHS Health Checks
programme and found no difference in detection rates. This is perhaps not surprising, as AF was not an aim of
the NHS Health Checks programme, although it could be in the future.
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Screening test
As discussed earlier, we do not consider photoplethysmography to be appropriate for a screening study
until further evidence on its diagnostic performance has been collected. The next most cost-effective
screening tests were modified blood pressure monitors and nurse pulse palpation. Modified blood pressure
monitors are not available in most practices. If modified blood pressure monitors were to be recommended
as the screening test in a national screening programme, an investment in the devices would be required
(see Chapter 6, Strengths and limitations). This could be implemented over a period of time by replacing
existing blood pressure monitors at the end of their lifespan with modified devices. As well as the capital
cost, training would be required in their use, although the automatic interpretation algorithm would
potentially be simpler to interpret than pulse palpation. A screening programme could therefore allow
both screening tests as options, with practices without a modified blood pressure monitor using pulse
palpation by a nurse for screening. Potentially, a nationwide screening programme could be rolled out in a
stepped or otherwise randomised fashion, enabling additional evidence to be collected on the optimal
screening strategies.
A recent review44 found enthusiasm for screening in primary care but a recognised need for the training of
nurses. Barriers to AF screening were listed as lack of time, workload, lack of appointments, staffing levels,
access to equipment, funding, waiting times at anticoagulation clinics and the cost of anticoagulation
therapies. These resource issues would need to be addressed if a national screening programme were to be
adopted. Taggar et al.44 found that health-care assistants and nurses were mostly responsible for conducting
ECGs, with interpretation by GPs, but these staff reported that they would benefit from training. In the
future, pulse palpation and use of modified blood pressure monitors and ECG machines could become a
core part of training and continued professional development for nurses and health-care assistants. The
review44 found that only 81% of practices had an ECG machine. Under all of our screening strategies, we
assumed that a diagnostic 12-lead ECG interpreted by a trained GP (with referral to a cardiologist/specialist
in cases that are unclear) would be conducted in those who screen positive, and so an additional investment
in an ECG machine would be required in the 19% of practices that do not already have one. This investment
would also be used for other indications as well as AF, and so would bring additional benefits.
Other arrhythmias
A consequence of screening for AF is that other arrhythmias, such as atrial flutter, may be detected.
This is not captured in our economic model. Assuming that routine care for patients with other
arrhythmias is cost-effective, then the detection of these patients through screening would only increase
the cost-effectiveness of a screening programme. It is important that individuals who are invited to be
screened understand that other arrhythmias, as well as AF, may be detected and that, if they are
diagnosed, they are fully informed of the risks and treatment options.
Future developments
New devices to detect AF are becoming available and are under evaluation (patches, smartphone/watch
devices, iPads, hand-held devices), as well as devices used for other reasons that can also detect AF
(pacemakers, ICDs and implantable loop recorder devices). These innovations may be of relevance to a
screening programme when their diagnostic performance is better understood.
Patient perspective
To validate an AF screening programme, it is essential to raise awareness and understanding of the
condition: its symptoms, impact and outcomes (stroke risk), lifestyle changes, how it can be managed and
surgical implications and drugs to correct heart rate and rhythm, as well as the need for anticoagulation.
Many people do not know what AF is unless they or someone close to them has personal experience of it.
Therefore, any screening programme must aim to increase awareness, diagnosis, treatment and prevention.
It is important that patients understand that anticoagulation therapy aims to prevent stroke and does not
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provide a cure for AF or reduce symptoms. Receiving a diagnosis of AF creates anxiety for patients, and
therefore appropriate counselling is important.
If a screening programme were introduced, a screening pathway would need to be developed with
step-by-step guidance with regard to the process and, most importantly, health-care professionals
conducting any screening process must have specialist knowledge of all aspects of the condition,
treatments, symptoms and risks.
Both the screening test and follow-up diagnostic test would need to be timely and convenient to the
individual. Lack of mobility and age were listed as reasons for not attending screening in the SAFE study.19
Community screening (e.g. pharmacy or similar) may be an option to increase uptake in the population
and raise awareness at the same time. Provision of transport to and from practices may also increase
participation. Another possibility would be to include a screening test for AF alongside another health
programme (e.g. NHS Health Check) to minimise visits to the GP. A one-stop shop approach with
screening test, diagnostic test, counselling and onward referral undertaken in one session may also be
more convenient for individuals and would minimise individuals being ‘lost’ in the screening process.
Conclusions
A national screening programme for AF is likely to represent a cost-effective use of resources. Systematic
opportunistic screening is more likely to be cost-effective than systematic population screening. Nurse
pulse palpation or modified blood pressure monitors (if available) would be appropriate screening tests,
followed by a diagnostic 12-lead ECG interpreted by a trained GP in those who screen positive, with
referral to a specialist in cases in which diagnosis is unclear. Implementation strategies to operationalise the
uptake of opportunistic screening in primary care should accompany any screening recommendations.
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Appendix 1 Search strategy for the diagnostic
test accuracy review
The MEDLINE search strategy for the DTA review is provided below.
1. exp Atrial Fibrillation/ (35,633)
2. (atrial adj3 fibrillat$).ti,ab. (41,204)
3. ((auricular adj3 fibrillat$) or (supraventricul$ adj3 arrhythmi$)).ti,ab. (3058)
4. or/1-3 (51,726)
5. “Sensitivity and Specificity”/ (282,088)
6. ((diagnos$ or screening or triage) adj3 (accurate$ or accuracy)).ti,ab. (57,907)
7. ((sensitivity or specificity) adj6 (diagnos$ or screen$ or detect$ or PAF or AF)).ti,ab. (75,779)
8. ((diagnos$ or detect$) adj3 (rate or yield or PAF)).ti,ab. (27,930)
9. or/5-8 (392,368)
10. 4 and 9 (1684)
11. exp *Atrial Fibrillation/di [Diagnosis] (2201)
12. ((diagnos$ or underdiagnos$ or detect$ or identif$ or screen$ or predictive value$) adj6 (PAF or AF or
atrial fibrillat$)).ti,ab. (4539)
13. *diagnosis/ or diagnosis, computer-assisted/ or diagnosis, differential/ or early diagnosis/ or predictive
value of tests/ or ROC curve/ (584,709)
14. 11 or 12 or (13 and 4) (8483)
15. Electrocardiography, Ambulatory/ (9052)
16. (holter or single lead or 12-lead or event monitor$ or event record$ or loop record$ or ELR).ti,ab.
(15894)
17. 15 and 16 (4003)
18. *Electrocardiography, Ambulatory/ (2842)
19. ((ECG or iECG or electrocardiogra$ or EKG) adj3 (single lead or serial or intermittent or bipolar or
bi-polar or thumb or short-term or 12-lead or ambulatory or portable)).ti,ab. (9039)
20. ((ECG or iECG or electrocardiogra$ or EKG) adj6 (ELR or holter or event monitor$ or event record$ or
loop record$)).ti,ab. (3589)
21. ((holter or cardiac event or R-test or 7-day) adj3 monitor$).ti,ab. (4951)
22. Pulse/ and (palpation/ or palpat$.ti,ab.) (217)
23. (pulse adj3 (finger-tip or palp$)).ti,ab. (404)
24. finger probe$.ti,ab. (87)
25. Watchbp.ti,ab. (18)
26. (exp Sphygmomanometers/ or Blood pressure Monitoring, ambulatory/) and (modified or atrial fibrillat$
or PAF or AF).ti,ab. (173)
27. ((modified or atrial fibrillat$ or PAF or AF) adj3 (BP monitor$ or blood pressure monitor$ or
sphygmomanomet$)).ti,ab. (41)
28. photoplethysmograph$.ti,ab. (1628)
29. ((reveal or implantable) adj3 device$).ti,ab. (3458)
30. ((mobile or i-phone) adj3 app$).ti,ab. (1564)
31. or/17-30 (24,262)
32. 14 and 31 (725)
33. 10 or 32 (2181)
34. letter/ (858,649)
35. editorial/ (366,888)
36. news/ (165,913)
37. exp historical article/ (322,828)
38. Anecdotes as topic/ (4584)
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39. comment/ (607,051)
40. case report/ (1,706,134)
41. (letter or comment$).ti. (100,072)
42. or/34-41 (3,406,548)
43. randomized controlled trial/ or Randomized Controlled Trials as Topic/ or random$.ti,ab. (883,882)
44. 42 not 43 (3,375,361)
45. animals/ not humans/ (3,881,514)
46. exp Animals, Laboratory/ (728,296)
47. exp Animal Experimentation/ (6461)
48. exp Models, Animal/ (422,793)
49. exp rodentia/ (2,679,540)
50. (rat or rats or mouse or mice).ti. (1,120,787)
51. or/44-50 (7,862,299)
52. 33 not 51 (1961)
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Appendix 2 QUADAS-2 quality assessment
Ideal study 
Population:  People who have not sought medical attention on account of 
symptoms associated with AF 
Presentation:  Asymptomatic/not sought medical attention on account of 
symptoms associated with AF presenting to primary care or the 
community (for example community pharmacists). Individuals 
may be invited to screening regardless of medical history (this 
may be done on the basis of age, systematic screening); present to 
the GP for an unrelated issues (for example flu vaccination, 
opportunistic screening); or based on their medical history/the 
presence of risk factors that are associated with AF (targeted 
screening)    
Prior tests:   No prior testing for AF 
Index test:  Any non-invasive test that could be utilised in a primary care 
setting or the community 
Purpose:  Screening test, to identify people with AF who have not sought 
medical attention on account of symptoms associated with AF 
Target disorder:  AF 
Reference standard:  12-lead ECG interpreted by a cardiologist  
 
The ‘ideal’ study for AF screening tests 
Low risk of bias 
• A consecutive or random sample of people was enrolled 
• A case-control design was avoided 
• Inappropriate exclusions were avoided (for example the presence of a different 
condition that may cause arrhythmia for example atrial flutter, supraventricular 
tachycardia, ventricular tachycardia, ventricular fibrillation, heart block, tachy-
brady syndrome) 
• The index test was objective or was interpreted without knowledge of the 
reference standard. 
• The reference standard was a gold standard diagnostic technique (12-lead ECG 
interpreted by a cardiologist) 
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• The reference standard was objective or was interpreted without the knowledge 
of the index test. 
• All index tests and the reference standard were performed concurrently. 
• If cut-offs were used these were pre-specified. 
• All participants received all tests and the reference standard.   
• There were no unclear/uninterpretable test results. 
• All participants were included in the analysis 
 
High applicability 
• The population is asymptomatic/has not sought medical attention on account of 
symptoms associated with AF. The population has undergone no prior testing 
for AF. 
• The population was recruited into the screening study based on: 
o No criteria or age (‘ideal’ for systematic screening) 
o Presentation to the GP/other setting for an issue unrelated to AF (‘ideal’ 
for opportunistic screening) 
o Medical history/presence of risk factors associated with AF (‘ideal’ for 
targeted screening) 
• The test is performed and interpreted in primary care or the community. 
• The reference standard is the gold standard diagnostic technique (12-lead ECG 
interpreted by a cardiologist) 
 
QUADAS-2 
Domain 1: Patient selection 
Risk of Bias:   Could the selection of patients have introduced bias? 
Describe the method of patient selection 
Signalling question 1:  Was a consecutive or random sample of patients enrolled? 
Yes/No/Unclear 
Yes    If a consecutive or random samples of patients was enrolled. 
Signalling question 2:  Was a case control-design avoided? 
Yes/No/Unclear 
Yes  If the study did not use a two-gate entry procedure (i.e did not 
include any patients on the basis of having diagnosed AF) 
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Signalling question 3:  Did the study avoid inappropriate exclusions? 
Yes/No/Unclear 
Yes  If inappropriate exclusions were avoided (for example excluding 
based on the presence of a different condition that may cause 
arrhythmia for example atrial flutter, supraventricular 
tachycardia, ventricular tachycardia, ventricular fibrillation, heart 
block, tachy-brady syndrome) 
 Appropriate exclusions: diagnosed AF; patients with paced 
rhythms/pacemakers/defibrillators/other cardiac devices; severe 
medical condition preventing participation (e.g. severe dementia 
or terminal illness); age  
Unclear If exclusions are not detailed 
Conclusion:  Could the selection of patients have introduced bias? 
High/Low/Unclear 
(If the response to all the signalling questions is ‘yes’ the study can be considered 
at a low risk of bias; if the response to question 2 is ‘no’ (i.e. a case-control design 
was used) then it will be judged that the study is at high risk of bias)  
 
Applicability:  Are there concerns that the included patients and setting do not 
match the review question? 
Describe included patients (prior testing, presentation, intended use of index test and 
setting) 
Signalling question 1:  Was the population asymptomatic/had not sought medical 
attention on account of symptoms associated with AF? 
Yes/No/Unclear 
Signalling question 2:  Was the population recruited from primary care/the 
community? 
Yes/No/Unclear 
Signalling question 3:  Was inclusion into the study independent of the results of 
prior testing that could be used to detect AF? 
Yes/No/Unclear 
Type of screening programme question:  
Was the population recruited based on:  
 No criteria or age (systematic screening)  
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 Presentation to the GP/other setting for an issue unrelated to AF 
(opportunistic screening)  
 Medical history/presence of risk factors associated with AF 
(targeted screening). NB GRASP-AF score includes items for 
congestive heart failure, hypertension, age≥75, diabetes mellitus, 
prior stroke/TIA/thromboembolism and vascular disease.  
 Other   
Signalling question 4:  Was the population representative of the population that 
would be expected to be tested by systematic screening, 
opportunistic screening or targeted screening? 
Yes/No/Unclear 
Conclusion:  Are there concerns that the included patients and setting do 
not match the review question?  
High/Low/Unclear 
(If the response to all the signalling questions is ‘yes’ then concerns over 
applicability are low. If the population was not recruited from primary care/the 
community then applicability concerns are high)  
 
Domain 2: Index test 
Risk of Bias:   Could the conduct or interpretation of the index test have 
introduced bias? 
Describe the index test and how it was conducted and interpreted: 
Signalling question 1:  Were the index test results interpreted without knowledge 
of the results of the reference standard? 
Yes/No/Unclear 
Yes  If the index test was always conducted and interpreted before the 
reference standard, or  
If the index test was objective, or  
If the interpreters of the index test were blinded to the results of 
the reference standard. 
Signalling question 2:  If a threshold was used, was it pre-specified? 
Yes/No/Unclear/NA 
Yes  If threshold used were pre-specified, and were not defined post-
hoc based on study data.  
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Signalling question 3: Did the person interpreting the index test have access to 
information or training that would not be available if the test was 
to be performed in the community/in primary care? 
Conclusion:   Could the conduct or interpretation of the index test have 
introduced bias?  
Yes/No/Unclear 
(If the response to all the signalling questions is ‘yes’ the study can be considered 
at a low risk of bias. If the threshold was not pre-specified then the risk of bias is 
high)  
 
Applicability:  Are there concerns that the index test, its conduct, or its 
interpretation differ from the review question? 
Signalling question 1: Was the index test performed in primary care or the community? 
Yes/No/Unclear 
Signalling question 2: Was the index test interpreted in primary care, in the community, 
or using an automated method? 
Yes/No/Unclear 
Signalling question 3: Was the index test performed and interpreted without the person 
performing and interpreting the test having to undergo special 
training? 
Signalling question 4: Were the same clinical data available when the test was 
interpreted as would be available when the test was used in 
practice? 
Yes If interpreters had accesses to the same clinical data as when the 
test would be interpreted in practice. NB studies that blinded 
interpreters to clinical data are still of high applicability because 
it may be that GP notes and medical records are not available in a 
screening setting. 
Conclusion:  Are there concerns that the index test, its conduct, or its 
interpretation differ from the review question? 
High/Low/Unclear 
(If the response to all the signalling questions is ‘yes’ then concerns over 
applicability are low. If the index test was interpreted by a cardiologist/someone in 
secondary care then the concerns about applicability are high.)  
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Domain 3: Reference standard 
Risk of Bias:  Could the reference standard, its conduct or its interpretation 
have introduced bias? 
Describe the reference standard and how it was conducted and interpreted 
Signalling question 1: Is the reference standard likely to correctly classify AF 
Yes  If 12-lead ECG interpreted by a cardiologist  
 
Signalling question 2:  Were the reference standard results interpreted without 
knowledge of the results of the index test? 
Yes/No/Unclear 
Yes  If the reference standard was always conducted and interpreted 
before the reference standard or if the reference standard was 
objective or if the interpreters of the reference standard were 
blinded to the results of the index test. 
Conclusion:  Could the conduct or interpretation of the reference test have 
introduced bias? 
High/Low/Unclear 
(If the response to all the signalling questions is ‘yes’ the study can be considered 
at a low risk of bias.)  
 
Applicability: Are there concerns that the target condition as defined by the 
reference standard does not match the condition?  
Conclusion:  Are there concerns that the target condition as defined by the 
reference standard does not match the condition?  
 High/Low/Unclear 
(Low if 12-lead ECG interpreted by a cardiologist) 
Domain 4: Flow and timing 
Risk of Bias:   Could the patient flow have introduced bias? 
Describe any patients who did not receive the index test(s) and/or reference standard or 
who were excluded from the 2x2 table (refer to flow diagram) 
Describe the time interval and any interventions between index test(s) and reference 
standard 
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Signalling question 1: Were the index test and reference standard performed within 7 
days of each other? 
Yes/No/Unclear 
Signalling question 2: Did all patients receive the same reference standard? 
 Yes/No/Unclear 
Yes If all patients received the same reference standard 
Signalling question 3: Were ≥80% of patients included in the analysis?  
Yes/No/Unclear 
Yes  If <20% of participants were excluded due to missing/un-
interpretable tests? 
Conclusion:  Could the patient flow have introduced bias? 
High/Low/Unclear 
(If the response to all the signalling questions is ‘yes’ the study can be considered 
at a low risk of bias) 
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Appendix 3 Methods for meta-analysis of the
diagnostic test accuracy studies
We assumed that the reference test is perfectly accurate, and so we used the HSROC model ofRutter and Gatsonis53 to estimate the sensitivity and specificity of the index (experimental) test. We
reparameterised the slope/asymmetry of their model to be multiplicative rather than exponential, thus
easing interpretation, but the two parameterisations are equivalent. Each study i can include several groups
j being tested by the same test. Each of these groups within studies are referred to as separate observations
and are the unit of our analysis. All included studies reported the number of true positives, false positives,
true negatives and false negatives for each of these observations.
For each separate index test, we used the notation in Table 53 where riD is the number of ‘true positives’,
niD – riD is the number of ‘false negatives’, siD is the number of ‘false positives’ and niD− siD is the number of
‘true negatives’ in observation j of study i of the index test.
We used the following likelihood for these observations:
rijD ∼ Bin(π ij1, nijD) (sensitivity or 0true positives0) (1)
sijD ∼ Bin(π ij2, nijD) (1− specificity or 0false positives0), (2)
for i = 1,. . .,N1 indicating the trials comparing the index to the reference test and observations j = 1,. . .,
Nobsi in trial i. Logistic link functions were used to model the probabilities:
logit(π ij1) = β × θij +
1
2
αij (3)
logit(π ij2) = θij −
1
2
αij, (4)
with a random effect on the parameters to model between-observation (within-trial) variation:
θij ∼ N(qi,ω
2
1) (5)
αij ∼N(ai,ω22). (6)
We used a hierarchical model for the parameters to capture between-study variation:
qi ∼ N(Θ, σ
2
1) (7)
ai ∼ N(Λ, σ22), (8)
TABLE 53 Notation for DTA study results for observation group j of study i
AF status Positive test Negative test Total
AF rijD nijD − rijD nijD
No AF sijD nijD − sijD nijD
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with priors on the hyper-parameters:
β ∼ N(0, 104) (9)
θ ∼ N(0, 104) (10)
Λ∼N(0, 104) (11)
ωm ∼ U(0, 5), l = 1, 2 (12)
σm ∼ U(0, 5), l = 1, 2, (13)
where θ is the (absolute) threshold of the index test and increasing it increases both the number of true
positives and the number of false positives, Λ is the (absolute) accuracy of the test and determines how
good it is at distinguishing between true positives and false positives, and β is a slope parameter
representing asymmetry around the central diagonal of the SROC curve. This slope may be dropped if too
few data are available to fit the model or if model choice criteria (e.g. residual deviance, DIC) indicate that a
symmetric SROC would provide a better fit.
The ω2m and σ
2
m are the between-observation and between-study variances respectively. We investigated a
fixed-effects model, which assumes no such variation between tests:
logit(π ij1) = β × Θ +
1
2
Λ (14)
logit(π i j2) = Θ −
1
2
Λ. (15)
Some test groups (observations) in the same study differed only in the interpreter used (e.g. two different
nurses or a GP in one group and a cardiologist in another, interpreting the same single-lead ECG).
These are considered as independent observations (e.g. two separate groups of individuals receiving an
ECG interpreted by nurse). However, two analyses of included tests were conducted. One defined tests
independently of interpreter (i.e. a single-lead ECG interpreted by a nurse and a GP were considered the
same test) and the other defined tests by interpreter (e.g. a single-lead ECG interpreted by a nurse and a
GP was considered to comprise two different types of test). A choice between these units of analyses was
made on the basis of convergence, residual deviance and DIC.
Summary sensitivities and specificities were produced using the posterior means of the following functions
of the hyper-parameters:
logit(sensitivity) = β × Θ +
1
2
Λ (16)
logit(1− specificity) = Θ−
1
2
Λ. (17)
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The DOR is defined as:
DOR =
sensitivity2
(1− specificity)2
, (18)
which reduces to:
DOR = eΛ. (19)
Subgroup analyses were mostly binary categories, in which the model was fitted for each group separately.
The exception was prevalence of AF, which was explored using regression with covariates xij (AF prevalence),
centred on mean x over all studies and observations, using the model:
θij ∼ N(qi + (xij −x)γ,ω
2
1) (20)
αij ∼N(ai + (xij −x)λ,ω22), (21)
in which the index test-specific regression coefficients were given the following priors:
γ ∼ N(0, 104) (22)
λ∼ N(0, 104). (23)
Alternative assumptions: independent and exchangeable slopes
In the above model, a common slope β was assumed for every test. We also considered the model in
which the slope βk for each test k is independent with priors:
βk ∼ N(0, 10
4). (24)
We also considered the model in which the slopes are exchangeable and follow the distribution:
βk ∼ N(β, σ
2
β ), (25)
with priors:
β ∼ N(0, 104) (26)
σβ ∼ U(0, 5). (27)
We chose between the four possible slope assumptions (no slope, common slope, independent slope,
exchangeable slope) on the basis of convergence, residual deviance and DIC.
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WinBUGS code
Random-effects hierarchical summary receiver operating characteristic model
# Inputs needed are 
# tp[i,j,k], fp[i,j,k], pos[i,j,k], neg[i,j,k] i.e. summaries from 
the 2x2 tables for replication i, study j, the kth test for study j 
# You may want to re-order the indexes to make it easier for data 
input to the arrays. 
# ntests[j] a vector with number of tests per study 
# nreps[j,k] the number of replcations of the kth test of study j 
# t[j,k] indicates the test number for the kth test of study j. 
# NTests is the total number of tests 
# N1 is the number of studies with 2x2 data (ie your type 1 and type 
3 studies) 
# N2 is the number of studies with sensitivity/specificity data 
# sens.mean[i,j,k] is the estimated sensitivity in ith rep of the 
k'th test in study j, and sens.prec[i,j,k] is it's precision. 
 
Model{ 
#Loop over studies reporting 2x2 tables. i=rep no., k=test no. in 
study j 
for (j in 1:N1){ 
 for (k in 1:ntests[j]){ 
  for (i in 1:nreps[j,k]){ 
   tp[i,j,k]~dbin(pi1[i,j,k],pos[i,j,k]) 
 #Likelihood 
   fp[i,j,k]~dbin(pi2[i,j,k],neg[i,j,k]) 
   tphat[i,j,k]<-pi1[i,j,k]*pos[i,j,k]  
 #Fitted values 
   fphat[i,j,k]<-pi2[i,j,k]*neg[i,j,k] 
   dev.tp[i,j,k]<-(2*(tp[i,j,k]*(log(tp[i,j,k])-
log(tphat[i,j,k]))  #Deviance contibution tp 
            +  (pos[i,j,k]-tp[i,j,k])*(log(pos[i,j,k]-tp[i,j,k]) - 
log(pos[i,j,k]-tphat[i,j,k])))) 
   dev.fp[i,j,k]<-(2*(fp[i,j,k]*(log(fp[i,j,k])-
log(fphat[i,j,k]))  #Deviance contibution fp 
            +  (neg[i,j,k]-fp[i,j,k])*(log(neg[i,j,k]-fp[i,j,k]) - 
log(neg[i,j,k]-fphat[i,j,k]))))   
  } 
  dev[j,k]<-sum(dev.tp[1:nreps[j,k],j,k]) + 
sum(dev.fp[1:nreps[j,k],j,k])  
 } 
 sumdev[j]<-sum(dev[j,1:ntests[j]]) 
} 
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totresdev<- sum(sumdev[]) 
 
#Loop over all studies 
for (j in 1:(N1)){ 
 for (k in 1:ntests[j]){ 
  for (i in 1:nreps[j,k]){ 
   logit(pi1[i,j,k])<- beta[t[j,k]]*theta[i,j,k] 
+alpha[i,j,k]/2  #Model for sensitivity 
   logit(pi2[i,j,k])<- theta[i,j,k] - alpha[i,j,k]/2
      #Model for (1-specificity) 
   theta[i,j,k]~dnorm(q[j,k],p.reps[1])  
 #Between rep variability 
   alpha[i,j,k]~dnorm(a[j,k],p.reps[2]) 
  } 
  q[j,k]~dnorm(Q[t[j,k]],p.stud[1])   #Between 
study variability 
  a[j,k]~dnorm(A[t[j,k]],p.stud[2]) 
 } 
} 
 
#PRIORS 
for (k in 1:NTests){ #Loop over tests 
 Q[k]~dnorm(0,.0001) 
 A[k]~dnorm(0,.0001) 
 log(beta.true[k])<-l.beta.true 
 beta[k]<- include.slope[k]*beta.true[k] + (1-include.slope[k]) 
} 
l.beta.true~dnorm(0,.0001) 
 
for (m in 1:2){ 
 p.stud[m]<-pow(sd.stud[m],-2) 
 p.reps[m]<-pow(sd.reps[m],-2) 
 sd.stud[m]~dunif(0,5) 
 sd.reps[m]~dunif(0,5) 
 
 # Save the prior distributions 
 sd.stud.prior[m]~dunif(0,5) 
 sd.reps.prior[m]~dunif(0,5) 
} 
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 # Posterior and posterior predictive distritbutions 
 for(k in 1:NTests){ 
  theta.pred[k]~dnorm(Q[k],p.stud[1]) 
  alpha.pred[k]~dnorm(A[k],p.stud[2]) 
  logit(sens.pred[k])<-
beta[k]*theta.pred[k]+0.5*alpha.pred[k] 
  logit(fpr.pred[k])<-theta.pred[k]-0.5*alpha.pred[k] 
  spec.pred[k]<- 1 - fpr.pred[k]  
 
  logit(TPR[k])<-(beta[k]*Q[k]+A[k]/2) 
  logit(FPR[k])<-(Q[k]-A[k]/2) 
  sensitivity[k]<-TPR[k] 
  specificity[k]<-1-FPR[k] 
 
  # Diagnostic odds ratio 
  dor[k]<-(sensitivity[k]*specificity[k])/((1-
sensitivity[k])*(1-specificity[k])) 
  #DOR[k] <- exp(A[k]) 
 } 
} 
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Fixed-effects model
# Fixed effects over both studies and reps 
model.DTA.meta.analysis.noType2.fixed<-function(){ 
#Loop over studies reporting 2x2 tables. i=rep no., k=test no. in 
study j 
for (j in 1:N1){ 
 for (k in 1:ntests[j]){ 
  for (i in 1:nreps[j,k]){ 
   tp[i,j,k]~dbin(pi1[i,j,k],pos[i,j,k]) 
 #Likelihood 
   fp[i,j,k]~dbin(pi2[i,j,k],neg[i,j,k]) 
   tphat[i,j,k]<-pi1[i,j,k]*pos[i,j,k]  
 #Fitted values 
   fphat[i,j,k]<-pi2[i,j,k]*neg[i,j,k] 
   dev.tp[i,j,k]<-(2*(tp[i,j,k]*(log(tp[i,j,k])-
log(tphat[i,j,k]))  #Deviance contibution tp 
            +  (pos[i,j,k]-tp[i,j,k])*(log(pos[i,j,k]-tp[i,j,k]) - 
log(pos[i,j,k]-tphat[i,j,k])))) 
   dev.fp[i,j,k]<-(2*(fp[i,j,k]*(log(fp[i,j,k])-
log(fphat[i,j,k]))  #Deviance contibution fp 
            +  (neg[i,j,k]-fp[i,j,k])*(log(neg[i,j,k]-fp[i,j,k]) - 
log(neg[i,j,k]-fphat[i,j,k]))))   
  } 
  dev[j,k]<-sum(dev.tp[1:nreps[j,k],j,k]) + 
sum(dev.fp[1:nreps[j,k],j,k])  
 } 
 sumdev[j]<-sum(dev[j,1:ntests[j]]) 
} 
 
totresdev<- sum(sumdev[]) 
 
#Loop over all studies 
for (j in 1:(N1)){ 
 for (k in 1:ntests[j]){ 
  for (i in 1:nreps[j,k]){ 
   logit(pi1[i,j,k])<- beta[t[j,k]]*Q[t[j,k]] + 
A[t[j,k]]/2  #Model for sensitivity 
   logit(pi2[i,j,k])<- Q[t[j,k]] - A[t[j,k]]/2 
     #Model for (1-specificity) 
  } 
  
 } 
} 
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#PRIORS 
for (k in 1:NTests){ #Loop over tests 
 Q[k]~dnorm(0,.0001) 
 A[k]~dnorm(0,.0001) 
 log(beta.true[k])<-l.beta.true 
 beta[k]<- include.slope[k]*beta.true[k] + (1-include.slope[k]) 
} 
l.beta.true~dnorm(0,.0001) 
 
for (m in 1:2){ 
 p.stud[m]<-pow(sd.stud[m],-2) 
 p.reps[m]<-pow(sd.reps[m],-2) 
 sd.stud[m]~dunif(0,5) 
 sd.reps[m]~dunif(0,5) 
 
 # Save the prior distributions 
 sd.stud.prior[m]~dunif(0,5) 
 sd.reps.prior[m]~dunif(0,5) 
} 
 
 # Posterior and posterior predictive distritbutions 
 for(k in 1:NTests){ 
  theta.pred[k]~dnorm(Q[k],p.stud[1]) 
  alpha.pred[k]~dnorm(A[k],p.stud[2]) 
  logit(sens.pred[k])<-
beta[k]*theta.pred[k]+0.5*alpha.pred[k] 
  logit(fpr.pred[k])<-theta.pred[k]-0.5*alpha.pred[k] 
  spec.pred[k]<- 1 - fpr.pred[k]  
 
  logit(TPR[k])<-(beta[k]*Q[k]+A[k]/2) 
  logit(FPR[k])<-(Q[k]-A[k]/2) 
  sensitivity[k]<-TPR[k] 
  specificity[k]<-1-FPR[k] 
 
  # Diagnostic odds ratio 
  dor[k]<-(sensitivity[k]*specificity[k])/((1-
sensitivity[k])*(1-specificity[k])) 
  #DOR[k] <- exp(A[k]) 
 } 
} 
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Meta-regression model
Model{ 
#Loop over studies reporting 2x2 tables. i=rep no., k=test no. in 
study j 
for (j in 1:N1){ 
 for (k in 1:ntests[j]){ 
  for (i in 1:nreps[j,k]){ 
   tp[i,j,k]~dbin(pi1[i,j,k],pos[i,j,k]) 
 #Likelihood 
   fp[i,j,k]~dbin(pi2[i,j,k],neg[i,j,k]) 
   tphat[i,j,k]<-pi1[i,j,k]*pos[i,j,k]  
 #Fitted values 
   fphat[i,j,k]<-pi2[i,j,k]*neg[i,j,k] 
   dev.tp[i,j,k]<-(2*(tp[i,j,k]*(log(tp[i,j,k])-
log(tphat[i,j,k]))  #Deviance contibution tp 
            +  (pos[i,j,k]-tp[i,j,k])*(log(pos[i,j,k]-tp[i,j,k]) - 
log(pos[i,j,k]-tphat[i,j,k])))) 
   dev.fp[i,j,k]<-(2*(fp[i,j,k]*(log(fp[i,j,k])-
log(fphat[i,j,k]))  #Deviance contibution fp 
            +  (neg[i,j,k]-fp[i,j,k])*(log(neg[i,j,k]-fp[i,j,k]) - 
log(neg[i,j,k]-fphat[i,j,k]))))   
  } 
  dev[j,k]<-sum(dev.tp[1:nreps[j,k],j,k]) + 
sum(dev.fp[1:nreps[j,k],j,k])  
 } 
 sumdev[j]<-sum(dev[j,1:ntests[j]]) 
} 
 
totresdev<- sum(sumdev[]) 
 
#Loop over all studies 
for (j in 1:(N1)){ 
 for (k in 1:ntests[j]){ 
  for (i in 1:nreps[j,k]){ 
   logit(pi1[i,j,k])<- beta[t[j,k]]*theta[i,j,k] 
+alpha[i,j,k]/2  #Model for sensitivity 
   logit(pi2[i,j,k])<- theta[i,j,k] - alpha[i,j,k]/2
      #Model for (1-specificity) 
   theta[i,j,k]~dnorm(qreg[i,j,k],p.reps[1])  
 #Between study variability 
   alpha[i,j,k]~dnorm(areg[i,j,k],p.reps[2]) 
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   # Regression 
   qreg[i,j,k]<-q[j,k]+(x[i,j,k]-
mean.x[t[j,k]])*gamma[t[j,k]] 
   areg[i,j,k]<-a[j,k]+(x[i,j,k]-
mean.x[t[j,k]])*lambda[t[j,k]] 
  } 
  q[j,k]~dnorm(Q[t[j,k]],p.stud[1])   #Between 
study variability 
  a[j,k]~dnorm(A[t[j,k]],p.stud[2]) 
 } 
} 
 
#PRIORS 
for (k in 1:NTests){ #Loop over tests 
 Q[k]~dnorm(0,.0001) 
 A[k]~dnorm(0,.0001) 
 
 # Regression coefficients 
 gamma[k]~dnorm(0,.0001) 
 lambda[k]~dnorm(0,.0001) 
 
 log(beta.true[k])<-l.beta.true 
 beta[k]<- include.slope[k]*beta.true[k] + (1-include.slope[k]) 
} 
l.beta.true~dnorm(0,.0001) 
 
for (m in 1:2){ 
 p.stud[m]<-pow(sd.stud[m],-2) 
 p.reps[m]<-pow(sd.reps[m],-2) 
 sd.stud[m]~dunif(0,5) 
 sd.reps[m]~dunif(0,5) 
 
 # Save the prior distributions 
 sd.stud.prior[m]~dunif(0,5) 
 sd.reps.prior[m]~dunif(0,5) 
} 
 
 # Posterior and posterior predictive distritbutions 
 for(k in 1:NTests){ 
  theta.pred[k]~dnorm(Q[k],p.stud[1]) 
  alpha.pred[k]~dnorm(A[k],p.stud[2]) 
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  logit(sens.pred[k])<-
beta[k]*theta.pred[k]+0.5*alpha.pred[k] 
  logit(fpr.pred[k])<-theta.pred[k]-0.5*alpha.pred[k] 
  spec.pred[k]<- 1 - fpr.pred[k]  
 
  logit(TPR[k])<-(beta[k]*Q[k]+A[k]/2) 
  logit(FPR[k])<-(Q[k]-A[k]/2) 
  sensitivity[k]<-TPR[k] 
  specificity[k]<-1-FPR[k] 
 
  # Diagnostic odds ratio 
  dor[k]<-(sensitivity[k]*specificity[k])/((1-
sensitivity[k])*(1-specificity[k])) 
  #DOR[k] <- exp(A[k]) 
 } 
} 
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Appendix 4 Search strategy for the systematic
review of randomised controlled trials comparing
screening strategies
The search strategy and MEDLINE search terms for the systematic review of RCTs comparing screeningstrategies are provided in Table 54.
Database: Ovid MEDLINE(R) < 1946 to present>
TABLE 54 Search protocol and MEDLINE search strategy for the systematic review of RCTs comparing screening strategies
Component Description
Review area Screening strategies for AF
Objectives To investigate the effectiveness of systematic screening for AF
Populations/aspect Adults of unknown AF disease status
Target condition AF
Interventions Systematic screening strategies – population, opportunistic, targeted
Comparisons/aspects
covered by search
Usual care – no screening
Study designs RCTs (including cluster and quasi-types), interrupted times series, controlled before-and-after
studies
Exclusions Animal studies
How the information
was searched
Databases: MEDLINE and PreMEDLINE, EMBASE, CENTRAL – Cochrane Central Register of
Controlled Trials
Date parameters: April and May 2012; July–December 2015
Note: because of the large number of conference abstracts added to EMBASE since the original
search, these were excluded unless they met very specific AF/screening criteria
Search date 22 January 2016
Search terms Atrial Fibrillation/ (38,865)
(atrial fibrillation* or atrium fibrillation* or auricular fibrillation*).tw. (45,810)
(af or a-fib).tw. (25,013)
Atrial Flutter/ (5240)
(atrial flutter* or auricular flutter*).tw. (4909)
or/1-5 (67,777)
Mass Screening/ (85,789)
screen*.tw. (522,680)
Diagnosis/ (16,823)
“diagnostic techniques and procedures”/ (2609)
(diagnos* or identif* or detect* or prevalence or incidence*).tw. (5,517,698)
((systemat* or opportunist* or target* or population or mass) adj2 (test* or assess*)).tw. (20,842)
Electrocardiography/ (171,668)
continued
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TABLE 54 Search protocol and MEDLINE search strategy for the systematic review of RCTs comparing screening
strategies (continued)
Component Description
Electrocardiography, Ambulatory/ (9377)
(electrocardiogram* or electrocardiograph* or ecg or ekg or holter or event monitor*).tw.
(112,189)
pulse/ (16,648)
(pulse adj3 (test or tests)).tw. (867)
or/7-17 (5,920,125)
6 and 18 (31,631)
randomized controlled trial.pt. (404,537)
controlled clinical trial.pt. (90,002)
randomi#ed.ab. (398,345)
placebo.ab. (165,463)
clinical trials as topic.sh. (174,355)
randomly.ab. (240,675)
trial.ti. (144,385)
or/20-26 (1,012,739)
19 and 27 (3572)
exp animals/ not humans.sh. (4,175,239)
28 not 29 (3504)
intervention*1.ti. or (intervention*1 adj6 (clinician*1 or collaborat* or community or complex or
DESIGN$ or GP*1 or educational or family GP* or family physician*1 or family practitioner*1
or financial or GP or general practice*1 or hospital*1 or impact*1 or improv$ or individuali?e*1
or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or
multi-disciplin$ or multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e*1 or
personali?ing or pharmacies or pharmacist*1 or pharmacy or physician*1 or practitioner*1
or prescrib$ or prescription*1 or primary care or professional$ or provider*1 or regulatory or tailor$
or target$ or team$ or usual care)).ab. (191204)
(pre-intervention*1 or preintervention*1 or post-intervention*1 or postintervention*1).tw.
(12,843)
(hospital$ or patient*1).hw. and (study or studies or care or health$ or practitioner*1 or
provider*1 or physician*1 or nurse*1 or nursing or GP*1).ti,hw. (775,070)
demonstration project*1.ti,ab. (2091)
(pre-post or pre-test* or pretest$ or posttest$ or post-test* or (pre adj5 post)).ti,ab. (77,200)
(pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (723)
(trial or study).ti. or ((study adj3 aim*1) or present study or our study).ab. (2,200,119)
(before adj10 (after or during)).ti,ab. (389,176)
(time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or
eleven or twelve or month$ or hour*1 or day*1 or more than)).ab. (11,012)
pilot.ti. (46,287)
(multicentre or multicenter or multi-centre or multi-center).ti. (33,605)
random$.ti,ab. or controlled.ti. (849,995)
*experimental design/ or *pilot study/ or quasi experimental study/ (29,846)
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TABLE 54 Search protocol and MEDLINE search strategy for the systematic review of RCTs comparing screening
strategies (continued)
Component Description
(quasi-experiment$ or quasiexperiment$ or quasi-random$ or quasirandom$ or quasi control$ or
quasicontrol$ or ((quasi$ or experimental) adj3 (method$ or study or trial or design$))).ti,ab.
(113,933)
(time series adj2 interrupt$).ti,ab. (1329)
controlled before-after studies/ or interrupted time series analysis/ (200)
or/31-46 (3,952,382)
19 and 47 (9786)
review.ti. (301,040)
(animal$ not human$).sh,hw. (4,135,024)
49 or 50 (4,428,155)
48 not 51 (9136)
30 or 52 (9895)
(201204$ or 201205$ or 201507$ or 201508$ or 201509$ or 201510$ or 201511$ or 201512$
or 2016$).ed,ep,dc. (1,388,357)
53 and 54 (1160)
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Appendix 5 Studies excluded at full text
T able 55 presents the studies that were excluded from the DTA review at full-text stage. Althoughthere was consensus between reviewers that these studies should be excluded, there were often
multiple reasons for exclusion and consensus was not always obtained. One reviewer’s reason for the
exclusion of each study is presented in the table. Reasons for exclusion were:
l not a DTA study
l target condition not AF (this included studies from which DTA data for AF could not be extracted,
for example when AF and atrial flutter were combined)
l information not per person (unit of analysis not the person, for example the unit of analysis was the
reading or the segment of a reading)
l population – people with a diagnosis of AF who had had curative treatment such as ablation or
cardioversion, people with pacemakers/paced rhythms, stroke inpatients and outpatients, cardiology
inpatients and outpatients, anticoagulant outpatients, patients in intensive care and studies with
< 40 participants
l index test – invasive, not possible in primary care or does not detect arrhythmia
l reference standard – when the reference standard was not a 12-lead ECG interpreted by a cardiologist.
TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion
Study Reason for exclusion
Abe 1995175 Index test
Albilali 2014176 Not a DTA study
Al-Fahoum 2013177 Information not per person
Alis 2009178 Population
Amir 2011179 Information not per person
Andrikopoulos 2000180 Index test
Anh 2006181 Not a DTA study
Aras 2005182 Index test
Asl 2008183 Information not per person
Aytemir 1999184 Not a DTA study
Aytemir 2000185 Index test
Babaeizadeh 2009186 Information not per person
Bae 2011187 Information not per person
Bae 2012188 Information not per person
Bansil 2004189 Population
Barrett 2013190 Not a DTA study
Barrett 2014191 Population
Barthéleémy 2003192 Population
Benavente 2013193 Not a DTA study
Bernard 1981194 Population
Boudaoud 2003195 Index test
continued
DOI: 10.3310/hta21290 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 29
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Welton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
195
TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Bourdillon 1978196 Population
Boyle 2013197 Reference standard
Budeus 2003198 Index test
Budeus 2005199 Index test
Caldwell 2012200 Population
Chao 2011201 Index test
Chee 2010202 Not a DTA study
Choi 2010203 Information not per person
Clavier 2002204 Index test
Cole-Haskayne 2014205 Not a DTA study
Coutts 2014206 Not a DTA study
Cubanski 1994207 Information not per person
Czaplik 2010208 Target condition not AF
Dash 2009209 Information not per person
Dash 2009210 Population
Dash 2011211 Population
Davidenko 2007212 Information not per person
Davy 2014213 Reference standard
Deelawar 2013214 Population
Dilaveris 1998215 Index test
Dilaveris 1999216 Index test
Dirschedl 1996217 Population
Dobbels 2014218 Population
Dogan 2012219 Population
Doliwa 2009220 Population
Doliwa Sobocinski 2012221 Population
Dotan 2011222 Population
Douen 2008223 Population
Du 2014224 Information not per person
Dukes 2014225 Reference standard
Duverney 2002226 Index test
Elgendi 2008227 Information not per person
Elijovich 2008228 Not a DTA study
Engdahl 2012229 Not a DTA study
Engdahl 201322 Not a DTA study
Feruglio 1975230 Target condition not AF
Filos 2011231 Not a DTA study
Finucane 2013232 Population
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TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Foley 2011233 Population
Franczuk 2004234 Index test
Fukunami 1991235 Index test
Fukunami 1992236 Not a DTA study
Gaillard 2008237 Population
Ghrooda 2014238 Not a DTA study
Gialafos 1999239 Index test
Gomis 2009240 Population
Goricke 2011241 Population
Gradl 2012242 Target condition not AF
Graja 2005243 Index test
Grond 2011244 Population
Grond 2013245 Population
Guidera 1993246 Population
Güler 2005247 Information not per person
Gumbinger 2010248 Population
Gumbinger 2012249 Population
Gunalp 2006250 Population
Haberman 2014251 Target condition not AF
Haberman 2015252 Target condition not AF
Haeberlin 2012253 Target condition not AF
Haeberlin 2014254 Information not per person
Hakacova 2012255 Target condition not AF
Hallioglu 2004256 Target condition not AF
Harrington 2013257 Target condition not AF
Helfenbein 2010258 Population
Hendrikx 2012259 Population
Hendrikx 2014260 Population
Hickey 2004261 Reference standard
Higgins 2014262 Not a DTA study
Hiraki 1998263 Index test
Hoffmann 2010264 Information not per person
Hong-Wei 2009265 Information not per person
Horstmann 2013266 Population
Hoshino 2015267 Population
Howlett 2014268 Population
Howlett 2014269 Not a DTA study
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TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Hsieh 2005270 Information not per person
Inoue 2001271 Population
Jang 2011272 Information not per person
Jeon 2014273 Information not per person
Jiang 2012274 Information not per person
Joseph 1999275 Target condition not AF
Kallmünzer 2012276 Population
Kallmünzer 2014277 Population
Kandel 2012278 Population
Kar 2009279 Population
Karapinar 2009280 Index test
Kessler 1993281 Not a DTA study
Kikillus 2007282 Information not per person
Kikillus 2008283 Information not per person
Kim 2008284 Information not per person
Kim 2013285 Not a DTA study
Kinlay 1996286 Target condition not AF
Klein 1997287 Population
Köse 2003288 Index test
Koskinen 2005289 Not a DTA study
Kostka 2007290 Population
Kostka 2008291 Population
Kostka 2008292 Population
Kostka 2008293 Population
Kostka 2010294 Population
Kostka 2011295 Information not per person
Krasteva 2007296 Target condition not AF
Krummen 2010112 Population
Lagido 2014297 Population
Lalani 2013298 Population
Langley 2001299 Index test
Lau 2012300 Population
Lavallee 2013301 Not a DTA study
Lazzaro 2010302 Population
Lazzaro 2012303 Population
Lee 2011304 Information not per person
Lee 2013305 Information not per person
Lee 2013306 Population
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TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Lelakowska-Piela 2013307 Not a DTA study
Lepage 2001308 Index test
Lever 2009309 Not a DTA study
Lewalter 2007310 Population
Lim 2008311 Not a DTA study
Linker 2013312 Population
Liu 2010313 Information not per person
Locati 2011314 Population
Logan 2005315 Information not per person
Lowres 201421 Reference standard
Lu 2010316 Information not per person
Madsen 2009317 Population
Mahagne 2009318 Population
Mahagne 2011319 Population
Maier 2001320 Index test
Mairesse 2013321 Not a DTA study
Maitas 2012322 Information not per person
Maitas 2012323 Information not per person
Mäkijaärvi 1993324 Population
Makowska 2000325 Target condition not AF
Manina 2014326 Population
Martínez 2012327 Index test
Martinez-Sanchez 2011328 Population
Martinez-Sanchez 2012329 Population
Martis 2014330 Information not per person
Maslowsky 2012331 Index test
McCarthy 2014332 Not a DTA study
Miller 2012333 Population
Miller 2014334 Not a DTA study
Mohebbi 2008335 Information not per person
Mohebbi 2012336 Information not per person
Montereggi 1996337 Index test
Moreira 2006338 Index test
Morgan 200282 Reference standard
Mueller 2006339 Information not per person
Müller 2009340 Reference standard
Murgatroyd 1995341 Information not per person
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TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Opolski 1995342 Index test
Ozdemir 2004343 Index test
Ozer 2000344 Index test
Park 2009345 Information not per person
Pastor-Pérez 2010346 Population
Peer 2003347 Not a DTA study
Pellise 2011348 Not a DTA study
Poon 2005349 Information not per person
Portet 2008350 Target condition not AF
Potpara 2014351 Not a DTA study
Pryor 1972352 Target condition not AF
Pusalkar 2012353 Population
Quinto Villani 1993354 Index test
Rabinstein 2014355 Not a DTA study
Reddy 1998356 Information not per person
Reifart 1997357 Population
Renier 2012358 Target condition not AF
Rhys 2012359 Population
Rhys 2013117 Population
Rincon 2012360 Information not per person
Rizikou 2013361 Population
Rizos 2010362 Population
Rizos 2012363 Population
Roche 2002364 Population
Ros 2004365 Index test
Roten 2012366 Information not per person
Samol 2013367 Reference standard
Sanak 2014368 Population
Sato 2009369 Index test
Sawant 2014370 Population
Schaefer 2014371 Population
Schaer 2003372 Not a DTA study
Schreier 2001373 Index test
Schuchert 1999374 Population
Sezgin 2013375 Information not per person
Shafqat 2004376 Not a DTA study
Sheldon 2014377 Population
Shiyovich 2010378 Not a DTA study
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TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Singh 2010379 Population
Sobocinski-Doliwa 2010380 Population
Stafford 1995381 Index test
Stahrenberg 2010382 Population
Sudlow 1998383 Reference standard
Sugai 2009384 Target condition not AF
Suissa 2011385 Population
Suissa 2012386 Population
Suissa 2012387 Population
Suissa 2013388 Population
Suissa 2014389 Population
Sun 2008390 Information not per person
Sutamnartpong 2014391 Not a DTA study
Tagawa 2007392 Population
Tateno 2001393 Information not per person
Temiz 2014394 Population
aTieleman 2014395 Population/reference standard
Torbey 2013396 Population
Tu 2014397 Population
Tung 2014398 Information not per person
Ustrell 2011399 Population
Velthuis 2013400 Information not per person
Veltkamp 2011401 Population
Veltkamp 2012402 Population
Villani 1996403 Index test
Villani 1996404 Index test
Vinther 2014405 Population
Vyas 2014406 Information not per person
Wallmann 2007407 Population
Wiesel 2004408 Information not per person
Wiesel 2007409 Population
Wiesel 2009410 Population
Wiesel 2010411 Reference standard
Wiesel 2013412 Reference standard
Wiesel 2014413 Population
Wiesel 2014414 Population
Winkler 2011415 Population
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TABLE 55 Articles excluded at full text and one reviewer’s reason for exclusion (continued )
Study Reason for exclusion
Wyse 2008416 Not a DTA study
Xu 2002417 Information not per person
Yaghouby 2010418 Information not per person
Yig˘it 2003419 Not a DTA study
Yung 2010420 Population
Zenk 2004421 Target condition not AF
Zhou 2014422 Information not per person
a This article represents two studies.
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Appendix 6 Meta-analysis of diagnostic test
accuracy studies
Summary of included data
There were 14 studies with a total of 50 test groups, and all either directly reported the number of true
positives, false positives, true negatives and false negatives, or reported enough data for these numbers to
be correctly calculated. Assuming that tests are the same no matter the interpreter, there are six groups of
tests to be analysed (modified blood pressure monitor, single-lead ECG, two-stage screening strategy,
12-lead ECG, > 1- and < 12-lead ECG and pulse palpation). Assuming that tests are further split by
interpreter (denoted ‘Test/interpreter’ category in Tables 41–46 and 60–69), there are 12 categories of test
with single-lead ECG split into four categories (automatic/algorithm, cardiologist, GP and nurse) and 12-lead
ECG split into three categories (automatic/algorithm, GP and nurse). The final two columns of Table 2
summarise the number of test groups (arms/observations) and their test classifications and interpreter.
Model fit and model selection
We found that all three slope models (independent, common and exchangeable) would not converge for
either categorisation of tests, and so we assumed all SROC curves to be symmetric. Alternative
(mathematically equivalent) parameterisations of the slope did not help convergence.
In the no slope models, sensitivity and specificity converged for all tests except ‘12-lead ECG – GP’ in the
split by interpreter model. This group had only one data point. Models with and without splitting by
interpreter both gave an adequate fit based on the posterior residual deviance, which is similar to the
number of data points, 92 (Table 56). The DIC was very similar for both models, indicating that there is no
evidence that DTA depends strongly on interpreter (see Table 57).
Heterogeneity across studies (σi in our model notation) and across observations (within studies) (ωi in our
notation) was assessed by comparing their respective standard deviations with the standard deviations
of the model parameters Λ and Θ. The results of this assessment are presented in Table 57 for the tests
not split by interpreter analysis and Table 58 for the split by interpreter analysis. We found evidence of
heterogeneity across and within studies as the parameter standard deviations were comparable to the
heterogeneity standard deviations.
TABLE 56 Model fit summaries comparing models for the index test defined with or without interpreter, assuming
a random-effects modela
Summary statistic Tests not split by interpreter Tests split by interpreter
Posterior mean residual deviance 91.77 88.22
Effective number of parameters (pD) 57.64 61.22
DIC 149.40 149.45
a Models with a posterior mean residual deviance close to the number of data points (n= 92) indicate a good fit.
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TABLE 57 Internal model parameters for the model heterogeneity estimate, tests not split by interpreter modela
Model parameter Mean SD 2.50% 97.50% Rhat
Λ[1] 5.94 0.82 4.32 7.60 1.00
Λ[2] 6.14 0.52 5.21 7.27 1.00
Λ[3] 6.56 0.80 4.97 8.15 1.00
Λ[4] 41.70 21.37 10.12 85.39 1.06
Λ[5] 6.32 0.46 5.41 7.24 1.00
Λ[6] 7.12 0.97 5.38 9.26 1.00
Λ[7] 4.09 0.84 2.48 5.84 1.00
Θ[1] 0.35 0.60 –0.83 1.56 1.00
Θ[2] 0.24 0.36 –0.50 0.95 1.00
Θ[3] –0.27 0.56 –1.35 0.89 1.00
Θ[4] 18.61 10.72 2.72 40.41 1.05
Θ[5] –0.54 0.33 –1.24 0.09 1.00
Θ[6] –1.69 0.66 –3.04 –0.42 1.00
Θ[7] 0.60 0.63 –0.64 1.84 1.00
SD.stud[Θ] (σ1) 0.51 0.28 0.05 1.11 1.04
SD.stud[Λ] (σ2) 0.66 0.38 0.06 1.53 1.02
SD.obs[Θ] (ω1) 0.66 0.13 0.43 0.95 1.00
SD.obs[Λ] (ω2) 0.79 0.27 0.28 1.33 1.00
Rhat, Brooks-Rubin-Gelman convergence diagnostic reported by WinBUGS version 1.4.3; SD, standard deviation;
SD.stud, across-study standard deviation; SD.obs, across-observation standard deviation.
a The across-study and across-observation (within-study) heterogeneity standard deviations should be compared with the
individual parameter standard deviations.
TABLE 58 Internal model parameters for the model heterogeneity estimate, split interpreter modela
Mean SD 2.50% 97.50% Rhat
Λ[1] 5.90 0.87 4.18 7.63 1.00
Λ[2] 6.02 0.85 4.41 7.77 1.00
Λ[3] 6.52 0.85 4.81 8.23 1.00
Λ[4] 6.11 0.82 4.65 7.93 1.00
Λ[5] 51.33 31.51 10.79 125.20 2.21
Λ[6] 6.32 0.53 5.28 7.40 1.00
Λ[7] 6.48 1.09 4.26 8.65 1.00
Λ[8] 4.14 0.90 2.41 5.98 1.00
Λ[9] 5.88 1.25 3.44 8.43 1.00
Λ[10] 8.38 2.13 4.52 12.88 1.00
Λ[11] 6.30 1.69 3.27 10.03 1.00
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A further investigation was to apply the fixed-effects model described in Appendix 3, which assumes fixed
parameters across studies and across observations within studies. The model fit statistics are presented in
Table 59 and should be compared with those presented in Table 56. Although the fixed-effects models
have fewer effective parameters (pD), the residual deviance and DIC clearly favour the random-effects
models. This confirms our assessment that heterogeneity is present across studies and observations.
TABLE 58 Internal model parameters for the model heterogeneity estimate, split interpreter modela (continued )
Mean SD 2.50% 97.50% Rhat
Λ[12] 55.53 23.13 16.70 101.60 1.29
Λ[13] 73.80 45.49 20.51 171.70 1.61
Θ[1] 0.35 0.63 –0.89 1.62 1.00
Θ[2] 0.65 0.58 –0.48 1.82 1.00
Θ[3] –0.26 0.60 –1.42 0.97 1.00
Θ[4] 0.33 0.56 –0.81 1.49 1.00
Θ[5] 23.41 15.78 3.09 60.36 2.23
Θ[6] –0.85 0.38 –1.63 –0.13 1.00
Θ[7] –1.38 0.81 –3.00 0.21 1.00
Θ[8] 0.62 0.64 –0.66 1.91 1.00
Θ[9] 0.12 0.85 –1.56 1.84 1.00
Θ[10] –0.50 1.30 –3.09 2.11 1.00
Θ[11] 1.19 1.04 –0.74 3.37 1.00
Θ[12] 23.14 11.57 3.57 45.48 1.31
Θ[13] 2.38 19.05 –28.17 51.36 1.22
SD.stud[Θ] (σ1) 0.59 0.32 0.06 1.29 1.00
SD.stud[Λ] (σ2) 0.76 0.44 0.04 1.74 1.00
SD.obs[Θ] (ω1) 0.61 0.14 0.36 0.92 1.00
SD.obs[Λ] (ω2) 0.78 0.28 0.21 1.33 1.02
SD, standard deviation.
a The across-study and across-observation (within-study) heterogeneity standard deviations should be compared with the
individual parameter standard deviations.
TABLE 59 Model fit summaries comparing models for the index test defined with or without interpreter, assuming
a fixed-effects modela
Summary statistic Tests not split by interpreter Tests split by interpreter
Posterior mean residual deviance 672.44 549.35
Effective number of parameters (pD) 13.01 22.54
DIC 685.44 571.88
a Models with a posterior mean residual deviance close to the number of data points (n= 92) indicate a good fit, so fixed-
effects models did not fit well.
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Appendix 7 Results tables for diagnostic test
accuracy subgroup and sensitivity analyses
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TABLE 61 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for
cohort study subgroup analysis
Test/interpreter
Number of
observations
restricted to
cohort studies
Number of
observations
excluding
cohort studies
DOR
restricted
to cohort
studies
(95% CrI)
DOR excluding
cohort studies
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
3 0 2.5
(2.08 to 2.68)
– (– to –) 2.5
(2.14 to 2.67)
Single-lead ECG – automatic/
algorithm
1 2 2.07
(1.26 to 2.64)
2.47
(1.34 to 2.72)
2.46
(2.1 to 2.65)
Single-lead ECG – nurse 0 3 – (– to –) 2.38
(1.08 to 2.72)
2.52
(2.01 to 2.7)
Single-lead ECG – GP 0 1 – (– to –) 2.55
(1.28 to 2.72)
2.65
(2.31 to 2.72)
Single-lead ECG – cardiologist 9 0 2.53
(2.2 to 2.68)
– (– to –) 2.53
(2.23 to 2.67)
Two-stage screening strategy 1 6 2.47
(1.77 to 2.7)
2.54
(1.28 to 2.72)
2.62
(2.43 to 2.7)
Photoplethysmography 1 0 2.38
(1.61 to 2.69)
– (– to –) 2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
8 1 2.65
(2.57 to 2.7)
2.71
(2.69 to 2.72)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 0 2 – (– to –) 2.21
(1.03 to 2.72)
2.33
(1.62 to 2.67)
12-lead ECG – GP 0 1 – (– to –) 2.55
(1.27 to 2.72)
2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
2 0 2.67
(2.52 to 2.72)
– (– to –) 2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
2 0 2.72
(2.72 to 2.72)
– (– to –) 2.72
(2.72 to 2.72)
Pulse palpation – nurse 1 2 2.18
(1.33 to 2.66)
2.1
(1.02 to 2.72)
2.21
(1.64 to 2.58)
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TABLE 62 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for
systematic or targeted screening studies subgroup analysis
Test/interpreter
Number of
observations
restricted to
systematic or
targeted
screening
studies
Number of
observations
excluding
systematic or
targeted
screening
studies
DOR
restricted to
systematic
or targeted
screening
studies
(95% CrI)
DOR excluding
systematic or
targeted
screening
studies
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
3 0 2.46
(1.7 to 2.7)
– (– to –) 2.5
(2.14 to 2.67)
Single-lead ECG – automatic/
algorithm
2 1 2.3
(1.42 to 2.69)
2.56
(1.81 to 2.71)
2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.47
(1.47 to 2.71)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.61
(1.89 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG – cardiologist 8 1 2.42
(1.39 to 2.71)
2.52
(1.68 to 2.71)
2.53
(2.23 to 2.67)
Two-stage screening strategy 7 0 2.6
(2.13 to 2.71)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 0 1 – (– to –) 2.36
(1.36 to 2.7)
2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
0 9 – (– to –) 2.67
(2.58 to 2.71)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.29
(1.21 to 2.71)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.61
(1.89 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
0 2 – (– to –) 2.65
(2.31 to 2.72)
2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
0 2 – (– to –) 2.72
(2.7 to 2.72)
2.72
(2.72 to 2.72)
Pulse palpation – nurse 2 1 2.15
(1.14 to 2.7)
2.16
(1.19 to 2.69)
2.21
(1.64 to 2.58)
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TABLE 63 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for
primary care studies subgroup analysis
Test/interpreter
Number of
observations
restricted to
primary care
studies
Number of
observations
excluding
primary care
studies
DOR restricted
to primary
care studies
(95% CrI)
DOR
excluding
primary care
studies
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
1 2 2.31
(1.2 to 2.71)
2.46
(1.4 to 2.71)
2.5
(2.14 to 2.67)
Single-lead ECG – automatic/
algorithm
2 1 2.29
(1.38 to 2.69)
2.53
(1.53 to 2.72)
2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.46
(1.4 to 2.71)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.61
(1.84 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG – cardiologist 8 1 2.41
(1.33 to 2.71)
2.5
(1.46 to 2.72)
2.53
(2.23 to 2.67)
Two-stage screening strategy 7 0 2.59
(2.08 to 2.71)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 0 1 – (– to –) 2.33
(1.21 to 2.71)
2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
1 8 2.64
(2.1 to 2.72)
2.66
(2.51 to 2.71)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.28
(1.18 to 2.71)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.61
(1.84 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
0 2 – (– to –) 2.63
(2.07 to 2.72)
2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
0 2 – (– to –) 2.72
(2.72 to 2.72)
2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 0 2.17
(1.28 to 2.67)
– (– to –) 2.21
(1.64 to 2.58)
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TABLE 64 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for risk
of bias in relation to patient selection sensitivity analysis
Test/interpreter
Number of
observations
restricted to
low RoB patient
selection
Number of
observations
excluding low
RoB patient
selection
DOR
restricted
to low RoB
patient
selection
(95% CrI)
DOR
excluding
low RoB
patient
selection
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
2 1 2.29
(1.01 to 2.72)
2.35
(1.47 to 2.7)
2.5
(2.14 to 2.67)
Single-lead ECG – automatic/
algorithm
0 3 – (– to –) 2.45
(2 to 2.67)
2.46
(2.1 to 2.65)
Single-lead ECG – nurse 0 3 – (– to –) 2.49
(1.82 to 2.7)
2.52
(2.01 to 2.7)
Single-lead ECG – GP 0 1 – (– to –) 2.63
(2.18 to 2.72)
2.65
(2.31 to 2.72)
Single-lead ECG – cardiologist 1 8 2.31
(1.01 to 2.72)
2.45
(1.77 to 2.69)
2.53
(2.23 to 2.67)
Two-stage screening strategy 0 7 – (– to –) 2.61
(2.34 to 2.7)
2.62
(2.43 to 2.7)
Photoplethysmography 1 0 2.16
(1 to 2.72)
– (– to –) 2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
1 8 2.46
(1.03 to 2.72)
2.66
(2.57 to 2.7)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 0 2 – (– to –) 2.31
(1.46 to 2.69)
2.33
(1.62 to 2.67)
12-lead ECG – GP 0 1 – (– to –) 2.64
(2.21 to 2.72)
2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
2 0 2.48
(1.06 to 2.72)
– (– to –) 2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardio
0 2 – (– to –) 2.72
(2.71 to 2.72)
2.72
(2.72 to 2.72)
Pulse palpation – nurse 0 3 – (– to –) 2.2
(1.52 to 2.62)
2.21
(1.64 to 2.58)
RoB, risk of bias.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
212
TABLE 65 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for RoB
in relation to index test sensitivity analysis
Test/interpreter
Number of
observations
restricted to
low RoB index
test
Number of
observations
excluding low
RoB index test
DOR
restricted to
low RoB
index test
(95% CrI)
DOR
excluding
low RoB
index test
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
3 0 2.51
(2.19 to 2.66)
– (– to –) 2.5
(2.14 to 2.67)
Single-lead ECG – automatic/
algorithm
3 0 2.46
(2.14 to 2.64)
– (– to –) 2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.52
(2.07 to 2.69)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.66
(2.38 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG – cardiologist 5 4 2.51
(2.21 to 2.66)
2.3
(1.02 to 2.72)
2.53
(2.23 to 2.67)
Two-stage screening strategy 7 0 2.62
(2.45 to 2.7)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 0 1 – (– to –) 2.19
(1.01 to 2.72)
2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
6 3 2.69
(2.64 to 2.71)
2.25
(1.01 to 2.72)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.34
(1.71 to 2.66)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.65
(2.35 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
2 0 2.68
(2.57 to 2.71)
– (– to –) 2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
2 0 2.72
(2.72 to 2.72)
– (– to –) 2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 0 2.21
(1.7 to 2.56)
– (– to –) 2.21
(1.64 to 2.58)
RoB, risk of bias.
DOI: 10.3310/hta21290 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 29
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Welton et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
213
TABLE 66 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for RoB
in relation to reference test selection sensitivity analysis
Test/interpreter
Number of
observations
restricted to
low RoB
reference test
Number of
observations
excluding low
RoB reference
test
DOR
restricted to
low RoB
reference test
(95% CrI)
DOR
excluding
low RoB
reference test
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
3 0 2.5
(2.1 to 2.68)
– (– to –) 2.5
(2.14 to 2.67)
Single-lead ECG – automatic/
algorithm
3 0 2.46
(2.06 to 2.66)
– (– to –) 2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.51
(1.97 to 2.7)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.64
(2.26 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG –
cardiologist
9 0 2.53
(2.22 to 2.68)
– (– to –) 2.53
(2.23 to 2.67)
Two-stage screening strategy 7 0 2.63
(2.43 to 2.7)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 1 0 2.38
(1.59 to 2.69)
– (– to –) 2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
2 7 2.69
(2.62 to 2.72)
2.63
(2.43 to 2.71)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.33
(1.58 to 2.68)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.64
(2.26 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
0 2 – (– to –) 2.65
(2.21 to 2.72)
2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
2 0 2.72
(2.72 to 2.72)
– (– to –) 2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 0 2.21
(1.59 to 2.6)
– (– to –) 2.21
(1.64 to 2.58)
RoB, risk of bias.
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TABLE 67 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for
studies with a low level of concern about patient selection applicability sensitivity analysis
Test/interpreter
Number of
observations
restricted to low
applicability of
patient selection
concerns
Number of
observations
excluding low
applicability of
patient selection
concerns
DOR
restricted
to low
applicability
of patient
selection
concerns
(95% CrI)
DOR
excluding
low
applicability
of patient
selection
concerns
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
1 2 2.31
(1.2 to 2.71)
2.46
(1.4 to 2.71)
2.5
(2.14 to 2.67)
Single-lead ECG –
automatic/algorithm
2 1 2.29
(1.38 to 2.69)
2.53
(1.53 to 2.72)
2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.46
(1.4 to 2.71)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.61
(1.84 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG –
cardiologist
8 1 2.41
(1.33 to 2.71)
2.5
(1.46 to 2.72)
2.53
(2.23 to 2.67)
Two-stage screening
strategy
7 0 2.59
(2.08 to 2.71)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 0 1 – (– to –) 2.33
(1.21 to 2.71)
2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
1 8 2.64
(2.1 to 2.72)
2.66
(2.51 to 2.71)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.28
(1.18 to 2.71)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.61
(1.84 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
0 2 – (– to –) 2.63
(2.07 to 2.72)
2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
0 2 – (– to –) 2.72
(2.72 to 2.72)
2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 0 2.17
(1.28 to 2.67)
– (– to –) 2.21
(1.64 to 2.58)
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TABLE 68 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for
studies with a low level of concern about index test applicability sensitivity analysis
Test/interpreter
Number of
observations
restricted to low
applicability of
index test
concerns
Number of
observations
excluding low
applicability of
index test
concerns
DOR
restricted
to low
applicability
of index test
concerns
(95% CrI)
DOR
excluding
low
applicability
of index test
concerns
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
3 0 2.5
(2.11 to 2.67)
– (– to –) 2.5
(2.14 to 2.67)
Single-lead ECG –
automatic/algorithm
3 0 2.47
(2.12 to 2.65)
– (– to –) 2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.48
(1.86 to 2.7)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.64
(2.31 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG –
cardiologist
0 9 – (– to –) 2.43
(1.25 to 2.72)
2.53
(2.23 to 2.67)
Two-stage screening
strategy
7 0 2.6
(2.35 to 2.7)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 1 0 2.4
(1.7 to 2.68)
– (– to –) 2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
9 0 2.67
(2.62 to 2.7)
– (– to –) 2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.33
(1.58 to 2.68)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.65
(2.33 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
2 0 2.67
(2.52 to 2.72)
– (– to –) 2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardio
0 2 – (– to –) 2.72
(2.72 to 2.72)
2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 0 2.2
(1.62 to 2.58)
– (– to –) 2.21
(1.64 to 2.58)
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TABLE 69 Diagnostic test accuracy summaries for different categories of test and interpreter combinations for
studies with a low level of concern about reference test applicability sensitivity analysis
Test/interpreter
Number of
observations
restricted to low
applicability of
reference test
concerns
Number of
observations
excluding low
applicability of
reference test
concerns
DOR
restricted
to low
applicability
of reference
test concerns
(95% CrI)
DOR
excluding
low
applicability
of reference
test concerns
(95% CrI)
DOR all
(95% CrI)
Modified blood pressure
monitor
3 0 2.51
(2.2 to 2.67)
– (– to –) 2.5
(2.14 to 2.67)
Single-lead ECG –
automatic/algorithm
3 0 2.47
(2.13 to 2.65)
– (– to –) 2.46
(2.1 to 2.65)
Single-lead ECG – nurse 3 0 2.52
(2.09 to 2.69)
– (– to –) 2.52
(2.01 to 2.7)
Single-lead ECG – GP 1 0 2.65
(2.37 to 2.72)
– (– to –) 2.65
(2.31 to 2.72)
Single-lead ECG –
cardiologist
9 0 2.53
(2.28 to 2.67)
– (– to –) 2.53
(2.23 to 2.67)
Two-stage screening
strategy
7 0 2.63
(2.47 to 2.7)
– (– to –) 2.62
(2.43 to 2.7)
Photoplethysmography 1 0 2.41
(1.74 to 2.68)
– (– to –) 2.39
(1.68 to 2.69)
12-lead ECG – automatic/
algorithm
6 3 2.69
(2.64 to 2.71)
2.25
(1.01 to 2.72)
2.67
(2.61 to 2.7)
12-lead ECG – nurse 2 0 2.34
(1.7 to 2.66)
– (– to –) 2.33
(1.62 to 2.67)
12-lead ECG – GP 1 0 2.65
(2.37 to 2.72)
– (– to –) 2.65
(2.32 to 2.72)
> 1- and < 12-lead ECG –
automatic/algorithm
2 0 2.68
(2.58 to 2.71)
– (– to –) 2.68
(2.55 to 2.71)
> 1- and < 12-lead ECG –
cardiologist
2 0 2.72
(2.72 to 2.72)
– (– to –) 2.72
(2.72 to 2.72)
Pulse palpation – nurse 3 0 2.21
(1.7 to 2.56)
– (– to –) 2.21
(1.64 to 2.58)
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Appendix 8 Consolidated Health Economic
Evaluation Reporting Standards checklist
TABLE 70 Consolidated Health Economic Evaluation Reporting Standards checklist for economic evaluations
identified in the review
CHEERS checklist
item
Aronsson
2015100
aAronsson
201599
bGordon
2012118
Moran
2015105
Hobbs
200519
cLord
2013116
Lowres
201421
Maeda
200496
bRhys
2013117
1 Title identified as
economic
evaluation
Y N N Y Y N Y Y N
2 Structured abstract Y N N Y Y N N Y N
3 Background and
objectives
Y Y N Y Y Y Y Y N
4 Population
characteristics
Y Y Y Y Y Y Y Y Y
5 Setting and
location
Y N Y Y Y Y Y Y Y
6 Study perspective Y N N Y N Y Y Y N
7 Comparators N Y N Y Y Y Y Y N
8 Time horizon Y N N Y Y Y Y Y N
9 Discount rate Y N N Y Y Y Y Y N
10 Description of
health outcomes
and relevance
Y Y Y Y Y Y Y N Y
11 Measurement of
effectiveness
Y N Y Y Y Y Y Y Y
12 Measurement of
preference-based
outcomes
NA NA NA NA NA NA NA NA NA
13 Unit costs and
methods reported
N N N Y Y Y Y Y Y
14 Currency, date
and conversion
Y N N Y Y Y Y Y N
15 Choice of model
described
Y Y N Y Y Y N Y N
16 Model
assumptions
Y N N Y Y Y Y Y N
17 Analytical methods
described
Y Y N Y Y Y N Y N
18 Study parameters
reported in full
N N N Y Y Y Y Y N
19 Incremental costs
and outcomes
reported
Y Y N Y Y Y Y Y N
20 Sensitivity analysis
undertaken
Y N N Y Y NA N Y N
continued
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TABLE 70 Consolidated Health Economic Evaluation Reporting Standards checklist for economic evaluations
identified in the review (continued )
CHEERS checklist
item
Aronsson
2015100
aAronsson
201599
bGordon
2012118
Moran
2015105
Hobbs
200519
cLord
2013116
Lowres
201421
Maeda
200496
bRhys
2013117
21 Heterogeneity
explored
N N N N N NA N Y N
22 Findings,
limitations and
generalisability
Y N N Y Y NA Y Y N
23 Funding source Y N N Y Y Y Y N Y
24 Conflicts of
interest
Y N Y Y Y Y Y N Y
Score 19/23 7/23 5/23 22/23 21/23 18/23 18/23 20/23 7/23
N, no; NA, not applicable; Y, yes.
a Based on abstract.
b Insufficient information on economic evaluation – secondary to the objectives of the paper; included in the discussion section.
c Guideline economic evaluation developed for NICE using AF screening as a case study.
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Appendix 9 Search strategy for the review of the
natural history of atrial fibrillation screening
The search strategy for the review of the natural history of AF screening for use in the economicmodelling is provided below.
1. *Atrial Fibrillation/ep (1706)
2. *atrial fibrillation/ or Atrial fibrillation/ep (31,285)
3. (atrial fibrillation* or atrium fibrillation* or auricular fibrillation*).tw. (45,795)
4. (af or a-fib).tw. (25,007)
5. Atrial Flutter/ (5240)
6. (atrial flutter* or auricular flutter*).tw. (4909)
7. or/2-6 (63,948)
8. Mass Screening/ (85,782)
9. disease progression/ (114,587)
10. incidence/ or prevalence/ (391,325)
11. ((AF or atrial fibrillation) adj6 (prevalence or incidence or screen*)).tw. (3318)
12. or/8-10 (574,026)
13. or/8-11 (576,168)
14. 1 and 12 (963)
15. 7 and 11 (3318)
16. 14 or 15 (3826)
17. letter/ (898,830)
18. editorial/ (391,744)
19. news/ (173,688)
20. exp historical article/ (363,693)
21. Anecdotes as topic/ (4684)
22. comment/ (647,935)
23. case report/ (1,760,067)
24. (letter or comment$).ti. (107,532)
25. animals/ not humans/ (4,142,787)
26. exp Animals, Laboratory/ (753,015)
27. exp Animal Experimentation/ (7739)
28. exp Models, Animal/ (448,998)
29. exp rodentia/ (2,813,026)
30. (rat or rats or mouse or mice).ti. (1,171,895)
31. or/17-30 (8,328,614)
32. 16 not 31 (3524)
33. epidemiologic studies/ (6952)
34. exp case control studies/ (748,592)
35. exp cohort studies/ (1,484,230)
36. cross-sectional studies/ (204,195)
37. (case control or cohort analys$).ti,ab. (92,391)
38. (cohort adj (study or studies)).ti,ab. (107,645)
39. ((follow up or prospective or retrospective or observational) adj (study or studies)).ti,ab. (318,257)
40. (Longitudinal or cross sectional).ti,ab. (351,536)
41. or/33-40 (2106,518)
42. 32 and 41 (1757)
43. (child* or paediatric or pediatric or neonat* or newborn* or infant*).ti. (978,749)
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44. 42 not 43 (1754)
45. limit 44 to english language (1641)
46. limit 45 to yr=”2000 –Current” (1469)
47. limit 45 to yr=”2005-current” (1257)
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Appendix 10 Cost-effectiveness planes: base-case
economic evaluation
F igures 29–34 show the cost-effectiveness planes for each age group in the base-case economicevaluation. Although there is uncertainty in the incremental costs and QALYs, systematic population
screening has both higher costs and higher QALYs than systematic opportunistic screening in all cases.
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FIGURE 29 Cost-effectiveness plane for a single screen at age 55 years. Screening strategies that have a < 5%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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FIGURE 30 Cost-effectiveness plane for a single screen at age 60 years. Screening strategies that have a < 5%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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FIGURE 31 Cost-effectiveness plane for a single screen at age 65 years. Screening strategies that have a < 5%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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FIGURE 32 Cost-effectiveness plane for a single screen at age 70 years. Screening strategies that have a < 5%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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FIGURE 33 Cost-effectiveness plane for a single screen at age 75 years. Screening strategies that have a < 5%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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FIGURE 34 Cost-effectiveness plane for a single screen at age 80 years. Screening strategies that have a < 5%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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Appendix 11 Results of the economic evaluation
sensitivity analyses
Screening test
Using a modified blood pressure monitor as the screening test
The results for the across-age analysis are presented in Table 71 and the CEACs are presented in Figure 35. We
see almost no change in the estimated INBs for screening at each age. The conclusion that screening at age
80 years had the highest probability of being cost-effective and the highest expected INB was also unchanged.
TABLE 71 Sensitivity analysis using opportunistic screening with a modified blood pressure monitor as the
screening test: age cohort population mean incremental costs, incremental QALYs and net benefit for willingness
to pay per QALY thresholds of £20,000 for different screening ages
Screening
age (years)
Population
size of age
cohort for
given ages
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 14,305
(6411 to 30,346)
2147
(1074 to 3652)
28,628
(10,672 to 51,349)
29,849
(11,152 to 53,445)
75 379,913.4 15,275
(6672 to 32,993)
2088
(1052 to 3505)
26,484
(7590 to 47,568)
27,603
(8010 to 49,625)
70 466,605.4 12,631
(5738 to 27,323)
1766
(893 to 3009)
22,697
(7509 to 41,679)
23,593
(7570 to 43,372)
65 633,658.8 10,930
(5247 to 21,845)
1423
(718 to 2433)
17,532
(5904 to 32,195)
18,137
(5959 to 33,476)
60 620,292.8 6818
(3316 to 14,226)
813
(405 to 1389)
9449
(1763 to 18,066)
9700
(1721 to 18,876)
55 675,855.0 5037
(2623 to 9870)
574
(281 to 992)
6443
(1598 to 12,496)
6556
(1240 to 12,932)
No screening
70 years, systematic opportunistic – modified 
blood pressure monitor
75 years, systematic opportunistic – modified 
blood pressure monitor
80 years, systematic opportunistic – modified 
blood pressure monitor
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FIGURE 35 Cost-effectiveness acceptability curves comparing different ages for a single one-off screen in a given
age cohort, with a modified blood pressure monitor as the screening test. Screening strategies that have a < 10%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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Using pulse palpation interpreted by a nurse as the screening test
The results for the across-age analysis are presented in Table 72 and the CEACs are presented in Figure 36.
Although the estimated INBs for screening are slightly lower than in the base case at each age, the same
patterns with age are observed. The conclusion that screening at age 80 years had the highest probability
of being cost-effective and the highest expected INB was unchanged.
TABLE 72 Sensitivity analysis using opportunistic screening with pulse palpation by a nurse as the screening test:
age cohort population mean incremental costs, incremental QALYs and net benefit for willingness to pay per
QALY thresholds of £20,000 for different screening ages
Screening
age (years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 13,942
(6204 to 29,584)
2054
(1014 to 3527)
27,129
(9749 to 49,368)
29,849
(11,152 to 53,445)
75 379,913.4 14,996
(6654 to 32,434)
1998
(986 to 3424)
24,962
(6565 to 45,866)
27,603
(8010 to 49,625)
70 466,605.4 12,564
(5817 to 27,064)
1690
(833 to 2896)
21,245
(6475 to 39,661)
23,593
(7570 to 43,372)
65 633,658.8 11,110
(5449 to 21,973)
1362
(677 to 2343)
16,132
(4730 to 30,512)
18,137
(5959 to 33,476)
60 620,292.8 7154
(3577 to 14,185)
777
(378 to 1359)
8393
(990 to 16,949)
9700
(1721 to 18,876)
55 675,855.0 5491
(2928 to 10,085)
550
(267 to 971)
5507
(743 to 11,482)
6556
(1240 to 12,932)
No screening
70 years, systematic opportunistic – 
pulse palpation – nurse
75 years, systematic opportunistic – 
pulse palpation – nurse
80 years, systematic opportunistic – 
pulse palpation – nurse
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FIGURE 36 Cost-effectiveness acceptability curves comparing different ages for a single one-off screen in a given
age cohort, with pulse palpation by a nurse as the screening test. Screening strategies that have a < 10%
probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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Uptake of an electrocardiogram in those with a positive screening result
In a sensitivity analysis, we assumed that only 72.5% of those with a positive screening test result agree to
have an ECG, compared with 100% in the base case. The results of this sensitivity analysis are presented
in Table 73; the CEACs are presented in Figure 37.
TABLE 73 Sensitivity analysis assuming a lower uptake of an ECG in screen-positive individuals: age cohort
population mean incremental costs, incremental QALYs and net benefit for willingness to pay per QALY thresholds
of £20,000 for different screening ages, all under opportunistic screening with photoplethysmography
Screening
age (years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age-cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 11,045
(5032 to 23,014)
1628
(821 to 2740)
21,513
(7832 to 38,566)
29,849
(11,152 to 53,445)
75 379,913.4 11,868
(5347 to 25,258)
1583
(798 to 2679)
19,795
(5509 to 35,883)
27,603
(8010 to 49,625)
70 466,605.4 9929
(4664 to 21,201)
1338
(676 to 2269)
16,832
(5310 to 31,042)
23,593
(7570 to 43,372)
65 633,658.8 8772
(4380 to 17,146)
1078
(548 to 1836)
12,792
(3862 to 23,892)
18,137
(5959 to 33,476)
60 620,292.8 5637
(2838 to 11,265)
615
(307 to 1054)
6663
(769 to 13,272)
9700
(1721 to 18,876)
55 675,855.0 4319
(2340 to 8004)
435
(215 to 743)
4382
(420 to 9056)
6556
(1240 to 12,932)
No screening
70 years, systematic opportunistic – 
photoplethysmography
75 years, systematic opportunistic – 
photoplethysmography
80 years, systematic opportunistic – 
photoplethysmography
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FIGURE 37 Sensitivity analysis assuming a lower uptake of ECGs in screen-positive individuals: CEACs comparing
different ages for a single one-off screen in a given age cohort. Screening strategies that have a < 10% probability
of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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Meta-analysis of previous history of stroke in UK screen-detected atrial fibrillation
In sensitivity analysis, we used the results of a random-effects meta-analysis for the proportion of screen-
detected AF patients with a previous history of stroke (0.112, 95% CrI 0.072 to 0.170); the value used in
the base case, based on the SAFE study,19 was 0.074 (95% CI 0.032 to 0.116. The results of this sensitivity
analysis are presented in Table 74 and the CEACs are presented in Figure 38.
TABLE 74 Sensitivity analysis using the meta-analysis estimate of the previous history of stroke rather than the
SAFE study estimate: age cohort population mean incremental costs, incremental QALYs and net benefit for
willingness to pay per QALY thresholds of £20,000 for different screening ages, all under opportunistic screening
with photoplethysmography
Screening
age (years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age-cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 13,868
(6273 to 27,412)
2189
(1045 to 3967)
29,920
(11,869 to 57,838)
29,849
(11,152 to 53,445)
75 379,913.4 15,263
(6493 to 29,999)
2225
(975 to 3970)
29,233
(9653 to 57,245)
27,603
(8010 to 49,625)
70 466,605.4 12,786
(5796 to 26,126)
1809
(817 to 3374)
23,394
(7475 to 46,322)
23,593
(7570 to 43,372)
65 633,658.8 11,153
(5057 to 22,089)
1477
(673 to 2768)
18,393
(5024 to 37,705)
18,137
(5959 to 33,476)
60 620,292.8 6974
(3507 to 13,692)
843
(377 to 1537)
9890
(2617 to 20,142)
9700
(1721 to 18,876)
55 675,855.0 5283
(2612 to 10,228)
570
(258 to 1082)
6114
(784 to 13,820)
6556
(1240 to 12,932)
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FIGURE 38 Sensitivity analysis using the meta-analysis estimate of the previous history of stroke rather than the
SAFE study estimate: CEACs comparing different ages for a single one-off screen in a given age cohort. Screening
strategies that have a < 10% probability of being cost-effective at any willingness-to-pay threshold are not shown
for clarity.
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Proportion of anticoagulant patients receiving directly acting oral anticoagulants
instead of warfarin
We ran sensitivity analyses on the proportion of OAC patients prescribed DOACs instead of warfarin,
assuming values of 50% and 100%. The results are presented in Tables 75 and 76, respectively, and the
CEACs are presented in Figures 39 and 40, respectively.
TABLE 75 Sensitivity analysis assuming that 50% of anticoagulant patients take apixaban instead of warfarin: age
cohort population mean incremental costs, incremental QALYs and net benefit for willingness to pay per QALY
thresholds of £20,000 for different screening ages, all under opportunistic screening with photoplethysmography
Screening
age (years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age-cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 14,395
(6394 to 30,655)
2244
(1141 to 3792)
30,478
(11,425 to 54,297)
29,849
(11,152 to 53,445)
75 379,913.4 15,450
(6678 to 34,129)
2185
(1100 to 3692)
28,255
(8431 to 50,552)
27,603
(8010 to 49,625)
70 466,605.4 12,833
(5795 to 27,805)
1846
(926 to 3093)
24,085
(7887 to 43,922)
23,593
(7570 to 43,372)
65 633,658.8 11,212
(5366 to 22,474)
1489
(755 to 2523)
18,562
(6199 to 33,984)
18,137
(5959 to 33,476)
60 620,292.8 7065
(3396 to 14,528)
848
(420 to 1468)
9897
(1902 to 19,199)
9700
(1721 to 18,876)
55 675,855.0 5305
(2735 to 10,305)
601
(296 to 1039)
6710
(1294 to 13,424)
6556
(1240 to 12,932)
TABLE 76 Sensitivity analysis assuming that 100% of anticoagulant patients take apixaban instead of warfarin: age
cohort population mean incremental costs, incremental QALYs and net benefit for willingness to pay per QALY
thresholds of £20,000 for different screening ages, all under opportunistic screening with photoplethysmography
Screening
age
(years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age-cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 15,646
(7131 to 32,450)
2243
(1137 to 3767)
29,209
(10,679 to 52,239)
29,849
(11,152 to 53,445)
75 379,913.4 16,718
(7478 to 35,834)
2184
(1112 to 3703)
26,955
(7600 to 49,211)
27,603
(8010 to 49,625)
70 466,605.4 13,824
(6389 to 29,241)
1844
(929 to 3125)
23,051
(7304 to 42,443)
23,593
(7570 to 43,372)
65 633,658.8 12,020
(5888 to 23,666)
1488
(754 to 2544)
17,737
(5853 to 32,598)
18,137
(5959 to 33,476)
60 620,292.8 7530
(3678 to 15,152)
850
(419 to 1454)
9462
(1534 to 18,435)
9700
(1721 to 18,876)
55 675,855.0 5600
(2939 to 10,565)
599
(296 to 1028)
6381
(1115 to 12,688)
6556
(1240 to 12,932)
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FIGURE 39 Sensitivity analysis assuming that 50% of anticoagulant patients take apixaban instead of warfarin:
CEACs comparing different ages for a single one-off screen in a given age cohort. Screening strategies that have a
< 10% probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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FIGURE 40 Sensitivity analysis assuming that 100% of anticoagulant patients take apixaban instead of warfarin:
CEACs comparing different ages for a single one-off screen in a given age cohort. Screening strategies that have a
< 10% probability of being cost-effective at any willingness-to-pay threshold are not shown for clarity.
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Uptake of oral anticoagulants
In sensitivity analyses we assumed (1) a reduced OAC uptake of 50% and (2) that all 87% of patients who
are not contraindicated or who prefer not to take OACs receive OACs. The results of the sensitivity analysis
assuming an OAC uptake rate of 50% are presented in Table 77, with the CEACs in Figure 41, and the
results of the sensitivity analysis assuming an OAC uptake rate of 87% are presented in Table 78, with the
CEACs in Figure 42. Overall, the INB was lower if the OAC uptake rate was lower, but this did not alter
our conclusions.
TABLE 77 Sensitivity analysis assuming an OAC uptake rate of 50%. Age cohort population mean incremental
costs, incremental QALYs and net benefit for willingness to pay per QALY thresholds of £20,000 for different
screening ages, all under opportunistic screening with photoplethysmography
Screening
age (years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age-cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 13,297
(5836 to 28,334)
2044
(1005 to 3506)
27,574
(9839 to 50,323)
29,849
(11,152 to 53,445
75 379,913.4 14,337
(6170 to 31,485)
1989
(966 to 3392)
25,437
(6796 to 46,770)
27,603
(8010 to 49,625)
70 466,605.4 12,048
(5421 to 26,654)
1682
(822 to 2896)
21,601
(6125 to 40,455)
23,593
(7570 to 43,372)
65 633,658.8 10,688
(5141 to 21,546)
1356
(667 to 2344)
16,429
(4713 to 30,622)
18,137
(5959 to 33,476)
60 620,292.8 6925
(3428 to 13,980)
773
(377 to 1334)
8538
(1102 to 17,059)
9700
(1721 to 18,876)
55 675,855.0 5327
(2805 to 9950)
546
(257 to 960)
5584
(660 to 11,700)
6556
(1240 to 12,932)
No screening
70 years, systematic opportunistic – 
pulse palpation – nurse
75 years, systematic opportunistic – 
pulse palpation – nurse
80 years, systematic opportunistic – 
pulse palpation – nurse
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FIGURE 41 Sensitivity analysis assuming an OAC uptake rate of 50%: CEACs comparing different ages for a single
one-off screen in a given age cohort. Screening strategies that have a < 10% probability of being cost-effective at
any willingness-to-pay threshold are not shown for clarity.
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TABLE 78 Sensitivity analysis assuming an OAC uptake rate of 87%: age cohort population mean incremental costs,
incremental QALYs and net benefit for willingness to pay per QALY thresholds of £20,000 for different screening
ages, all under opportunistic screening with photoplethysmography
Screening
age
(years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age-cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 15,401
(6987 to 31,998)
2251
(1141 to 3821)
29,628
(10,982 to 53,262)
29,849
(11,152 to 53,445)
75 379,913.4 16,457
(7317 to 35,160)
2190
(1110 to 3703)
27,342
(7846 to 49,353)
27,603
(8010 to 49,625)
70 466,605.4 13,635
(6311 to 29,174)
1852
(927 to 3138)
23,400
(7499 to 43,012)
23,593
(7570 to 43,372)
65 633,658.8 11,852
(5779 to 23,143)
1492
(758 to 2528)
17,987
(5720 to 33,227)
18,137
(5959 to 33,476)
60 620,292.8 7438
(3623 to 15,098)
852
(425 to 1460)
9601
(1607 to 18,690)
9700
(1721 to 18,876)
55 675,855.0 5554
(2866 to 10,523)
603
(297 to 1040)
6510
(1190 to 12,996)
6556
(1240 to 12,932)
No screening
70 years, systematic opportunistic – 
photoplethysmography
75 years, systematic opportunistic – 
photoplethysmography
80 years, systematic opportunistic – 
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FIGURE 42 Sensitivity analysis assuming an OAC uptake rate of 87%: CEACs comparing different ages for a single
one-off screen in a given age cohort. Screening strategies that have a < 10% probability of being cost-effective at
any willingness-to-pay threshold are not shown for clarity.
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Hazard ratios for stroke and mortality risk for routine-detected atrial fibrillation
compared with screen-detected atrial fibrillation
In sensitivity analysis, we set the HR for symptomatic AF (representing non-screen-detected AF) compared
with asymptomatic AF (representing screen-detected AF) equal to 1.31 (95% CI 1.04 to 1.65), based on
the unadjusted analysis reported by Flaker et al.,35 rather than 1, as assumed in the base case. The results
of the sensitivity analysis are shown in Table 79 and the CEACs are shown in Figure 43. Our conclusions
were unchanged from the base case.
TABLE 79 Sensitivity analysis using a lower hazard of stroke and mortality in asymptomatic AF compared with
symptomatic AF: age cohort population mean incremental costs, incremental QALYs and net benefit for willingness
to pay per QALY thresholds of £20,000 for different screening ages, all under opportunistic screening with
photoplethysmography
Screening
age (years)
Population
size of age
cohort
Age cohort
population
incremental
costs (£000)
(95% CrI)
Age cohort
population
incremental
QALYs
(95% CrI)
Age cohort
population INB
at £20,000 (£000)
(95% CrI)
Age cohort
population INB
at £20,000
(£000): base case
(95% CrI)
80 279,437.0 13,814
(5898 to 28,017)
2138
(983 to 3945)
28,948
(10391 to 56,452)
29,849
(11,152 to 53,445)
75 379,913.4 15,153
(6557 to 31,669)
2238
(997 to 4227)
29,598
(8116 to 58,651)
27,603
(8010 to 49,625)
70 466,605.4 12,623
(5544 to 26,710)
1806
(810 to 3304)
23,498
(8579 to 45,520)
23,593
(7570 to 43,372)
65 633,658.8 10,918
(4890 to 22,992)
1470
(679 to 2680)
18,474
(4819 to 36,787)
18,137
(5959 to 33,476)
60 620,292.8 7021
(3342 to 13,994)
825
(377 to 1561)
9472
(1389 to 20,005)
9700
(1721 to 18,876)
55 675,855.0 5234
(2597 to 10,563)
579
(249 to 1079)
6337
(871 to 13,594)
6556
(1240 to 12,932)
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FIGURE 43 Sensitivity analysis using a lower hazard of stroke and mortality in asymptomatic AF compared with
symptomatic AF: CEACs comparing different ages for a single one-off screen in a given age cohort. Screening
strategies that have a < 10% probability of being cost-effective at any willingness-to-pay threshold are not shown
for clarity.
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